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Abstract 
Regulatory T cells (Treg) are CD4+ FOXP3+ T lymphocytes whose function is to 
prevent autoimmunity and immune cell-mediated damage on infected tissues. They 
carry out their suppressive effects either by direct cell-cell contact or through the use 
of soluble mediators such as IL-10 and TGFb. Activated Treg express the epidermal 
growth factor receptor (EGFR), a tyrosine kinase receptor found in most tissue types 
and leukocytes. EGFR signalling induces behavioural changes in Treg: in particular, 
the ligand Amphiregulin (AREG) is required for optimal Treg function in various in-
vitro and in-vivo experimental models. The aim of my thesis has been to explore the 
effects of EGFR signalling on Treg function in the context of infection, induced either 
from endogenously expressed or pathogen-derived ligands. 
 
In Chapter 2 I examined the effects of Vaccinia (VACV) virus-derived Vaccinia 
Growth Factor (VGF), a pathogen-derived soluble protein with EGF-like activity, on 
Treg function. I showed that Treg function is increased when exposed to UV-
inactivated Vaccinia virus, but that this activation can be blocked by deleting EGFR 
expression on Treg. Using an in-vivo pneumonitis model, I showed that mice 
deficient in EGFR expression on their Tregs were more resistant to VACV infection 
compared to wildtype, and that following infection there was less bioactive TGFb in 
the bronchoalveolar lavage supernatant of these animals. Taken together, these 
data imply that Vaccinia virus derived VGF enhances the suppressive capacity of 
Tregs and use this enhanced activation as a means of immune escape.  
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In Chapter 3 I used the filariasis model Litomosoides sigmodontis (a chronic 
helminth infection of rodents) to examine the effects of EGFR signalling in Tregs 
induced by the endogenous ligand Amphiregulin, and to study the effects of EGFR 
blockade on the helminth-specific immune response using the commercially 
available tyrosine kinase inhibitor Gefitinib. We found that EGFR deletion on Treg 
lead to no increase in TH2 cytokine production or parasite rejection. Also, complete 
deletion of Amphiregulin in Areg-/- mice had no significant effect; nor did the 
administration of Gefitinib over several weeks in WT mice. From these findings, we 
conclude that AREG-EGFR signalling on Tregs (or EGFR signalling in general) is not 
a significant factor influencing the immune response to L.sigmodontis infection.  
 
In Chapter 4 I examined the effects of the complete deletion of Amphiregulin in  
Areg-/- mice, and the deletion of Amphiregulin in specific cell types, on the activity of 
activated Tregs in an airway allergy model. To induce and activate Tregs we used 
the murine helminth Heligmosomoides polygyrus, which infects the gastrointestinal 
tract but also induces Treg expansion systemically. Previous work in our group had 
determined that Amphiregulin deletion in mice led to a decreased Treg-mediated 
immunosuppression following H. polygyrus infection and airway OVA challenge, as 
evidenced by greater eosinophilia in the lungs of Areg-/- than wildtype mice. 
However, I failed to replicate the initial findings of our group’s work, seeing no 
difference in Treg activity or TH2 response between infected and noninfected 
animals, and also no significant differences in different mouse strains with a cell 
type-specific deletion of Amphiregulin.  
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Taken together, my thesis provides evidence for the enhanced suppressive 
capacity of Tregs by a viral pathogen derived EGFR ligand, in order to create a local 
immunosuppressive environment. To our knowledge, this is the very first time such 
an immune escape mechanism has been demonstrated. It also demonstrates that in 
the face of helminth-mediated activation of Treg, EGFR signalling is not a significant 
factor contributing to local immune suppression. This further clarifies the role of 
EGFR signalling on Tregs in the setting of both acute and chronic infection.  
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Lay Summary 
Regulatory T cells (Treg) are a type of white blood cell whose function is to prevent 
autoimmune disease and stop other white blood cells damaging infected tissues. 
They do this either by directly contacting cells and giving a suppressive signal, or by 
releasing chemicals into the environment such as IL-10 and TGFb. Activated Treg 
express a receptor on their cell surface called the Epidermal Growth Factor Receptor 
(EGFR), which is also present on many other cells. When EGFR is activated by 
specific proteins, for example by Amphiregulin (AREG), the cell is activated and 
starts suppressing other white blood cells. The aim of my thesis was to clarify the 
effects of EGFR activation on Treg function, either when EGFR is activated by 
AREG or by a virus-derived protein that behaves similarly to AREG.  
 
In Chapter 2 I use a virus called Vaccinia (VACV), which produces a protein called 
VGF that can activate EGFR. Using virus that can’t replicate, but can make VGF 
protein, I showed that Treg can suppress other cells when they are exposed to the 
nonreplicating virus. Treg that don’t have EGFR on their cell surfaces don’t do this. 
Then, using mice infected with VACV in their lungs, I show that normal mice are 
much more susceptible to infection than animals with EGFR deleted on the cell 
surface of their Tregs. The gene-deficient mice also had less of the suppressive 
chemical TGFb in their lungs, implying that their Treg were less activated than those 
in the normal mice. Taken together, these data imply that Vaccinia virus uses VGF to 
activate Tregs, which in turn will suppress the rest of the immune response to 
infection, ultimately harming the host and benefiting the virus.  
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In Chapter 3 I used a helminth worm infection of rodents called Litomosoides 
sigmodontis, to look at the effects of AREG produced by the host’s own body on 
Tregs, and with a drug called Gefitinib tried to block this signal. Comparing normal 
mice to mice with EGFR deleted on their Tregs, I found no differences in the immune 
response to L.sigmodontis infection. Using mice with the gene for AREG deleted 
completely also didn’t change this. Finally, I tried administering Gefitinib to block 
AREG-EGFR signals, and again this did not have an effect compared to mice who 
didn’t receive Gefitinib. In conclusion, AREG-EGFR signalling on Tregs, or using a 
drug to block EGFR signals in general, doesn’t affect the immune response to or 
outcome of L.sigmodontis infection.  
 
In Chapter 4 I looked at AREG-EGFR signalling in a mouse airway allergy model. To 
induce Treg production in some mice, I infected half of my animals with a gut worm 
called Heligmosomoides polygyrus: the infected mice would have more Treg in the 
lungs, as H.polygyrus infection makes the host body to produce Tregs. We had 
expected to see a reduced Treg response in the lungs of mice where the AREG 
gene has been deleted, as previous work in our lab had shown this, and it is known 
that AREG is an important EGFR signal for Tregs in general. We were then going to 
use mice with the AREG gene deleted on specific white blood cell types in order to 
determine where the AREG is coming from that is activating the Treg in the lungs. 
However, we weren’t able to repeat the initial findings, and didn’t see any difference 
between wildtype animals and animals where AREG is deleted completely. No other 
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strains of mice we used had significant differences when compared to wildtype 
animals either.  
 
In summary, I have shown that in an acute infection that viruses can exploit EGFR 
signalling by using their own proteins to activate regulatory T cells. This in turn 
makes them suppress the rest of the immune system, to the benefit of the virus and 
detriment of the host. AREG-EGFR signalling is not a significant factor in the 
activation of regulatory T cells in L.sigmodontis infection.  
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1 Overview of the immune system 
1.1 The immune system’s evolution over time is 
defined by increasing complexity, leading to the 
development of adaptive immunity 
With the development of multicellular life (metazoans) came a requirement 
for successful organisms to defend against invasion by parasites (Beutler 
2004; Akira, Uematsu, and Takeuchi 2006; Cosson and Soldati 2008). Cells 
with a similar phenotype to amoeba (migrate along chemoattraction 
gradients, consume nonself microbes) were essential for this, and are the 
likely origins of phagocytic cells that constitute the innate immune system 
(Cosson and Soldati 2008; Wynn, Chawla, and Pollard 2013). The innate 
immune system’s main function is to recognise pathogens and eliminate 
them without damaging host tissues in the process (i.e. there must be self-
tolerance) (Beutler 2004). It is composed of a variety of barrier methods (e.g. 
skin, mucosa, coagulation cascade, mucus production) and phagocytic cells 
such as the macrophages mentioned above (Beutler 2004; Akira, Uematsu, 
and Takeuchi 2006). These cells function by constitutively recognising 
pathogen-associated molecular antigens, and then triggering an immune 
response to those pathogens.  
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The adaptive immune system responds to pathogens by clonal amplification 
of specific lymphocytes with affinity for the pathogen’s antigenic structure(s), 
differentiation of those lymphocytes and production of antibodies against that 
specific pathogen (Cooper and Alder 2006; Flajnik and Kasahara 2010). 
Increasing parasite burden seems to be the main driver for the development 
of adaptive immunity, which has evolved separately on at least 2 occasions: 
once in jawed vertebrates (Gnathostomes), and a second time in jawless fish 
(Agnathostomes) (Cooper and Alder 2006; Flajnik and Kasahara 2010). 
There are 2 types of lymphocyte, B cells and T cells, which are subdivided 
into Cytotoxic (express CD8 on their cell surface) and ‘Helper’ (Express 
CD4). CD4+ T cells are discussed below.  
 
1.2 CD4 T cells are an essential component of 
adaptive immunity 
CD4+ T cells are termed Helper T cells, and function to establish and 
maintain the immune response to infection, tissue homeostasis, and the 
generation of immunological memory (Kumar, Connors, and Farber 2018). 
They do this via recognition of a diverse range of antigens from pathogens, 
tumour cells and the environment via the T cell receptor (TCR) (Zhu, 
Yamane, and Paul 2010). The TCR binds to antigen presented in a peptide-
MHC complex, either from an infected cell or an antigen-presenting cell 
(Murphy and Reiner 2002). T cell phenotype is then decided both by the 
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nature of antigen binding to the TCR and the surrounding cytokine milieu 
(Zhu, Yamane, and Paul 2010; Murphy and Reiner 2002; Mosmann et al. 
1986; O’Garra and Murphy 1994).  
 
Naïve T cells differentiate to either TH1, TH2 or TH17 cells by means of 
transcription factors that alter gene expression: Tbet promotes a TH1 
phenotype, without which the activated cell will ‘default’ to TH2 or TH17. The 
main transcription factors for TH2 and TH17 cells are GATA3 and RORgt, 
respectively. Once the relevant transcription factor is acquired, expression 
and activity of the others is suppressed (Yu et al. 2015; Kanhere et al. 2012; 
Murphy and Reiner 2002). Tbet promotes expression of IFNg by using 
chromosomal looping to bring the IFNg gene closer to a promoter region; 
GATA3 does the same to the genes for IL-4, IL-5 and IL-13 (Kanhere et al. 
2012). Note that the above picture is simplified, and many other extrinsic 
signals affect the T cell’s eventual fate (Murphy and Reiner 2002). 
 
TH1 cells are responsible for cell-mediated defence against intracellular 
pathogens; they produce large amounts of IFNg and lymphotoxin in order to 
facilitate this (Glimcher and Murphy 2000; Murphy and Reiner 2002; Chakir 
et al. 2003). 
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TH2 cells are produced in response to extracellular parasites with complex 
antigenic structures, such as helminth worms, as well as chronic infections 
such as tuberculosis (Gomez-Escobar, Gregory, and Maizels 2000; Elson et 
al. 1998). They are involved in the generation of a type 2 immune response, 
where cytokines such as IL-4, IL-5, IL-10, IL-13 and Amphiregulin are present 
(Zaiss et al. 2006; Chen et al. 2012; Gomez-Escobar, Gregory, and Maizels 
2000; Haben et al. 2013; Glimcher and Murphy 2000; O’Garra and Murphy 
1994; Romagnani 2000). As well as repelling the pathogen, type 2 immune 
responses aim to minimise tissue damage caused by a runaway immune 
response (Allen and Sutherland 2014; Gause, Wynn, and Allen 2013). 
Derangement of the TH2 response contributes to the development of atopic 
reactions and allergy (Elson et al. 1998). 
 
TH17 cells are involved in mucosal immunity, and are produced in response 
to a variety of bacterial and fungal pathogens, where they play a protective 
role (Pan et al. 2011; Abi Abdallah et al. 2011; Guglani and Khader 2010). 
Naïve CD4 T cells express the transcription factor RORgt in response to 
TGFb, IL-6 and IL-21 signals, though TH17 cells can also be produced upon 
exposure to IL-1b, IL-6 and IL-21 without TGFb (Ghoreschi et al. 2010; Pan 
et al. 2011; Lee et al. 2009). TH17 cells express high levels of IL-17, as well 
as IL-17F and IL-22. As well as functioning in pathogen clearance, TH17 
cells are implicated in autoimmunity and inflammatory conditions such as 
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multiple sclerosis, collagen-induced arthritis and colitis (Korn et al. 2009; 
Guglani and Khader 2010).  
 
A fourth kind of T cell, the regulatory T cell, is discussed below.  
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2 Regulatory T cells are essential for optimal 
immune function 
Regulatory T cells (Treg) are defined as CD4 T cells which express the 
intracellular transcription factor Forkhead Box Protein 3 (FOXP3) (Li et al. 
2008; Veiga-Parga, Sehrawat, and Rouse 2013). FOXP3 in turn binds and 
regulates up to 700 other genes as well as various microRNAs to generate 
the Treg ‘phenotype’. The main function of Treg is to prevent 
immunopathology, either from autoimmune disease or direct damage of 
infected tissue by the host immune response (Veiga-Parga, Sehrawat, and 
Rouse 2013; Li et al. 2008); and depletion of Treg leads to both more 
autoimmune lesions and increased effector T cell-mediated tissue damage.  
 
Tregs maximally activate when they have migrated to the site of inflammation 
(Zhang et al. 2009). There they expand in response to TCR activation, 
typically from dendritic cells, but also ILC2 cells as well as costimulatory 
signals, such as IL-2 and ICOS (Li et al. 2008; Redpath et al. 2013; Veiga-
Parga, Sehrawat, and Rouse 2013; Halim et al. 2018). Treg are more 
sensitive to IL-2 than effector T cells, and IL-2 is essential for the generation 
of tolerance.  
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2.1 Classification of regulatory T cells 
Tregs have been divided into 2 subsets, natural (nTreg) and induced (iTreg). 
nTreg are derived from thymic tissue, where T cell precursors with self-
affinity are retained, express FOXP3 and proliferate when they exit the 
thymus in response to specific signals. They mostly reside in the skin and 
mucosa, and are activated by a range of signals, including Toll-like receptors, 
antigen-presentation, and cytokines from virus-infected antigen-presenting 
cells (IL-2, TGFb, TNFa); their main role is in suppressing autoimmunity 
(Veiga-Parga, Sehrawat, and Rouse 2013). Their mechanism of action is 
antigen-specific, and works via membrane-bound TGFb, or by cytoplasmic 
transfer of granzyme-B and galectin-1 in order to kill specific cells (usually 
effector T cells).  
 
It is proposed that iTreg ‘class-switch’ from other T cell subsets in the 
infective milieu (e.g. naïve or effector T cells) in response to certain signals 
(e.g. antigen presentation, IL-2 & TGFb), and start to express both FOXP3 
and CD25 (Li et al. 2008; Veiga-Parga, Sehrawat, and Rouse 2013; Yu et al. 
2015). Their main role is in altering the antigen-specific immune response, 
and this is achieved through soluble mediators such as IL-10 and TGFb. Treg 
function is variable, and can be suppressed by activated NK cells, IL-6 and 
TLR signalling (Veiga-Parga, Sehrawat, and Rouse 2013; Zaiss et al. 2013; 
Brillard et al. 2007; Okoye et al. 2014) 
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It should be noted that neither Treg subtype uses these mechanisms of 
action exclusively; nor are these the only regulatory cells: Tr1 cells are 
FOXP3- CD4+ T cells that produce mostly IL-10, and are induced by chronic 
antigenic stimulation in the presence of IL-10 (Zeng et al. 2015; Veiga-Parga, 
Sehrawat, and Rouse 2013; Brockmann et al. 2018). 
 
2.2 Treg immunotherapy 
Researchers have investigated the utility of Tregs as a therapy against 
conditions where there is an excessive immune response: These involve 
either transfusion of activated and expanded Tregs or attempts to induce 
Treg production in the host (Kretschmer et al. 2006). This can be done using 
TGFb, galectins 1 & 9, and an IL-2-IL-2 monoclonal antibody, as well as 
antibodies to TNF-R25 (Reddy et al. 2012; Veiga-Parga, Sehrawat, and 
Rouse 2013). 
 
The utility of Tregs as a therapy to prevent established disease was 
confirmed in a T cell colitis model, where transfer of CD4+ CD25+ cells 
rescued RAG1-/- mice from further injury, and in fact reversed the colitis 
(Mottet, Uhlig, and Powrie 2003). Since then Treg therapy has been trialled in 
graft-versus-host disease, as well as autoimmune conditions such as type 1 
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diabetes; whilst in-vivo work in mice has helped to clarify the signals and 
mechanisms which influence Treg function, First-In-Human trials are less 
impressive (Read et al. 2006; Marek-Trzonkowska et al. 2014; Whibley, 
Tucci, and Powrie 2019; Hartemann et al. 2013; Heinrichs et al. 2016; Hull, 
Peakman, and Tree 2017; Marco Romano et al. 2019). Notably, phase I/II 
trials in type 1 diabetic patients have produced more impressive results, and 
phase II studies are ongoing (Hartemann et al. 2013). 
 
In infectious disease models, such as HSV keratosis, transfusion of Tregs 
also appears to be effective at preventing immunopathology (Veiga-Parga, 
Sehrawat, and Rouse 2013). Expansion of Treg populations using anti-TNF-
R25 also reduces inflammation in this model system; however, use after D6 
postinfection also expanded proinflammatory effector T cells, which also 
express TNF-R25 (Reddy et al. 2012). Hence, it appears that the timing of 
therapy, and method of expansion is important to the final outcome.  
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3 The Epidermal Growth Factor Receptor is a 
Tyrosine Kinase Receptor with Numerous 
Functions Across Multiple Cell Types 
The Epidermal Growth Factor Receptor (EGFR) was the first tyrosine kinase 
receptor to be identified in 1975: initially the effects of epidermal growth 
factor (EGF) were noted when Cohen and colleagues injected a 
submandibular gland extract (containing EGF) into neonatal mice, and 
induced hyperproliferation and keratinisation of epithelial cells (Levi-
Montalcini and Cohen 1960); the receptor for EGF was found shortly after, 
and was noted to incorporate radiolabelled phosphorus after stimulation with 
EGF (Carpenter, King, and Cohen 1978). Molecular methods soon clarified 
EGFR’s structure as a tyrosine kinase receptor, the first of its kind to be 
identified (Chen et al. 2016; Gschwind, Fischer, and Ullrich 2004). 
 
EGFR (also termed Human epidermal receptor type 1 [HER1]) is the first in 
the ErbB superfamily of tyrosine kinase receptors (Zhang et al. 2007). ErbB 
receptors are composed of monomers that are activated upon dimerisation 
and binding to specific ligands (see below) (Avraham and Yarden 2011). 
There are 4 monomers, termed ErbB1-4. EGFR (HER1) is a homodimer 
composed of two ErbB1 monomers, HER2 (also called Neu in mice) has two 
ErbB2 monomers, HER3 has two ErbB3 monomers, and HER4 two ErbB4 
Control of regulatory T cell activity by endogenous and pathogen-derived EGFR ligands 
Chapter 1: Introduction  
 12 
monomers. In addition to these receptor homodimers, heterodimers can 
occur, and in fact HER2 is the preferred ‘partner’ fort ErbB3/4 (Zhang et al. 
2007; Tzahar et al. 1996). In order to dimerise, an ErbB1 monomer bound to 
a ligand undergoes a conformational change revealing a dimerization ‘arm’, 
which can then initiate contact with another ErbB monomer. In ErbB2 this 
dimerization ‘arm’ is permanently exposed, explaining its constitutive activity 
(Linggi and Carpenter 2006). 
 
3.1 Intracellular signalling from EGFR 
Once a ligand binds to a receptor (except HER2/neu, which is constitutively 
active), various tyrosine residues are phosphorylated, which then act as 
docking sites for intracellular messenger molecules: these occur via 2 main 
signal transduction pathways.  
 
In the first pathway, GRB2 is phosphorylated and subsequently recruits RAS; 
subsequent signalling cascades down RAF – MEK – ERK, which when 
phosphorylated triggers downstream signals that regulate entry into the cell 
cycle. In the second pathway, PI3K – AKT – mTOR signalling triggers a 
propensity for reduced apoptosis and cell survival. After internalisation the 
receptor-ligand complex can continue to signal, though AKT signalling is 
rapidly terminated (Avraham and Yarden 2011; Gschwind, Fischer, and 
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Ullrich 2004). Overall, at EGFR engages with at least 6 separate biochemical 
pathways (Avraham and Yarden 2011). 
 
Note that the 2 signal transduction pathways described do not account for all 
the downstream effects of EGFR activation; ligands have different affinities 
for different receptors, activation can result in different tyrosine residues 
being phosphorylated, and the effect can vary by cell type; but in general, 
stimulation of EGFR usually triggers proliferation or differentiation of the 
target cell (Avraham and Yarden 2011; Schlessinger 2000).  
 
3.2 Tissues expressing EGFR 
3.2.1 Epithelial cells 
EGFR is mandatory for optimal epithelial cell development. EGFR signalling 
is required for development and migration of epithelial tissue during 
embryogenesis, explaining the near-lethality of a full deletion in mice (Bublil 
and Yarden 2007); EGFR knockout mice either die in-utero or survive for a 
few weeks postpartum, and show defects in epithelial development in the 
skin, kidney, lung and GI tract (Threadgill et al. 1995; Miettinen et al. 1995; 
Sibilia and Wagner 1995). By contrast, deletion of genes for individual EGFR 
ligands results in mild or no abnormal phenotype, indicating considerable 
ligand redundancy. 
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In addition to this, EGFR signalling has some importance in maintenance of 
optimal tissue function in infection: EGFR ligands EGF and Amphiregulin 
both promote migration of gut epithelial cells after injury, and EGF has 
protective effects in bowel perforation sepsis models in mice (Clark et al. 
2008). This may be by encouraging the preservation of bowel epithelial 
integrity, and minimising subsequent bacterial translocation from the GI tract 
to the systemic circulation (Liu et al. 1997). EGFR responses in the lung 
include epithelial and goblet cell proliferation and mucin production (Burgel 
and Nadel 2004); hence, EGFR signalling partially contributes to the barrier 
function of the innate immune system in the lung and GI tract. 
 
3.2.2 Leukocytes, including regulatory T cells, express EGFR 
In recent years EGFR has been detected on the cell surfaces of various 
leukocytes, including monocytes, plasma cells and myeloma cells (Mahtouk 
et al. 2005; Chan, Nogalski, and Yurochko 2009). Activated CD4 T cells also 
express EGFR, which is the most upregulated transmembrane receptor after 
STAT5 signalling (Liao et al. 2008; Zaiss et al. 2013).In addition to the above, 
EGFR signalling influences T cell function: Garrido and colleagues showed 
that T cells were essential for the antimetastatic effect of a monoclonal 
antibody to EGFR in a murine lung carcinoma model. (Garrido et al. 2007).  
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Previous work in our lab has shown that regulatory T cells express EGFR: 
the receptor was detected on 15% of resting Treg in healthy volunteers, and 
100% of activated Treg in-vitro. These findings were confirmed in a murine 
B16 melanoma model (Zaiss et al. 2013). Others have found increased 
EGFR expression in a skin wound model, and kinome profiling in human 
Tregs has shown that EGFR is strongly upregulated after Treg activation 
(Nosbaum et al. 2016; Tuettenberg et al. 2016). Thus, activated Treg express 
EGFR and respond to EGFR signalling.  
 
3.3 EGFR signalling and cancer 
Over 60% of tumour cells contain abnormal ErbB receptors. (Yang et al. 
2005), and EGFR in particular is notable for its presence (and overactivity) on 
several epithelial cancers such as pancreatic, breast, brain, colorectal, non-
small cell lung cancer and head and neck squamous cell carcinoma 
(HNSCC) (Boran et al. 2012). Overexpression of EGFR in these tumours 
(e.g. HNSCC) is associated with increased mortality (Dassonville et al. 1993; 
Chung et al. 2006; Kumar et al. 2008). 
 
Additionally, some tumours such as myeloma, overproduce the EGFR ligand 
Amphiregulin, which signals via the PI3K-AKT pathway, and contributes to 
myeloma cell proliferation by inducing IL-6 production from bone marrow 
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stromal cells (Mahtouk et al. 2005). Interestingly, blocking EGFR signalling 
induced apoptosis in myeloma cells.  
 
The high prevalence of EGFR overexpression (or ligand production) in 
various tumours led to the development of EGFR antagonist agents, namely 
monoclonal antibodies (e.g. cetuximab) and small molecule tyrosine kinase 
inhibitors of EGFR (e.g. Gefitinib, erlotinib etc.), which have been used to 
treat a number of cancers (Boran et al. 2012). By inhibiting EGFR signalling 
the tumour cells are denied a growth signal and are more susceptible to 
destruction either by the immune system or chemotherapeutic agents 
(Mahtouk et al. 2005; Garrido et al. 2007). Resistance to these agents has 
been documented, either by modification of EGFR in lung cancer, or the 
generation of KRAS mutants (Boran et al. 2012). However, it has also been 
noted that some EGFR-negative tumours appear to respond to EGFR 
blockade: this interesting observation led researchers to examine the 
peritumoural space, where activated regulatory T cells inhibit antitumour 
responses (Zitvogel et al. 2008). Potentially this has the advantage of limiting 
tissue damage, but would also impair cytotoxic T cell activity against cancer 
cells, allowing tumour growth (Garrido et al. 2007). As discussed, activated 
Treg express EGFR, and blocking this signal appears to shift the 
peritumoural environment to a more proinflammatory state; for example, 
Garrido and colleagues found that in the presence of a monoclonal antibody 
antagonist of EGFR that dendritic, NK and T cells infiltrated a murine lung 
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tumour in a T-cell dependent manner (Garrido et al. 2007). Others have 
found the same, and hypothesised that tumour responses to EGFR blockade 
may rely partially on Treg deactivation (Zaiss et al. 2013; Ferris, Jaffee, and 
Ferrone 2010; MacDonald and Zaiss 2017).  
 
3.4 Ligands for EGFR have different effects in 
different cell types 
After the discovery of epidermal growth factor (EGF), several other ErbB 
ligands have been identified. These are Heparin-Binding Epidermal Growth 
Factor (HBEGF), Amphiregulin, Transforming Growth Factor alpha (TGFa), 
Epiregulin, Betacellulin, Epigen and Neuregulins 1-4 (Avraham and Yarden 
2011; Monick 2004). Not all ErbB receptors respond to all of these: EGFR 
binds to all except the Neuregulins; HER2/Neu doesn’t bind to any known 
ligand; HER3 only binds Neuregulins 1 & 2, and ErbB4 binds all ligands 
except EGF, TGFa and Epigen (Linggi and Carpenter 2006). ErbB ligands 
are synthesised as type 1 transmembrane precursor proteins, which once 
inserted into the cell membrane undergo extracellular domain cleavage to 
release the soluble ligand that is capable of binding ErbB receptors (Singh, 
Carpenter, and Coffey 2016; Singh and Coffey 2014; Schneider and Yarden 
2014). 
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These ligands can be subdivided according to their affinity: high-affinity 
EGFR ligands, such as EGF, TGFa and HBEGF, induce a strong but 
transient signal, as high-affinity ligand-EGFR binding induces rapid 
internalization and degradation of the EGFR by negative-feedback (Zaiss et 
al. 2013; 2015). Subsequent signalling is ‘oscillatory’ (Shankaran et al. 2009), 
and typically would result in cell proliferation. 
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Figure 3-1 Illustration of the differing outcomes when EGFR is bound to a high-affinity 
ligand (e.g. HBEGF) as opposed to a low-affinity ligand (AREG). Reproduced with 
permission from (Zaiss et al. 2015) 
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3.4.1 Amphiregulin is a weak-affinity EGFR ligand which 
functions as a type 2 cytokine 
In contrast to the above, Amphiregulin (AREG) activates in a more sustained, 
tonic manner, due to a point mutation in the EGFR binding site leading to 
weaker ligand-EGFR binding, and subsequent weaker activation of the 
receptor (Zaiss et al. 2015; 2013; Zaiss et al. 2006; Chen et al. 2012; Solic 
and Davies 1997). Subsequent signalling is more tonic and sustained, which 
does not promote internalisation and destruction of the ligand-EGFR 
complex, but instead promotes cell activation/differentiation (Stern, Place, 
and Lill 2008; Zaiss et al. 2015). Though AREG displays a preference for 
ErbB1/ErbB1 homodimers (i.e. the EGFR), or for ErbB1/ErbB2 heterodimers, 
it has, surprisingly, also been shown to work via ErbB3/4 in an oncology 
model (Mahtouk et al. 2005).  
 
AREG is classified as a type 2 cytokine, whose main functions are to 
promote tissue integrity and promote tolerance to pathogens, so as to enable 
tissue repair and prevent loss of function (Zaiss et al. 2015; Zaiss et al. 
2006). AREG is constitutively expressed by a variety of epithelial and 
mesenchymal tissues (Berasain and Avila 2014), but notably also in several 
types of leukocyte, including dendritic cells, ILC2s, Plasma cells, neutrophils, 
eosinophils, basophils and mast cells in response to a variety of inflammatory 
stimuli (Zaiss et al. 2006; Bles et al. 2010; Monticelli et al. 2011; Adib-Conquy 
et al. 2008; Matsumoto et al. 2009; Wang et al. 2005; Mahtouk et al. 2005; 
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Zaiss et al. 2013). In addition to the above, AREG has also been isolated 
from murine cytotoxic T cells in response to TGFβ, Prostaglandin E2 or IGF-1 
signals (Qi et al. 2012; Zhou et al. 2012). TH2 cells also produce AREG upon 
TCR stimulation (Qi et al. 2012; Zaiss et al. 2006). Finally, an IL-33R-positive 
subset of tissue-residential Tregs can also produce AREG (Burzyn et al. 
2013).  
 
AREG has been studied in association with several inflammatory states, 
including asthma, cancer, and acute and chronic infection (Monick 2004; 
Zaiss et al. 2006). AREG can also affect tissue repair in unexpected ways: 
tissue macrophages release AREG after detecting tissue damage, which 
stimulates EGFR on pericytes (myofibroblast precursor cells). These cells in 
turn activate integrin-aV complexes on target cells, which cleave latent TGFb 
to its active form; TGFb then gives the pericytes a differentiation signal, 
maturing them into myofibroblasts, which aids in the restoration of tissue 
barrier function (Minutti et al. 2019).  
 
Interestingly, AREG appears to have different effects in acute and chronic 
infections: for example, RSV promotes MMP-mediated cleavage of pro-
AREG to free AREG, which in turns activates EGFR in a paracrine manner; 
this promotes local cell survival in the short-term, and so improves virus 
proliferation (Monick 2004). However, in the helminth infection Trichuris muris 
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Areg-/- mice had significantly reduced clearance rates at D14 postinfection, 
indicating that AREG was crucial to TH2-mediated clearance of the parasite 
(Zaiss et al. 2006). AREG-EGFR stimulation is also required for IL-33 
mediated release of IL-13 from TH2 cells, which contributes to the expulsion 
of the gastric helminths Heligmosomoides polygyrus and Nippostrongylus 
brasiliensis (Minutti et al. 2017). Hence, AREG can be both beneficial and 
damaging to the parasite depending on the nature of infection.  
 
AREG in particular appears to be a prominent EGFR signal for regulatory T 
cells; total deletion of AREG in Listeria infection resulted in enhanced 
production of antigen-specific CD4 T cells (Zaiss et al. 2013), and further 
work with an in-vivo colitis model showed that activated Mast cells upregulate 
AREG production, and this was required for optimal Treg function. As well as 
promoting Treg activation, AREG could also be promoting the integrin-aV 
mediated conversion of inert to active TGFb, which is known to be an 
important mechanism Tregs use to mediate their immunosuppressive 
function (Worthington et al. 2015). 
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4 Pathogens manipulate both EGFR signalling 
and regulatory T cells to facilitate their own 
survival and proliferation.  
As pathogens have evolved alongside their host organisms, they have 
developed strategies both to aid their own proliferation and escape or 
minimise the host immune response. As both EGFR and T cells are strongly 
evolutionarily conserved, they are excellent candidates for manipulation by 
pathogens wishing to facilitate their own survival. A brief discussion of the 
evidence base in this field follows.  
 
4.1 Manipulation of regulatory T cells 
As Treg suppress the immune response to infection, they are an obvious 
target for manipulation by parasites. Consequently, there is evidence that 




Viruses generally manipulate Tregs to decrease the effector T cell response 
to infection. However, it should be noted that with some acute infections such 
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as influenza and LCMV depletion of Tregs makes little difference, either 
because the environment is too proinflammatory or there are mechanisms for 
suppressing Treg induction/function in the context of acute infection (Veiga-
Parga, Sehrawat, and Rouse 2013; Pasare and Medzhitov 2003).  
Blood-borne viruses tend to be chronic, and so are obvious candidates for 
viruses that would wish to manipulate Tregs. Hepatitis C virus (HCV) 
expands Tregs using specific HCV peptides; this leads to a decrease in 
cytotoxic T cell activity, as evidenced by IFNg production (Dietze et al. 2011; 
Li et al. 2008). Interestingly, a subset of chronic HCV-infected patients have 
decreased levels of Treg in their blood, and are more prone to developing 
mixed cryoglobulinaemia, an autoimmune B cell disorder, indicating that Treg 
are also benefitting the host despite being induced (in part) by the virus 
(Boyer et al. 2004). 
 
Hepatitis B virus (HBV) carriers and chronic active HBV patients also display 
high levels of circulating Treg, though whether this is induced by the virus or 
a host immunotolerant response is unclear (Yang et al. 2007). Treg 
suppressive activity correlated with impaired viral clearance and higher 
HBVDNA levels in plasma. This was especially the case for HBV carriers 
who have detectable levels of ‘e’ antigen in their plasma, who are known to 
have higher numbers of Treg in peripheral blood samples. Yang and 
colleagues showed that higher Treg levels correlated with higher levels of 
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TGFb, and hypothesised that this was driving Treg conversion from naïve 
CD4 T cells.  
 
HIV is a lifelong infection, and is known to induce Treg-mediated 
immunosuppression separately to its effects on the CD4 T cell population 
(Dietze et al. 2011); HIV antigens induce Treg proliferation, and subsequently 
T cell responses (cytotoxic and noncytotoxic, including IFNg production) are 
suppressed (Li et al. 2008). HIV can also induce/expand Treg indirectly 
through infection of dendritic cells (DC), promoting an immature DC 
phenotype; immature DCs are more likely to promote naïve CD4 T cells to 
differentiate into Treg (Li et al. 2008). 
 
In the murine Friend Virus infection model Tregs are induced to proliferate by 
the virus in an organ-specific manner (Zelinskyy et al. 2009), and depletion of 
Tregs leads to an increased effector T cell response and long-term 
suppression of viral load, likely due to increased cytotoxicity and IFNg 
production (Li et al. 2008; Dietze et al. 2011).  
 
Finally, HSV appears to decrease T cell migration and activation, acting via 
activated Tregs; this prolongs the duration of infection, but also appeared to 
reduce TH1-mediated corneal damage in a HSV keratitis model (Sehrawat et 
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al. 2008; Li et al. 2008). Hence, Treg responses in viral infections can benefit 
the host by reducing tissue damage, at the expense of prolonging the 
infection. 
 
In addition to the above, some viruses attempt to mimic the 
immunosuppressive effects of Tregs by encoding for homologues of IL-10, 
termed vIL-10; these proteins have been identified by members of the 
Herpesviridae, Alloherpesviridae and Poxviridae families (though not 
Vaccinia virus) (Ouyang et al. 2014). These display variable sequence 
homology to the host IL-10, but have suppressive effects that are beneficial 
to the virus; human CMV, for example, encodes a vIL-10 with little sequence 
homology to human IL-10, but binds with equal efficacy, and induces IL-10 
production in dendritic cells, macrophages and monocytes, and polarises 
macrophages towards an M2 phenotype (Rojas et al. 2017). A latent form of 
vIL-10 also contributes to CMV viral latency. EBV vIL-10, by contrast, 
appears to be important in acute infection only; it is 92% homologous to 
human IL-10, but binds IL-10R with much less affinity; this results in 
signalling which reduces production of proinflammatory cytokines, but not the 
stimulation of thymocytes and mast cells, as well as polarisation of 
macrophages to an M2 phenotype (Rojas et al. 2017; Jog et al. 2018). 
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In contrast to the above, Cowpoxvirus appears to induce the expression of 
host IL-10 (in-vitro work suggests possibly from dendritic cells or 
macrophages), which has an immunosuppressive effect; compared to 
intranasal infection with vaccinia virus, Cowpoxvirus-infected mice had more 
than double the amount of soluble IL-10 in bronchoalveolar lavage samples, 
and fewer numbers of dendritic, CD4 and CD8 T cells in lung samples, and 
IL-10-/- mice were more susceptible to reinfection with Cowpoxvirus (Spesock 
et al. 2011). Hence, viruses can induce Treg-style suppression either by use 
of viral IL-10 homologues or by induction of host IL-10.  
 
4.1.2 Helminths 
Many helminth infections appear to be associated with an expansion of Treg 
populations. This can be because of a response to chronic infection from the 
host, or as part of a deliberate strategy from the parasite to generate an 
immunosuppressive environment. There is evidence of an expansion of Treg 
populations in infections with Heligmosomoides polygyrus, Trichinella 
spiralis, and Schistosoma mansoni, amongst others (McSorley et al. 2008).  
 
Additionally, a number of helminths produce TGFb analogues, which in turn 
expand Treg populations and generate an immunosuppressive environment: 
the trematode Schistosoma mansoni egg antigen induces Treg formation 
from naïve CD4 T cells in a TGFb -dependent manner, which contributes to 
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generating a locally immunosuppressive environment in the host (Zaccone et 
al. 2009).  
 
The human filariasis Brugia malayi promotes Treg proliferation by the 
secretion of a retinoic acid analogue, which synergises with TGFb to induce 
Treg expansion (McSorley et al. 2008), and also secretes a TGFb analogue 
termed TGH-2, which ligates the mammalian TGFb receptor and suppresses 
T cell responses (Gomez-Escobar, Gregory, and Maizels 2000). Treg are 
induced and recruited to the site of B.malayi infection; notably, asymptomatic 
carriers have higher amounts of circulating IL-10 than controls, implying a 
role for Treg in parasite tolerance. Litomosoides sigmodontis also appears to 
produce a secretory product that promotes Treg expansion by stimulating 
TGFb signalling, but this secreted product was not amenable to neutralisation 
by anti-TGFb antibody (Hartmann, Schramm, and Breloer 2015). 
 
Finally, the murine helminth Heligmosomoides polygyrus produces a TGFb 
mimic several times larger than the TGFb molecule itself, called TGM 
(Grainger et al. 2010; Maizels, Smits, and McSorley 2018). 
 
A summary of the different pathways of Treg manipulation by the above 
pathogens is given below:  
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Figure 4-1: Treg manipulation by viruses and helminths. As well as nondefined 
expansion signals, particular methods of Treg expansion are described, including 
viral IL-10 (vIL-10) production, IL-10 induction, immature dendritic cell formation 
postinfection with HIV, and manipulation of the TGFb  pathway through various 
secreted products by helminth worms. HCV, Hepatitis C virus; HIV, Human 
immunodeficiency virus; DC, dendritic cell; TGFb, TGF beta; CMV, cytomegalovirus; 
EBV, Epstein-Barr virus; TGFbR, TGF beta receptor; TGH2, TGFb homologue 2; TGM, 
TGFb mimic; SEA, Schistosomal Egg Antigen; ES product, Excreted-Secreted 
product.   
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4.2 Manipulation of EGFR signalling 
4.2.1 Viruses 
Viruses have been shown to use EGFR signalling to promote their own 
survival (Zheng, Kitazato, and Wang 2014). Many of these have been shown 
to use EGFR as an attachment point to facilitate entry into the cell, but others 
have phenotypic effects beyond this, and still others act through promoting 
the release of EGFR ligands (including pathogen-derived EGF homologues).  
 
Influenza A virus (IAV) haemagglutinin, for example, binds sialic acid 
residues on the cell surface, which leads to lipid clustering and raft formation. 
Co-localisation of EGFR monomers in these rafts (along with other receptors) 
leads to their dimerization and activation, resulting in virion internalisation 
(Eierhoff et al. 2010). Notably, infection of epithelial cells promoted excretion 
of AREG and TNFa, and IAV binding onto the cell surface resulted in 
upregulated ERK, PKC and PI3K signalling. Increased production of the 
mucin MUC5AC was dependent on activation of these pathways (Barbier et 
al. 2012; Eierhoff et al. 2010).  
 
 Epstein-Barr Virus (EBV) protein LMP1, traditionally described as a 
constitutively active TNFa analogue that enables transformation of B cells to 
apoptosis-resistant host cells, also has effects on EGFR signalling; LMP1 
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activates PKCδ, which in turn generates a signalling cascade involving 
STAT3, Bcl-3 and NF-kB to upregulate expression of EGFR on the target 
cell. At the same time, PKCδ directly upregulates ERK signalling, and mildly 
upregulates epiregulin production. Thus, stimulation of EGFR-ERK signalling 
by LMP1 promotes cell survival, and directly contributes to the oncogenicity 
of EBV (Kung, Meckes, and Raab-Traub 2011; Miller, Earp, and Raab-Traub 
1995; Pratt, Zhang, and Sugden 2012).  
 
Respiratory Syncytial Virus (RSV) upregulates EGFR ligands rather than the 
receptor: the virus contains proteins that promote MMP-mediated cleavage of 
membrane-bound AREG to the soluble form; AREG then activates EGFR-
ERK signalling to promote infected cell survival (Monick 2004). 
 
Cytomegalovirus (CMV) envelope glycoprotein B (gB) binds EGFR (and 
possibly also PDGFR), triggering internalisation of the receptor (and so also 
the virus) (Monick 2004; Wang et al. 2003; Soroceanu, Akhavan, and Cobbs 
2008). However, gB activates EGFR differently in different cell types: in 
fibroblasts and trophoblasts the activation signal is more oscillatory, whereas 
in epithelial cells or monocytes the stimulation is more tonic (Chan, Nogalski, 
and Yurochko 2009). This results in different behaviours from the host cell: 
monocytes, for example, differentiate into a mobile, proinflammatory, 
macrophage-like phenotype which aids viral spread to other tissues (Chan, 
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Nogalski, and Yurochko 2009). This is not seen when epithelial cells are 
infected. Therefore, CMV does not just use EGFR as a means of cell entry, 
but also as a way of promoting cross-infection of tissues; chronic CMV 
infection also leads to upregulation of EGFR expression on the host cell 
(Melnick, Deluca, et al. 2013). Furthermore, CMV can induce AREG 
secretion, and subsequent EGFR-ERK signalling, by activating NFkB; 
downstream ERK signalling was in fact essential for pathogenicity in a 
submandibular gland model of disease (Melnick et al. 2011). Treatment of 
CMV-infected cells with EGFR inhibitors results in partial rescue, which can 
be improved to full rescue when combined with aciclovir (Melnick et al. 2011; 
Melnick, Sedghizadeh, et al. 2013), and pre-treatment with EGFR inhibitors 
in-vitro reduces viral entry into cells by 50% (Chan, Nogalski, and Yurochko 
2009).  
 
Rhinovirus appears to manipulate EGFR-ERK signalling to facilitate spread; 
Rhinovirus dsRNA stimulation of TLR3 upregulates the EGFR ligands AREG 
and TGFa, which in turn stimulate EGFR-ERK signalling and mucin 
expression via an autocrine/paracrine loop (Zhu et al. 2009).  
 
Herpes-simplex virus (HSV) also uses EGFR-PI3K-ERK signalling to 
indirectly trigger viral entry; binding of HSV-1 envelope activates EGFR-PI3K-
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ERK, leading to cofilin phosphorylation and F-actin polymerization, lipid raft 
clustering and subsequent virus internalisation (Zheng et al. 2014). 
 
There is some evidence that chronic viral infections also utilise EGFR 
signalling: Hepatitis C virus replication is improved in the presence of bile 
salts; it appears that bile salts promote EGFR-ERK signalling, which leads to 
HCV-infected cells entering S-phase, aiding their survival; furthermore, 
blocking this signalling pathway either at the level of EGFR or ERK inhibited 
HCV replication, and re-established the antiviral effects of IFNa (Patton, 
George, and Chang 2011). 
 
Poxviruses are known to produce soluble EGFR ligands, but this will be 
discussed in chapter 2.  
 
4.2.2 Bacteria 
Bacteria have also evolved strategies to manipulate EGFR signalling, 
typically by increasing the availability of EGFR ligands to the target cell.  
 
Helicobacter pylori is a gram-negative bacteria that infects the gastric 
mucosa. It increases EGFR-ERK signalling by promoting MMP-mediated 
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cleavage of membrane-bound AREG and HBEGF to their free forms, which 
then act in a paracrine/autocrine manner (Romano et al. 1998; Keates et al. 
2001). H.pylori also upregulates EGFR expression in infected cells, 
presumably in order to maximise the cell’s response to EGF ligands (Keates 
et al. 2007; Hardbower et al. 2016). EGFR stimulation has an antiapoptotic 
effect on the host cell, which favours parasite survival but is also implicated in 
the generation of gastric epithelial neoplasms (Yan et al. 2009). 
 
Haemophilus influenzae produces an EGF analogue that directly activates 
EGFR-ERK signalling, which amongst other effects downregulates TLR2 
expression, thereby limiting the innate immune response to the host cell 
(Mikami et al. 2005). 
 
Chlamydia species are obligate intracellular bacteria that have been known 
to exploit EGFR: The Chlamydia pneumoniae invasin protein PMP21 
attaches to EGFR, and modification of EGFR reduces both the amount of 
adhesion and bacterial cell internalisation. Blockade of either EGFR or ERK 
with monoclonal antibodies had no effect on attachment but abrogated 
internalisation, implying that C.pneumoniae uses EGFR as a cell entry 
mechanism (Mölleken, Becker, and Hegemann 2013). Chlamydia 
trachomatis, the causative agent of trachoma, attaches to EGFR when in 
their sporoid infectious form (termed Elementary Bodies), and triggers 
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phosphorylation of tyrosine residue pTyr1173, with downstream signalling via 
PLC-g1, Akt and STAT5 (Patel et al. 2014). 
 
Neisseria species recruit a range of ErbB monomers, and it is noteworthy 
that ErbB2 monomers accumulate underneath the attachment point of 
N.meningitidis, and that HER2 inhibition prevents cell entry (Hoffmann et al. 
2001). Either N.meningitidis is ‘riding in’ on an internalisation signal brought 
about by HER2 dimerisation and autophosphorylation, or it is itself attaching 
to HER2 in a ligand-like fashion. On top of this, N.meningitidis promotes 
HBEGF release from infected cells, which then activate EGFR and ErbB4 
receptors (Slanina et al. 2014). N.gonorrhoea recruits EGFR and ErbB 
monomers underneath its attachment point, and once entered upregulate 
production of HBEGF, AREG and TGFa, which presumably act in a 
paracrine/autocrine manner (Swanson et al. 2011). 
 
Pasteurella multocida secretes a dermatonecrotic toxin responsible for much 
of its virulence. This toxin appears to activate intracellular Gq/11 protein, 
which in turn can intracellularly activate EGFR-ERK signalling, which has a 
mitogenic effect on the host cell (Seo et al. 2000). 
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Pseudomonas aeruginosa is an important human pathogen of the respiratory 
and urinary tract; some strains create biofilms, which help the pathogen ‘hide’ 
inside host mucus in the lungs and provide an optimal environment for the 
bacteria (Kohri et al. 2002). MMP and TACE activity is increased in 
Pseudomonas-infected cells, leading to increased ‘shedding’ of HBEGF and 
TGFa, leading to EGFR-ERK/PI3K signalling, and ultimately delayed 
apoptosis in the target cell (Zhang et al. 2004; Burgel and Nadel 2004). 
Pseudomonas-mediated EGFR-ERK signalling also increases MUC5AC 
production from lung epithelial cells, resulting in mucin hypersecretion (Kohri 
et al. 2002; Burgel and Nadel 2004). 
 
Finally, Salmonella enterica use EGFR as a secondary invasion mechanism: 
Rck binds EGFR tightly and triggers internalisation (Wiedemann et al. 2016). 
Historically, S.typhimurium has also been shown to enter epithelial cells in an 
EGFR-dependent manner (Galán, Pace, and Hayman 1992). 
 
4.2.3 Protozoans (Toxoplasma) 
There is some (limited) evidence for EGFR manipulation by protozoa also: 
Toxoplasma infects epithelial and microglial cells and appears to use 
micronemal proteins (containing EGF domains) to stimulate EGFR-Akt 
signalling. This signalling reduces the chances of lysosome fusion with the 
parasite’s vacuole, thus aiding its survival (Muniz-Feliciano et al. 2013).  
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5 Summary  
Based on the above data, we observed that EGFR and regulatory T cells are 
common targets for exploitation by pathogens. It is also established that 
EGFR is expressed on Treg both at rest and when activated. Whether 
pathogens exploit Treg through direct manipulation of EGFR signalling, or if 
endogenous Amphiregulin affects Treg function in the context of infection, is 
not clear. My thesis will aim to answer these questions using virus and 
helminth models to examine EGFR-Treg interactions in both acute and 
chronic infections.  
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6 Hypothesis 
We hypothesise that regulatory T cells can be activated by EGFR signalling, 
either from endogenous or pathogen-derived ligands, and that this will affect 
Treg function in-vivo.  
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Chapter 2: Vaccinia Virus Growth Factor 
activates regulatory T cells through the 
Epidermal Growth Factor Receptor as a 
method of immune escape 
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7 Abstract 
Poxviruses such as Vaccinia Virus (VACV) encode soluble growth factors 
such as Vaccinia Growth Factor (VGF), which work by activating the 
Epidermal Growth Factor Receptor (EGFR) on epithelial cells to encourage 
cell proliferation, ultimately promoting spread of the virus. Whether there is 
an interaction between VACV-derived VGF and regulatory T cells (Treg) via 
the EGFR has remained unknown. Here we show that VGF enhances the 
suppressive capacity of EGFR-expressing Treg.  
 
Using an in-vitro Treg suppression assay, we show that UV-inactivated virus 
(which cannot replicate, though should still express early genes such as 
VGF) can induce Treg activity, measured as proliferation of cocultured 
effector T cells. Coculturing effector T cells and VACV without Treg had no 
effect on proliferation, and Treg suppressive capacity was not increased 
upon exposure to a strain of VACV which does not express VGF.  
 
Furthermore, mice with Treg deficient for EGFR (Egfrfl/fl x FoxP3cre) were 
more resistant to VACV infection, with less weight loss, more cellular lung 
infiltrate, and lower lung viral titres at D7 postinfection compared to wildtype 
C57BL/6. These findings correlated with a lower level of bioactive TGFb in 
bronchoalveolar lavage supernatant.  
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These data reveal a novel mechanism by which VACV creates a local 
immunosuppressive environment as a method of immune escape, i.e. 
through the VGF-EGFR mediated activation of Treg.  
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Poxviruses are large enveloped DNA viruses, which are characterised by 
linear dsDNA of length 150-300kbp, a cytoplasmic site of DNA replication, 
large size and complex internal structure (Fields et al. 2013).  
 
Poxviruses are divided into those with vertebrate (Chordopoxvirinae) and 
invertebrate hosts (Entomopoxvirinae). Of the former, Orthopoxviruses are 
the commonest studied genus, as it includes several human pathogens of 
importance, including Variola virus (VARV), Vaccinia virus (VACV), Cowpox 
(CPXV) and monkeypox. VARV and molluscum contagiosum virus are 
obligate human pathogens, but the remainder are zoonoses that infect 
humans to varying degrees (Fields et al. 2013). Of the above Variola virus, 
the causative agent of Smallpox, has had the most substantial effect on the 
human population due to its lethality on the general population, children in 
particular (Jacobs et al. 2009; Smith 2011). It was a major burden of disease 
up until its eradication through the use of mass-vaccination programmes 
(using Vaccinia virus and, to a lesser extent, cowpoxvirus), and remains a 
potential agent of bioterrorism, as most of the world’s population are now not 
vaccinated, and therefore susceptible (Jacobs et al. 2009; Smith 2011; Yang 
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et al. 2005; Langhammer et al. 2011; Clark 2006; Vermeer et al. 2007). Of all 
orthopoxviruses the most heavily studied is Vaccinia virus. 
8.2 Vaccinia 
8.2.1 History 
Historically, immunisation against smallpox was conducted by variolation, 
which involved transdermal inoculation with infected smallpox tissue taken 
from pox lesions of patients. Though less lethal than the disease itself (1-2% 
vs 20-30%), it still resulted in significant mortality (Smith 2011). Jenner’s 
development of the procedure of vaccinating individuals with samples of 
cowpox virus was much less lethal, produced only mild symptoms in vaccine 
recipients, and was similarly efficacious. The practice slowly supplanted 
variolation in the 19th century, and smallpox vaccination slowly became a 
standard preventative healthcare measure, eventually resulting in the 
worldwide eradication of endemic smallpox by 1980 (Jacobs et al. 2009; 
Smith 2011).  
 
With the advent of genetic testing, it became clear that smallpox vaccine was 
derived not only of cowpox, but also a separate viral species, which was 
termed Vaccinia virus (VACV). Subsequent gene sequencing has 
demonstrated that these viruses are significantly different from one another 
(Fields et al. 2013; Li et al. 2006). The original host of VACV is not currently 
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known, though it is theorised that Jenner’s original vaccine was derived from 
horsepox lesions rather than cowpox; there is some genetic evidence to 
support this (Smith 2011; Huygelen 1996; Schrick et al. 2017).  
 
The means by which two viruses were used for vaccination against smallpox 
is unclear, but following this discovery purified Vaccinia virus was chosen as 
the agent of choice, due to its low pathogenicity (Jacobs et al. 2009). Due to 
its ubiquity, use as a vaccine and relative safety (compared to Smallpox), 
Vaccina virus has been used for research in preference to other 
orthopoxviruses, and so has become the ‘default’ for study. 
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Figure 8-1 Scanning Electron Micrograph showing mature VACV virions (dark arrows) 
in the cytoplasm of a human carcinoma cell. Light arrow shows a mitochondrion. Note 
internal double-concave structure of capsid. VACV virions rival intracellular 
organelles in size, and are the largest viruses discovered. Licensed from ZE 
Vladimirovich, distributed under CC-ASA 4.0 license, available here: 
https://commons.wikimedia.org/wiki/File:Vaccinia_virus_particles.jpg  
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VACV virions are noted for their complex internal structure, and individual 
particles approach 300nm in size (Fields et al. 2013). DNA is arranged 
linearly alongside several proteins in a nucleosome, contained within a 
protein core (the double-concave internal structure seen in Figure 8-1).  
 
Internal structure is revealed in Figure 8-2. Outside the virus core are 2 
proteinaceous lateral bodies, which contain a variety of viral factors which 
modify host cell function and optimise the intracellular environment for virus 
replication (Bidgood and Mercer 2015). Surrounding this is a lipid bilayer 
which contains both host and virus-derived proteins (Moss 2016; Chung et al. 
2006; Yoder et al. 2006; Resch et al. 2007). The origin of this is not quite 
settled on, but likely derives from the endoplasmic reticulum (Moss 2015). On 
the surface of this are a variety of viral proteins (Moss 2016), as well as host 
proteins acquired along with the membrane (Resch et al. 2007). 
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Figure 8-2 Internal structure of Vaccinia virus. Image from (Fields et al. 2013) 
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There are several types of virion: Intracellular mature virions (IMV) are as 
described above: They make up 98-99% of virus particles, remain in the cell, 
are released on cell lysis and are responsible for host-host transmission 
(Moss 2012; Smith, Vanderplasschen, and Law 2002; Harrison et al. 2016). 
The remaining 1-2% are cell-associated enveloped virions (CEV) or 
extracellular enveloped virions (EEV). These acquire 2 more membranes, 
likely by manipulation of retrograde cellular transport pathways (Harrison et 
al. 2016; Pechenick Jowers et al. 2015), to become intracellular enveloped 
virions (IEV). This appears to be determined by just a few viral proteins (A27, 
B5 & F13), as deleting these genes stops the formation of IEVs (Bidgood and 
Mercer 2015). The outer membranes appear to also integrate a number of 
host proteins that have an effect on the virus’ virulence; purified EEVs 
express human proteins CD45, CD55, CD59, CD71, CD81 and MHC-I, and 
are resistant to complement-mediated lysis (as compared to EEVs generated 
& purified from a rat cell line which does not contain human CD55/CD59) 
(Vanderplasschen et al. 1998). Travelling to the cell surface, virions exit the 
cell by fusion of the outer (3rd) membrane with the plasma membrane (Smith, 
Vanderplasschen, and Law 2002). If the virion remains attached to the cell 
surface these are termed CEVs, and are implicated for local cell-cell 
transmission via the formation of actin ‘tails’ (Smith, Vanderplasschen, and 
Law 2002; Harrison et al. 2016). CEVs that leave the cell surface are termed 
Extracellular Enveloped Viruses (EEVs) and spread in a paracrine fashion to 
other cells. EEVs are hypothesised to be the main method for in-host 
dissemination, as a) antibodies targeting EEV are more effective than those 
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targeting IMV; b) EEV are relatively resistant to the effects of antibodies and 
complement, and c) VACV strains that do not produce EEVs cannot replicate 
in-vivo (Roberts and Smith 2008). 
 
Once a CEV/EEV encounters an uninfected cell an interaction with 
glycosaminoglycans disrupts the outer (2nd) membrane to ‘reveal’ the inner 
(Moss 2012). The virion enters the cell either by direct fusion with the cell 
membrane or an acidified endosome following macropinocytosis (NB: there is 
some evidence that Western Reserve strain of VACV favours endosomal 
entry (Townsley et al. 2006)). There are 4 attachment proteins, which bind 
chondroitin, heparan and laminin on the cell surface, and an Entry Fusion 
Complex composed of 11 fusion proteins, that facilitate the viral core’s entry 
into the cytoplasm (Moss 2016).  
 
8.2.3 Replication 
Once inside the host cell, the viral core travels to a juxtanuclear position 
within the cytoplasm. From here it will ‘breach’, releasing viral DNA into the 
cytoplasm; this area will become the “virus factory”. At this point early genes 
are transcribed using pre-existing viral factors and produce proteins essential 
for DNA/RNA replication and synthesis of intermediate genes. Intermediate 
and late genes occur post-replication and are transcribed from progeny DNA 
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(Fields et al. 2013; Moss 2013). Intermediate genes facilitate late gene 
expression, DNA packaging and the construction of core-associated proteins; 
late genes encode transcription factors (that will be packaged into new 
virions) and mature virion membrane proteins, including attachment proteins 
and the Entry Fusion Complex.  
 
Following viral assembly, naked virions are enveloped in one membrane (the 
source of which is controversial, but likely derived from modified endoplasmic 
reticulum) to become intracellular mature virions (Moss 2015; Smith, 
Vanderplasschen, and Law 2002).  
 
8.3 Vaccinia Growth Factor 
Of the roughly 200 genes encoded by VACV, almost half are not involved in 
viral replication, and are immunomodulatory (Clark 2006). Many of these 
target the immune system, aiming to thwart the host response to infection. 
These include various inhibitors of complement (Vaccinia Complement 
Protein), Interferon (various), NF- kB (various), and numerous cytokines such 
as IL-1, 18, TNF, chemokines and the apoptotic Bcl-2 proteins (Fields et al. 
2013; Smith et al. 2013; Becker 2003). For an excellent review of these, see 
(Smith et al. 2013). 
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Vaccinia Growth Factor is a small, soluble, heavily glycosylated protein 
composed of 77 amino acids that has considerable sequence homology to 
Epidermal Growth Factor (EGF) and Transforming Growth Factor alpha 
(TGFa) (Stroobant et al. 1985; Kim et al. 1995), as well as 95% sequence 
homology to the closely related Smallpox Growth Factor (SPGF) (Kim et al. 
2004). It is the product of the C11R gene, which is contained in the inverted 
terminal repeat sequences at either end of the VACV genome (though some 
strains contain only one copy) (Buller et al. 1988; Kim et al. 2004; Lai and 
Pogo 1989; Martin, Harris, and Shisler 2012). An early gene product, it is 
secreted 2-8 hours postinfection (Beerli et al. 2019), after viral uncoating but 
before viral replication occurs (Buller et al. 1988). 
 
Early reports stated that VGF was found in the medium of VACV-infected 
cells in-vitro, leading to the assumption that VGF was excreted from infected 
cells (Stroobant et al. 1985; Kim et al. 1995). Further characterisation of this 
has revealed that after secretion to the cell surface, a 25kDa precursor form 
is cleaved by ADAM10 to a 22kDa soluble form that then acts in a 
paracrine/autocrine manner (Beerli et al. 2019; Chang et al. 1988). This is 
remarkably similar to the extracellular cleavage processing undergone by 
native ErbB ligands, particularly EGF and betacellulin, which are also cleaved 
by ADAM10 (Singh and Coffey 2014; Singh, Carpenter, and Coffey 2016). 
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In contrast to other poxviral growth factors, but not SPGF, VGF binds 
preferentially to EGFR, and at a much lower affinity than EGF (Tzahar et al. 
1998; Kim et al. 2004). Following this, downstream signalling occurs via the 
MAP kinase pathways MEK/ERK, as well as PLC-g1 and NF- kB. These 
signals result in host cell proliferation, survival and motility, even before viral 
replication has occurred in the host cell (Postigo et al. 2009; Beerli et al. 
2019; Buller et al. 1988; Kim et al. 1995; Andrade et al. 2004; Prenzel 2001). 
Additionally, VGF has been shown to synergise with other signals, such as 
the viral antiapoptotic protein F1L, and promote expression of the mitotic 
gene egr-1 in host cells (Postigo et al. 2009; Andrade et al. 2004). 
Proliferation can even be induced in uninfected cells, demonstrating that VGF 
acts in a paracrine as well as autocrine manner (Buller et al. 1988). Deletion 
of VGF results in reduced downstream activation (particularly ERK), resulting 
in suboptimal viral proliferation, virulence, and replication in-vitro (particularly 
resting cells) and in-vivo (Buller et al. 1988; Andrade et al. 2004; Lai and 
Pogo 1989). 
 
At one time EGFR was proposed as a receptor used for entry into host cells, 
but this has been rejected as further research clarified the structure and 
function of the proteins comprising the attachment proteins and entry fusion 
complex (Lai and Pogo 1989; Moss 2016; Townsley et al. 2006; Marsh and 
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Eppstein 1987). Poxviruses can also enter EGFR-deplete cell lines in-vitro, 
though it should be noted that growth factor-mediated activation of EGFR 
seems to be required for optimal poxvirus cell entry (Buller et al. 1988; 
Stroobant et al. 1985). 
 
Upon exposure to VGF several behavioural changes are evident in epithelial 
cells: cell proliferation and motility are increased, resulting in rapid growth 
and dehiscence from the epithelial basement membrane, leading to the 
characteristic ‘pox’ lesions (Beerli et al. 2019; Buller et al. 1988; Tzahar et al. 
1998). in-vitro viral plaques are smaller in VGF-deplete mutants, likely due to 
reduced motility of infected cells (Beerli et al. 2019; Yang et al. 2005). 
 
8.3.1 Vaccinia virus blocks intracellular cytoplasmic DNA 
sensing to improve survival 
Previous work has shown that poxviruses manipulate ErbB receptors to 
facilitate their own survival: cytosolic DNA is a pathogen-associated signal, 
recognised by several intracellular pattern-recognition receptors, including 
DNA-dependent Protein Kinase (DNA-PK) and cyclic GMP-AMP Synthase 
(cGAS). Following recognition of this DNA, these proteins trigger the 
phosphorylation of STING (STimulator of IFN Gene), an endoplasmic 
reticulum-bound receptor that in turn activates Tank-Binding Kinase 1 
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(TBK1). TBK1 phosphorylates Interferon Regulatory Factor 3 (IRF3), which 
controls the expression of Type 1 interferons; these are deleterious to the 
virus (Dai et al. 2014; Ferguson et al. 2012; Liu et al. 2015).  
 
Several viruses produce proteins which interfere with STING function, 
including CMV, Human Papillomavirus and Dengue (Liu et al. 2015). 
Poxviruses do this also: VACV protein C16 inhibits IRF3 activation by 
disrupting dsDNA recognition by DNA-PK (Peters et al. 2013). It has also 
been observed that expression of type 1 interferons is reduced in VACV-
infected cells, together with reduced levels of STING phosphorylation and 
dimerization (which are prerequisites for downstream signalling). This signal 
is also seen even in the related poxviruses Cowpoxvirus and Ectromelia 
virus, as well as a C16-deficient strain of VACV, (Liu et al. 2015; Georgana et 
al. 2018). Cells infected with Modified Vaccinia Ankara (MVA, a highly 
attenuated strain of VACV which cannot replicate in human cells), on the 
other hand, exhibit activated IRF3, STING dimerization and phosphorylation. 
The mechanism by which non-MVA VACV produces this effect is unclear.  
 
Recent work has demonstrated that HER2/neu, a member of the ErbB 
receptor family, can inhibit STING function: Wu et al. found that HER2 bound 
to STING, leading to its dissociation from TBK1 and inhibition of downstream 
expression of type 1 interferons (Wu et al. 2019). The mechanism by which 
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HER is internalised and co-locates with STING is unknown, but is triggered 
after detection of DNA by cGAS. This effect was not seen with other ErbB 
receptor family members, including EGFR, and in fact EGF-EGFR signalling 
somewhat potentiated DNA sensing. However, this mild EGFR-induced 
activation of cGAS–STING signalling is similar in the absence or presence of 
HER2, suggesting that ErbB1-ErbB2 heterodimers do not participate in 
STING regulation.  Nonetheless, it is clear that ErbB receptor family 
members are involved in the regulation of the immune response to infection, 
and that blockade of ErbB signalling has the potential to aid or diminish 
pathogen survival. 
 
8.3.2 Blockade of EGFR signalling in Vaccinia infection 
Due to ongoing concerns regarding the use of Variola virus as a bioterrorism 
agent, research into antiviral treatments for poxviruses has been ongoing. 
Mass-vaccination of the human population is no longer viable for reasons of 
cost, and not an option for certain risk groups (e.g. immunocompromised, 
though vaccination with the attenuated strain Modified Vaccinia Ankara 
[MVA] could be used in these groups (Stittelaar et al. 2001)) as the vaccine 
consists of live virus (Kim et al. 2004; Langhammer et al. 2011). The only 
current treatment option is Cidofovir, which a) the virus can become resistant 
to, b) is only available intravenously, and c) causes renal impairment to a 
substantial minority of patients, requiring it to be coadministered with 
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probenecid and IV fluid to reduce nephrotoxicity (UpToDate 2019). As a 
Smallpox outbreak is a low probability but high impact event, this has driven 
further research into possible ways of counteracting poxvirus infections.  
 
Deletion of VGF reduces virulence, and this has been used to ‘temporise’ 
VACV to enable its use as a vector for antitumour immunotherapy (McCart et 
al. 2001; Foy et al. 2016), and wound healing (Norton, Peplinski, and Tsung 
1996). VGF-deplete VACV can be several orders of magnitude less 
infectious than wildtype counterparts (Lai and Pogo 1989). Therefore, some 
researchers have attempted to examine the effects of EGFR inhibition on 
viral proliferation and survival, in-vitro and in-vivo.  
 
Poxviral EGFR ligands, such as SPGF, have been studied in-vitro using 
small molecule tyrosine kinase inhibitors (TKI) of EGFR: Yang and 
colleagues used the TKI CI-1033 (Canertinib, now discontinued) to examine 
the effects of EGFR blockade on SPGF-mediated cell activity in-vitro. They 
found reduced EGFR internalisation, downstream phosphorylation and 
cellular DNA synthesis (Yang et al. 2005). Secondary viral spreading in-vitro 
(on BSC-40 cells) was also inhibited. Following on from this, Langhammer et 
al. observed paracrine ‘priming’ of Hep2 cells in-vitro for subsequent infection 
when exposed to Vaccinia virus, and activation of EGFR-ERK signalling in 
infected cells. Application of the EGFR TKI Gefitinib abrogated this effect, 
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reducing EGFR phosphorylation at Tyrosine residue 1068, which led to 
reduced ERK signalling, smaller plaque size and number, and loss of the 
‘priming’ effect in uninfected cells surrounding the plaque. 
 
In-vivo, results have been more mixed. In 2004 Kim et al. examined the 
effects of SPGF-neutralising antibodies on VACV in an in-vivo pneumonitis 
model. They found the SPGF neutralising antibody 13E8 failed to reduce 
mortality or lung viral titre at D7 when used in isolation. However, when 
combined with the IMV-neutralising antibody anti-L1R there was enhanced 
clearance of the virus in association with augmented CD8 T cell responses 
(seen in spleen and lung) (Kim et al. 2004).  
 
Following on from the above, Yang and colleagues examined the effects of 
the EGFR-blocking antibody CI-1033 (Canertinib) in an in-vivo VACV 
pneumonitis model; here, CI-1033 improved survival if given from the day of 
infection (out to D14), and increased T cell antiviral cytokine production. 
However, if given from D2 onwards, there was no effect on mortality unless 
again the drug was combined with anti-L1R antibody. Administration of CI-
1033 from D2 onwards did, however, result in lower lung viral titres and 
stronger CD8 T cell responses (Yang et al. 2005). 
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Thus, it would appear that tyrosine kinase inhibitors of EGFR are effective in-
vivo when compared to antibodies against poxviral growth factors, though 
overall the results are more muted when compared to in-vitro data.  
 
8.3.3 Vaccinia and regulatory T cells.  
Expansion and activation of regulatory T cells is a noted feature of multiple 
chronic viral infections: Hepatitis B and C are both associated with Treg 
expansion and resultant immunosuppression (though with HBV there is 
conflicting evidence) (Dietze et al. 2011; S. Li et al. 2008; Veiga-Parga, 
Sehrawat, and Rouse 2013), and HIV is also associated with Treg-mediated 
immunosuppression (Dietze et al. 2011). As these are chronic infections, it is 
perhaps not surprising that these pathogens have mechanisms to suppress 
the immune response long-term.  
 
The evidence for acute viral pathogens manipulating Treg to their own benefit 
is less clear. Treg depletion using anti-CD25 antibody improves CD8 T cell 
response to VACV infection (Amoah et al. 2013), and it has been previously 
noted that Treg tend to expand by D5-6 postinfection, particularly if the virus 
burden is high. Additionally, in a MVA-OVA viral vector study of CD8 T cell 
response, Treg led to decreased expression of T cell costimulatory molecules 
CD80 & CD86 on dendritic cells, leading to a decrease in endogenous IL-2 
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production by antigen-specific T cells and a reduction in CD8 T cell 
expansion, which could be overridden by application of IL-2/antibody 
complexes (Kastenmuller et al. 2011). As CD8 T cells are the main method of 
control for Vaccinia infection, manipulating Treg to control CD8 T cells would 
be beneficial to the virus.  
 
Bearing this in mind, it is possible that there is an indirect interaction between 
poxviruses and regulatory T cells, perhaps using their soluble EGFR-
stimulating factors.  
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9 Hypothesis 
We hypothesised that poxvirus-derived EGFR ligands could activate 
regulatory T cells via the EGFR, creating a locally immunosuppressive 
environment to aid virus survival.  
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10 Methods 
10.1 Western Blot 
10.1.1 Protocol 
HaCaT cells (RRID: CVCL_0038) (Boukamp et al. 1988) were cultured in 
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% Fetal 
Calf Serum (FCS; South America, Gibco), 1% L-glutamine, 1% 
penicillin/streptomycin and 5 x 10-5M 2-mercaptoethanol (hereafter termed 
“complete IMDM”) and incubated at 37 oC in a humidified atmosphere at 5% 
CO2. 
 
For experiments, HaCaT cells were seeded into 24-well plates at a 
concentration of 4 x 105 cells/well and incubated (as above) in serum-free 
media overnight (i.e. otherwise “complete” IMDM without FCS). The 
following day wells were exposed to serum-free IMDM only (negative 
control), or serum-free IMDM containing either HBEGF 10ng/ml (positive 
control) or the virus of interest for 20 minutes. Following this, cells were 
placed on ice and lysed with 72µl NP40 lysis buffer (50 mM Tris-HCl [pH 7.6], 
150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.05% Sodium Azide) supplemented 
with protease inhibitors (Phenylmethylsulfonyl fluoride 200mM) and 
phosphatase inhibitors (Sodium fluoride 100mM and Sodium Orthovanadate 
100mM) for 10 minutes. Lysates were then mixed with 18µl 5x Laemmli 
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loading buffer (60 mM Tris-Cl pH 6.8, 2% sodium dodecyl sulphate [SDS], 
10% glycerol, 5% 2-mercaptoethanol, 0.01% bromophenol blue) for a total 
volume of 90µl, of which 35-40µl samples were resolved onto a 10% SDS-
PAGE gel.  
SDS-PAGE gel was made up according to the following recipe (Available 
from Cytographica (Cytographica.com 2007). Recipe is per gel):  
 10% Separating Gel: 6% Stacking Gel: 
Distilled H2O 3.2ml 2.6ml 
30% Acrylamide 2.67ml 1ml 
1.5 M Tris HCl pH 8.8 2ml  
0.5 M Tris HCl pH 6.8  1.25ml 
10% SDS 80µl 50µl 
10% Ammonium 
Persulphate (APS) 80µl 50µl 
Tetramethylethylenediamine 
(TEMED) 8µl 5µl 
Total Volume (ml) 8 5 
 
TEMED and APS were not added the mixture initially. 1ml of the 10% mixture 
was taken, and 8µl of both APS and TEMED added; this was then injected 
into the gel mold and left to polymerise at the bottom, so as to form a ‘plug’ 
and prevent leaks. 10 minutes following this, the remaining 7ml of 10% gel 
mixture had proportional amounts of TEMED and APS added, and then was 
poured in on top of the ‘plug’. Following this, a 2-3mm film of isopropanol was 
gently pipetted on top of the gel, so that the boundary between the 
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separating and stacking gel was smooth and even. This mixture was left for 
15-30 minutes to set.  
 
Following this, the isopropanol was tipped out of the gel mould, and the 
remainder blotted with Whatman paper (#CHR1128, SLS). After this, the 6% 
stacking gel was finished with APS and TEMED, and the mixture added on 
top of the separating gel. The combs were instantly inserted, and any excess 
gel mixture blotted off. The gels were left to set for another 15-30 minutes. 
Gels were normally made up just prior to experimentation; if made up in 
advance, they were stored in Tris-Buffered Saline with 0.1% Tween-20 
(TBST; see 10.1.2 for recipe) at 4oC for no more than 72h.  
 
For examination of phosphorylated (pTyr1068) and total EGFR, samples 
were resolved onto the above gel for 12-24h at 70v continuously. Following 
this, the gels were removed from the tank apparatus and washed in Wet 
Tank Transfer Buffer (see 10.1.2 for recipe), as were 4 Whatman sheets cut 
to the size of the gel, and a nitrocellulose 0.45µm membrane (#1620155, Bio-
Rad). These were loaded into a wet transfer tank lattice in the following 
order: Absorbent sponge – 2 Whatman sheets – Gel – Nitrocellulose 
membrane – 2 Whatman sheets – Sponge. This lattice was then set to 
transfer overnight at 25v. Effective transfer was confirmed in the morning 
using Ponceau staining (Proteomics-grade, #K793-500, Amresco). Following 
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this, membranes were blocked using 5% Blocking Buffer (see 10.1.2) for 2-4 
hours, then washed with TBST (for 15 minutes x3) and incubated with 
primary antibodies against phospho-EGFR Tyr1068 (#2234, Cell Signalling 
Technologies) or total EGFR (#2232, Cell Signalling Technologies) at 
concentrations of 1:10,000 in 10ml 5% Blocking buffer + Sodium Azide 
0.02% overnight at 4oC. After further washing in TBST (15 minutes x3) 
membranes were incubated with Goat anti-rabbit Horseradish Peroxidase-
conjugated secondary IgG antibody (1:2000, #P0217, DakoCytomation) in 
10ml 5% Blocking buffer for 1h at room temperature. Membranes were then 
exposed to ECL reagents (see 3.1.2) and visualised using a MI-5 automatic 
X-ray film processor (Medical Index GMBH) at various timepoints. 
 
10.1.2 Recipes 
TBST: Tris-buffered Saline with Tween 0.1% (Tris 20mM, NaCl 150mM), 
made up as follows: 
• Water   900ml 
• Tris 10x Buffer  100ml 
• Tween20  1ml 
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Tris 10x Buffer 
• 24 g Tris base (formula weight: 121.1g) 
• 88 g NaCl (formula weight: 58.4g) 
• Dissolve in 900mL distilled water 
• Adjust pH to 7.6 with HCl. 
• Add distilled water to a final volume of 1 L 
 
Wet Tank Transfer Buffer 
• Water     700ml 
• Methanol 100%    200ml 
• Wet Tank 10x Transfer Buffer  100ml:  
o Water  800ml 
o Glycine  144g 
o Tris HCl  30.3g 
o Total volume adjusted with water to 1L.  
 
Blocking Buffer 5%:  
• TBST: 100ml 
• Bovine Serum Albumin (#A3294-100G, Sigma): 5g 
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ECL Reagent Recipes:  
• ECL buffer (Tris pH 8.2, 100mM) 10ml (5ml in two tubes) 
• Luminol     50µl (added to tube 1) 
• Coumaric acid    22µl (added to tube 1) 
• Hydrogen peroxide 30%   6µl (added to tube 2) 
Both tubes were kept in the dark and mixed just prior to exposing the 
membrane.  
 
10.1.3 Optimisation  
10.1.3.1 Cell lines: A431 vs HaCaT  
Vaccinia virus has been shown to favour epithelial cells, and poxvirus derived 
growth factors are implicated in the formation of the classic ‘pox’ lesion seen 
in smallpox (Tzahar et al. 1998). A431 cells (RRID: CVCL_0037), a human 
epidermoid carcinoma cell line, were initially chosen for experimentation as 
they are a cell line which readily expressed the EGFR, and used for many 
studies of EGFR-related intracellular signalling (Graness et al. 2000). 
However, when used for Western Blot there was a high background 
phosphorylation that made interpretation of pEGFR signalling impossible. 
Incubation for 24h in serum-free media prior to exposure to experimental 
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conditions did not decrease the size of background signal. Reculturing A431 
cells from fresh aliquots also did not remedy the issue.  
 
It was then decided to change over to HaCaT cells, an immortalized 
nontumorigenic human epidermal cell line (Boukamp et al. 1988). The 
HaCaT cell line mimics many of the properties of normal epidermal 
keratinocytes, expresses the EGFR, and can differentiate under appropriate 
experimental conditions (Boukamp et al. 1988; Koivisto et al. 2006). Previous 
in-vitro experiments with Vaccinia virus have also been conducted using 
HaCaT cells (Martin, Harris, and Shisler 2012). Western blots were 
subsequently conducted with HaCaT cells alone. 
  
10.1.3.2 Wet vs Semi-dry transfer methods 
Initial Western blots were performed with an Owl HEP series Hep-1 Semidry 
Electroblotter (Thermo fisher). However, we determined that electroblotting of 
a large protein such as EGFR (molecular weight 175kDa for both 
phosphorylated and total products) was inefficient, and often failed to transfer 
the larger proteins from the gel to the blotting paper. After moving to Wet tank 
transfer, it was determined that a slow overnight transfer at low voltage gave 
best results.  
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10.1.3.3 Membrane: Nitrocellulose vs PVDF 
Both nitrocellulose and PVDF membranes were tried; PVDF membranes 
were first soaked in methanol 100% for 2-5 minutes before soaking in Wet 
Tank Transfer Buffer and proceeding as normal. No improvement in protein 
transfer was seen when assessed by Ponceau staining, and success with 
PVDF membranes was variable between experiments. Therefore, 
nitrocellulose membranes were used for all experiments shown.  
 
10.2 Regulatory T Cell Suppression Assay 
10.2.1 Protocol 
Regulatory T cell suppression assays were carried out as previously 
described (Collison and Vignali 2011). Mouse splenocytes were obtained by 
homogenisation in a cell strainer (70µm nylon, #352350, Corning), using 
either end of the plunger of a 5ml syringe, and collected in a 50ml Falcon 
tube. Following this, cells were suspended in 10ml complete IMDM and left 
for 2-5 minutes, before transferring the suspension (but not any clumps that 
had aggregated at the base of the tube) to a new 15ml Falcon tube and 
centrifuged (300g, 10min, 4oC). The supernatant was discarded, and the 
cells resuspended by use of a plate shaker for 3-5 seconds. Cells were then 
resuspended in MACS buffer (see 10.2.2), using 450µl per spleen (estimate 
of 16-20 million CD4 T cells per spleen (Miltenyi Biotec 2018)), and to this 
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50µl CD4 (L3T3) MACS beads (#130-049-201, Miltenyi Biotec) were added. 
After incubation for 15 minutes at room temperature, the suspension was 
washed in 15ml MACS buffer, centrifuged (300g, 5min, 4oC; NB all further 
centrifugation steps use these settings unless otherwise stated), the 
supernatant discarded, and the cells resuspended in 1.5ml MACS buffer. 
Following this, the cell suspension was then pipetted into a LS MACS column 
(#130-042-401, Miltenyi Biotec) held in a magnetic cell separator. The 
suspension was added 0.5ml at a time, separated by 60 seconds. Following 
this the column was washed with 3ml MACS buffer 3x, leaving 2-5 minutes 
between washes.  
 
CD4- cells were collected if needed for subsequent experimentation in a 50ml 
Falcon, centrifuged and resuspended in 5ml Red Cell Lysis buffer (#R7757, 
Sigma-Aldrich). After 5 minutes at room temperature the solution was 
quenched with 35ml complete IMDM, and then centrifuged again. Following 
resuspension in 5ml complete IMDM, the CD4- cells were taken to a GSR C1 
irradiator and exposed to 40 Grays radiation. After this Cells were sieved with 
a 70µm cell strainer to remove dead cells, centrifuged, resuspended in 
complete IMDM and kept for use as antigen-presenting “feeder” cells.  
 
CD4+ cells were collected after the LS MACS column was removed from the 
magnetic cell separator, placed over a 15ml Falcon tube and washed with 
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3ml MACS buffer x4, the last 3ml pushed through the column with the 
plunger provided. CD4+ cells were centrifuged and resuspended in 400µl 
complete IMDM containing antibodies for CD4 (AF700, #100536, 
BioLegend), CD25 (APC, #553101, BD Pharmingen) and CD45rb (PE, 
#557192, BD Pharmingen) at concentration 1:100; samples were stored for 
20 minutes at 4oC. Following this, cells were washed (centrifuged and 
resuspended) in 1ml FACS buffer (see 10.2.2) two times, and then sorted by 
flow cytometry into Treg (defined as CD4+ CD25HI CD45RBLO) and naïve 
effector T cells (defined as CD4+ CD25LO CD45RBHI), to a purity of ³98% on 
a BD FACS Aria flow cytometer.  
 
After sorting, Effector T cells were then washed in phosphate-buffered saline 
(PBS) twice, then centrifuged again and resuspended in 1ml PBS containing 
0.5µM CellTrace Violet (CTV, #C34557, Invitrogen), and left at room 
temperature for 5-10 minutes. After this 5x original staining volume of 
complete IMDM was added, and the sample incubated for 5 minutes; this 
was repeated once more. The stained effector T cells were then centrifuged 
and resuspended in complete IMDM and incubated for a further 10 minutes 
at room temperature, before recounting with a haematocytometer. Cell loss 
varied between 30-95% depending on experimental conditions.  
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Treg and CTV-labelled effector Ts were recombined in a ratio 1:4 – 1:8 
together with 2 x 105 CD4- APC feeder cells per well in a 96-well plate, along 
with 2 µg/ml stimulatory anti-CD3 antibody (#553058, BD Pharmingen) in a 
final volume of 200µl complete IMDM per well. Wells were exposed in 
multiples of 3 or 4 to various experimental conditions and then incubated for 
72h. On the day of analysis samples were centrifuged and resuspended in 
PBS, before being centrifuged again. Live/dead stain (Zombie Aqua Fixable 
Viability Kit, #423101, Biolegend, diluted 1:500 in PBS) was added 
(20µl/well), and the cells left at room temperature for 10 minutes. Following 
this, cells were surface stained using CD4 (AF700, #100536, BioLegend) and 
Fc block (1mg/ml) in FACS buffer, each at a concentration of 1:200 (50µl per 
well) and left for 30 minutes at 4oC. Samples were then washed with 100µl 
FACS buffer, centrifuged and resuspended in 100µl FACS buffer for 
acquisition by flow cytometry.  
 
Proliferation of effector T cells was determined by measurement of CellTrace 
Violet dilution using a FACSCanto (BD Biosciences), after gating for singlets, 
live cells and staining for CD4. Proliferation was assessed using division 
index (average number of divisions of the whole cell population including 
undivided cells) and percentage divided (of the cell population of interest). 
FACS data was acquired using Flowjo v9.9.6, (Flowjo LLC). A typical gating 
strategy is shown below (Figure 10-1).  
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Figure 10-1 Gating strategy used to assess CVT dilution in effector T cells after 
incubation with Treg. Cells shown have not divided.  
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10.2.2 Recipes 
MACS Buffer:  
• PBS (pH 7.2)  500ml 
• BSA    0.5% (2.5g per 500ml PBS) 
• EDTA   2mM 
 
FACS Buffer: 
• PBS (pH 7.2)  500ml 
• FCS    2% (10ml per 500ml PBS) 
 
10.2.3 Optimisation 
10.2.3.1 Cell Proliferation Readout: Tritiated Thymidine vs 
CellTrace Violet 
Initially these experiments were performed with tritiated thymidine (3H-TdR) 
according to the protocol in Appendix A. However, despite variations in 
experimental conditions and time of acquisition, proliferation rates (as 
measured by radioactivity of samples) remained low. 3H-TdR has been 
replaced by other proliferation agents and dilution dyes, as they are poorly 
suited to analysis of specific cell populations, and only inform you about the 
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total amount of radioactivity in the sample, from which proliferative activity is 
inferred. Additionally, cell proliferation can only be analysed at one endpoint 
with 3H-TdR, as opposed to multiple timepoints with cell proliferation dyes 
(Lim, Berger, and Su 2016; Tario et al. 2018). CellTrace Violet is a reliable 
intracellular amine dye, which labels cells brightly and evenly, distributes 
equally to daughter cells, and as minimal transfer to nonlabelled cells in 
culture (Filby et al. 2015). 
 
Additionally, there were logistical issues that triggered a change to CTV as 
the proliferative agent of choice:  
 
1. Moving to CTV eliminated the need to work with radioactivity completely, 
which eliminated the chance of contamination of the laboratory 
environment.  
2. After working with 3H-TdR appropriate monitoring of the laboratory 
environment involved swabbing specific areas for analysis in a beta-
radiation-counter (Beckmann Coulter LS6500). These machines were 
located in another building on the King’s Buildings (KB) site, in near-
constant use and regularly broke down.  
3. The Scintillation reader used for data acquisition was located on another 
campus (Queen’s Medical Research Institute, Edinburgh), which 
necessitated transfer of radioactive samples by bicycle.  
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4. The Scintillation reader (1450 Microbeta Trilux, Wallac) was several 
decades old, required a 3.5” floppy disk to load its operating system 
when turned on, and inconsistently linked up to an attached Windows 95 
computer on which the analysis software resided. As far as I could tell, 
no quality control was performed on the machine in the time I was using 
it. Data readout was in the form of a table (showing scintillation counts 
per minute per well), which could be exported as a CSV file, but only onto 
a 3.5” floppy disk. A Floppy drive-to-USB-A extension was available, but 
difficult to locate within the institute and did not sync to my computer (a 
2015 MacBook, via a USB-C to USB-A dongle). To get around these 
limitations, a photo was taken of the table and the results manually 
transcribed into Excel. Despite visual verification of correct transcription 
twice (once by row, once by column) the possibility of human error using 
this method cannot be excluded.  
5. Following the above, the Scintillation reader was cleaned, and swabs 
taken for beta-radiation counting. For the first year of experiments a beta-
counter was only available on the KB site, requiring a bicycle ride with 
the samples to KB (and a repeat of this if the beta-counters showed 
contamination, as the machine would have to be recleaned and 
swabbed).  
For the above reasons, CTV incorporation was selected as the proliferation 
readout of choice.  
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10.2.3.2 Optimisation of CellTrace Violet assay 
Initial conditions for CTV proliferation assay were related to those for 3H-TdR 
assay. To verify that these were the correct conditions to use, a titration 
assay for various experimental conditions were carried out as follows:  
 
1. Time of Analysis: Wells were incubated for 72, 96 or 120 hours, and 
analysis of Division Index, Proliferation Index and Percent Divided was 
Performed. Cells incubated for 72h consistently showed significantly 
increased cell proliferation than later timepoints (Figure 14-2).  
2. Amount of feeder APC cells: The 72h samples were analysed for 
proliferation depending on the amount of feeder cells per well (1 or 2 x 
105). 2 x 105 feeder cells per well produced consistently more cell 
proliferation than 1 x 105 at all concentrations of anti-CD3 antibody 
(Figure 14-3).  
3. Concentration of stimulatory anti-CD3 antibody per well: the 72h samples 
with 2 x 105 feeder cells per well were analysed for optimal concentration 
of stimulatory anti-CD3 antibody (Figure 14-4). Concentrations ranged 
from 0.1µg  per well (0.5µg/ml final concentration) to 0.8 µg/well (4µg/ml 
final concentration). ANOVA showed statistical significance for all 
analysis methods, and subsequent t-testing with correction for multiple 
comparisons was carried out, comparing 0.4µg/well (final concentration 
2µg/ml) with others. 0.4µg/well caused variably superior proliferation 
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relative to the 0.1 and 0.2µg/well samples, and an increase above this 
did not reliably improve proliferation metrics.  
 
Therefore, the optimal experimental conditions for CTV proliferation assays 
were selected as follows: Incubation time 72h, feeder cells 2 x 105/well, CD3 
antibody final concentration 2µg/ml. This is similar to the experimental 
conditions that were used for the 3H-TdR assays.  
 
10.3 In-vivo Vaccinia Pneumonitis Model 
10.3.1 Animal strains used 
C57BL/6J mice (Egfrfl/fl, Egfrfl/fl x FoxP3cre and Egfrfl/fl x CD4cre, Hereafter 
referred to as WT, EGFRDFOXP3 and EGFRDCD4 respectively), and RAG1-/- 
mice (JAX stock #002216) were bred and maintained at the University of 
Edinburgh in specific pathogen free conditions. All mice were housed in 
individually ventilated cages at the Ashworth 3 Level 5 animal unit, King’s 
Buildings, University of Edinburgh, until required for experiments, when they 
were transferred either to the Ann Walker Unit or March Building, King’s 
Buildings Campus, University of Edinburgh. Both sexes were used for 
experiments, but all mice in one experiment were of the same sex. Mice were 
6-8-weeks old at the start of the experiment. Cages were randomly assigned 
to a treatment group; mice were not randomised within the cages 
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themselves, but cages could contain mice of mixed genotype or all one 
genotype. Experiments were performed in accordance with the United 
Kingdom Animals (Scientific Procedures) Act of 1986, and all researchers 
were accredited by the UK Home Office. Dispensation to carry out animal 
research at The University of Edinburgh was approved by the University of 
Edinburgh Animal Welfare and Ethical Review Body and granted by the UK 
government Home Office; all research was carried under the project licence 
70/8470. All in-vivo experiments were conducted with groups of 5-7 animals 
unless otherwise stated, and all results shown are representative of at least 2 
experiments.  
 
10.3.2 Infection Protocol 
C57BL/6J mice aged 6-12 weeks were transferred to the experimental site a 
minimum of 24h prior to start of experiment (and usually 48h), to acclimatise 
to a new environment.  
 
On the day of inoculation an aliquot of VACV stock (1 x 106 Plaque-Forming 
Units [PFU] in 100µl Tris-HCl 1mM pH 8.8), either VACVWR or VACVDVGF, 
was removed from a -20oC freezer and thawed in a water sonicator for 30 
seconds, then diluted 1:2 with Tris-HCl 1mM pH 8.8 to form a final 
concentration of 5 x 105 PFU/100µl. 20µl was then used to inoculate mice, 
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giving an inoculation dosage of 1 x 105 PFU per mouse. If higher amounts of 
VACV needed to be given (i.e. in dose-titration experiments as detailed 
below) then undiluted virus stock was used. The maximum volume inoculated 
was 50µl.  
 
Mice were place in a fume hood, then anaesthetised with isofluorane gas in a 
chamber until their respiratory rate had started to slow. They were then 
intranasally inoculated with 1 x 105 PFU VACV (in 20µl Tris-HCl pH 8.8) 
using a 200µl pipette tip, over 3-5 seconds. Mice were then returned to their 
cage and observed until awake and mobile.  
 
Mice were observed and weighed daily, and culling occurred early if any 
mouse in the group exhibited weight loss of greater than 20% of baseline 
(weight at Day 0, at time of inoculation). In all but one experiment the same 
set of scales was used for all measurements; where the same set of scales 
was not available for one experiment, standardised weights were used to 
determine a conversion factor between the 2 sets of scales to allow for 
comparison of weights taken with the different scales.  
 
Animals were sacrificed at 7 days (or earlier if indicated), as has been used 
in previous experiments (Buller et al. 1988; Kim et al. 2004; Yang et al. 
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2005). For studies where Bronchoalveolar Lavage Fluid (BALF) samples 
were not taken, mice were culled using CO2, then death confirmed with 
terminal exsanguination. For studies where BALF was required, culling using 
CO2 produced a marked decrease in viable cells, so the primary method was 
changed to overdose of anaesthesia using Pentobarbital 150µl/mouse 
(Euthatal 200mg/ml, Merial), and death confirmed by dislocation of the neck.  
 
Following this mice were dissected, and the spleen removed and placed in 
2ml complete IMDM (see 10.1.1) on ice. BALF was obtained by cannulating 
the trachea with a needle (19g, 1.1 x 40mm), and washing with BAL wash 
(see 10.3.7), 0.5ml, slowly 4 times, with the aim of recovering at least 1500µl 
in an Eppendorf tube, which was then placed on ice. Following this, the lungs 
were removed and placed in a 7ml Bijou tube and frozen. For some 
experiments the thoracic lymph nodes (paramediastinal and parathymic) 
were also removed and placed in 2ml complete IMDM on ice.  
 
10.3.2.1 Administration of PC61 antibody 
For experiments where we wished to deplete regulatory T cells, the anti-
CD25 antibody PC61 was used as previously described (Setiady, Coccia, 
and Park 2010). Briefly, mice were injected with 200μg PC61 antibody (kind 
donation from Dr Van Kooten, Utrecht University, Netherlands) at 3 and 1 
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days prior to inoculation with VACV; as viral infections typically only ran for 7 
days, this should have been enough to deplete Treg for the duration of the 
experiment.  
 
10.3.2.2 Administration of Gefitinib 
Gefitinib was administered by daily gavage, at a dose of 200mg/kg dissolved 
first in DMSO (5mg Gefitinib per 50µl DMSO), then Corn oil (450µl per 50µl 
DMSO). This fixed volume was administered to mice in both groups (placebo 
group: 50µl DMSO & 450µl corn oil only) daily from D0 to D7.  
 
10.3.3 Plaque Assay 
BSC-1 cells (RRID: CVCL_0607) were incubated (37oC, 5% CO2) in 150ml 
flasks in 20ml IMDM supplemented with 10% FCS, 1% L-glutamine, 1% 
penicillin/streptomycin but WITHOUT 2-mercaptoethanol. Flasks were split 
into new flasks 2-3 times weekly, when reaching 80% confluence. New flasks 
were seeded with 1 x 106 cells at a time.  
 
The day before a plaque assay was to be performed, BSC-1 cells were 
harvested from a flask and resuspended in IMDM as above, then seeded 
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onto 6-well tissue culture plates at a concentration of 5 x 105 cells/well in 
IMDM supplemented with 2.5% FCS, 1% L-glutamine and 1% 
penicillin/streptomycin (hereafter termed “virus IMDM”) and incubated 
overnight. Plaque assay was performed the following day.  
 
Lung samples were suspended in liquid nitrogen for a few seconds, then 
crushed with a mortar and pestle and resuspended in 3ml Tris-HCl 1mM, pH 
8.8 and transferred to a 15ml Falcon tube. After incubation on ice for 15 
minutes, samples were transferred to a Dounce Homogeniser. Samples were 
homogenised by raising and lowering the piston slowly 25 times, then 
transferred into fresh 15ml Falcon tubes. These were centrifuged (750g, 
5min, 4oC) and the supernatant discarded. The cell pellet was resuspended 
in 1ml Tris-HCl 1mM, pH 8.8, and either frozen until required or used 
immediately (no difference was observed in the yield of the same sample 
used immediately or within 1 week of preparation).  
 
On the day of initiating the assay, lung samples were thawed in a water bath 
sonicator for 1 minute, then a 10-1 solution prepared using 100µl lung sample 
and 900µl virus IMDM. Subsequent tenfold dilutions were made up from 
0.5ml of the previous dilution mixed with 4.5ml virus IMDM (e.g. the 10-2 
solution was made up of 0.5ml 10-1 solution and 4.5ml virus IMDM). Once 
tenfold serial dilutions from were made up to 10-8, these were seeded in 
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triplicate on the 6-well plates containing confluent BSC-1 cells, then 
incubated for 1-2h. After this, wells were aspirated and washed with 2ml 
PBS, then overlaid with 2ml virus IMDM, and incubated for 36h.  
 
At the time of analysis, media was removed from the wells and the cells 
stained with 2ml Crystal Violet solution (see 10.3.7). Wells were incubated for 
15-30 minutes at room temperature, then washed in water. Plaques were 
then counted by eye, and an average for each dilution step produced (NB: As 
no agar or carboxymethylcellulose was used to limit viral spread via the 
medium, small ‘daughter’ plaques were ignored, and only large plaques were 
counted; additionally, wells with <20 or >200 plaques/well were not counted 
unless they were the only wells available for analysis). After a plaque count 
for the dilution step was established, a PFU value for the whole mouse lung 
was calculated.  
 
10.3.4 Flow Cytometric sample preparation and analysis 
Single cell suspensions for each cell sample were prepared as follows:  
• Spleen: samples were forced through a 70µm cell strainer, followed by 
treatment with 5ml Red Cell Lysis buffer (#R7757, Sigma-Aldrich) for 5 
minutes, quenching in 25ml complete IMDM, centrifuged (5m, 300g, 
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4oC) and resuspended in 5ml complete IMDM. 0.5ml of this 
suspension (i.e. 10% of the spleen sample) was used for analysis.  
• BALF: samples were centrifuged (5m, 300g, 4oC) and resuspended in 
1ml complete IMDM; the supernatant was used for TGFβ 
quantification as per section 10.3.5. The whole sample was used for 
analysis.  
• Thoracic Lymph Node: Samples were homogenised as per spleen, 
then resuspended in 1ml complete IMDM. The whole sample was 
used for analysis. 
 
Samples were incubated for 6h in 200µl complete IMDM with the VACV 
immunodominant epitope B8R20-27 (concentration 2 µg/ml) and monensin 
10µM (Invitrogen), or monensin alone, in FACS tubes. Following this, 
samples were washed in 3ml FACS buffer, centrifuged (5m, 300g, 4oC) and 
resuspended in 150µl PBS, then transferred to a 96-well plate.  
 
Following centrifugation, wells were viability stained (10-20µl/well, see 10.3.7 
for details) and left at room temperature for 10 minutes. Following this, 
samples were stained with antibodies for surface markers (as detailed in 
10.3.7) and incubated at 4oC for 30 minutes. For intracellular staining, 
samples were fixed with 2% paraformaldehyde (in PBS) 100µl/well at room 
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temperature for 20 minutes, then permeabilised with 0.5% Saponin at room 
temperature for 20 minutes. Samples were then stained with intracellular 
antibodies for 30 minutes at 4oC. Following fixation with 2% 
paraformaldehyde (100µl/well, room temperature, 20 minutes), Samples 
were analysed by flow cytometry using a BD FACSCanto flow cytometer and 
FlowJo software v10.3 (FlowJo LLC).  
 
Cells were identified after gating for singlets and live cells, and CD45 
positivity for surface staining (for intracellular cytokine staining lymphocytes 
were gated by typical appearance on forward and side scatter). Cell types 
were gated as follows:  
• CD4 T cells:    Lymphocyte (FSc x SSc) – CD3+ – CD4+ 
• CD8 T cells:    Lymphocyte (FSc x SSc) – CD3+ – CD4- 
• B cells:    Lymphocyte (FSc x SSc) – CD19+ 
• Alveolar Macrophages:  CD11c + / SigF + / F4/80 + 
• Neutrophils:   Ly6G + 
• Eosinophils:    CD11c - / SigF + 
• Monocytes:    Ly6G - / Ly6C + 
Intracellular cytokine staining samples were gated as follows: Singlets – Live 
– Lymphocyte gate on FSc x SSc – CD4 or CD8, followed by intracellular 
cytokine staining.  
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10.3.5 Measurement of Bioactive TGFβ 
This analysis was conducted by a colleague, Dr Rucha Modak. Bioactive 
TGFβ from BALF supernatant was quantified using Transgenic Mink Lung 
Epithelial Cells (TMLCs). TMLCs express luciferase downstream of the PAI-1 
promoter activated by TGFβ; thus, luciferase expression correlates with 
bioactive TGFβ (Abe et al. 1994). The assay was carried out as described in 
Wipff et al. (Wipff et al. 2007). In brief, TMLCs were plated at a density of 2.5 
x 104 cells/well in a 96 well tissue culture plate and allowed to adhere for 3 
hours. Subsequently, well supernatant was replaced with either 100μl of 
TGF-β standards (20 – 2000 pg/ml), prepared in cell culture medium 
containing 2% FCS or BALF supernatant. Plates were then incubated for 20 
hours. Following this the TMLCs were washed twice with PBS and lysed 
using Firefly Lysis Buffer (#99923, Biotium). The lysate was read for 
luciferase activity using luciferase assay buffer (See 10.3.7) to which 750 μM 
ATP (Abcam) and 800 μM D-luciferin sodium salt (Cayman Chemicals) were 
freshly added prior to data acquisition on a Varioskan Flash spectral 
scanning reader (Thermo Scientific). Data was represented as pg/ml of TGFβ 
in the respective sample. 
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10.3.6 Statistics 
Student’s t-test was performed with GraphPad Prism 7 (GraphPad Software 
Inc.), with corrections for multiple comparisons where appropriate (See figure 
legends for details). Significant results were reported as follows: * = p<0.05, 
** = p<0.01, *** = p<0.001.  
 
10.3.7 Recipes 
Tris-HCl 1mM pH 8.8 
• Water:  500ml 
• Tris base:  605mg 
• Hydrochloric acid (Add base to Tris & 400ml water and mix; 
adjust pH to 8.8; add remaining water).  
 
BAL wash:  
• PBS   40ml 
• BSA 1%  10ml (BSA 5% stock) 
• EDTA 0.01mM 1µl (EDTA 0.5M stock) 
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Crystal Violet Solution:  
• Water      160ml 
• Methanol     30ml 
• Crystal Violet (Sigma HT901-8F0Z)  10ml 
 
FACS Buffer (PBS with 2% FCS):  
• PBS   500ml 
• Fetal Calf Serum 10ml 
 
Viability Stains:  
• Intracellular cytokine stains:  
o Zombie Aqua Fixable Viability Kit, #423101, Biolegend 
o Dilute 1:500 in PBS, use 20µl per well. 
• Surface stain for cellular characterisation in BALF samples:  
o Live/Dead Fixable Blue Dead Cell Stain Kit, L34961, Invitrogen 
o Dilute 1:300 in PBS, use 10µl per well.  
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Antibodies used: 
Antigen Fluorophore Product code Manufacturer 
CD3 BV421 100228 Biolegend 
CD4 AF700 100536 Biolegend 
CD4 FITC 11-0041-82 eBioscience 
CD8 PCP/Cy5.5 100734 Biolegend 
CD8 PE 553032 BD Pharmingen 
CD11b BV711 101241 Biolegend 
CD11c BV605 117334 Biolegend 
CD19 APC 17-0193-82 eBioscience 
CD45.2 PCP 108926 Biolegend 
F4/80 Pe-Cy7 25-4801-82 eBioscience 
IFNg FITC 505806 Biolegend 
Ly6c AF700 128024 Biolegend 
Ly6g APC-Cy7 127624 Biolegend 
SiglecF PE 552126 BD Pharmingen 
 
Surface Staining Recipe (per sample):  
• FACS buffer:   50µl 
• Fc Block (1mg/ml)  0.25µl  
• Surface Antibody 1:200 0.25µl  
 
Intracellular Cytokine Staining Recipe (per sample):  
• 0.5% Saponin (in FACS buffer):  50µl 
• Intracellular antibody 1:200 0.25µl 
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Luciferase Assay Buffer: 
Reagent Final concentration 
Tricine 20mM (pH7.8) 
Mg(CO3)4 . Mg(OH)2 .5H2O 1.07 mM 
MgSO4 2.67 mM 
EDTA 100 μM 
DTT 33.3 mM 
 
10.4 Vaccinia Virus Culture & UV inactivation  
10.4.1 Viral culture & Purification 
The following is a modification from a previously published protocol (Cotter et 
al. 2015). In order to prepare cultures of Vaccinia virus (both VACVWR and 
VACVDVGF) a culture of RK-13 cells (RRID: CVCL_3155) was prepared. Six 
150cm2 flasks of 80-90% fully confluent RK13 cells was infected with the 
relevant virus with an MoI of 0.1. Flasks were checked daily for signs of 
cytopathic effect. After ~48h, cells were freed into the media using a cell 
scraper, and the flask contents collected into a 50ml tube. Samples were 
centrifuged (1500g, 10mins, 4oC) and the supernatant discarded. Samples 
were resuspended in 50ml PBS, and centrifuged again (150g, 5mins, 4oC). 
The supernatant was again discarded; at this point the pellet could be frozen 
overnight if required.  
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The pellets were resuspended in 10ml Tris-HCl (1mM, pH 8.8) and kept on 
ice for 15 minutes. Samples were then transferred to a Dounce homogeniser 
and homogenised as per 10.3.3, transferred to a 15ml tube and centrifuged 
(750g, 5min, 4oC). The supernatant was removed from these tubes, leaving 
the pellet.  
 
A 36% sucrose cushion was prepared using 100ml Tris-HCl 1mM pH 8.8, to 
which 36g Sucrose crystals were added and the solutions magnetically 
stirred for 5-10mins at room temperature.  9ml of this solution was added to a 
polypropylene centrifuge tube (#331374, Beckman Coulter), and the 
supernatant gently poured on top; the remainder of the tube was filled with 
Tris-HCl 1mM pH 8.8. These tubes were then ultracentrifuged (SW28 Rotor, 
13,500rpm, 80mins, 4oC). Following this, the supernatant was aspirated and 
discarded, and the pellet resuspended in 1ml Tris-HCl 1mM pH8.8. This 1ml 
preparation was aliquoted, and a plaque assay conducted to determine PFU 
concentration (see 10.3.3 for details). Using the results of these plaque 
assay, samples were standardised to a concentration of 1 x 106 PFU/100µl. 
 
10.4.2 UV Inactivation 
In order to UV inactivate vaccinia virus, a sample of 1 x 106 PFU virus in 1ml 
Tris-HCl 1mM pH 8.8 was added to one well of a 6-well plate. This was kept 
Control of regulatory T cell activity by endogenous and pathogen-derived EGFR ligands 
Chapter 2: VGF activates Treg via EGFR  
 92 
on ice, placed in a CL-1000 UV crosslinker (UVP) and exposed for 15 
minutes. Following this, a plaque assay was performed on a part of the 
sample to confirm UV inactivation. If necessary this process was repeated 
until UV inactivation was confirmed.  
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11 Results 
11.1 Early EGFR phosphorylation occurs when cells 
are exposed to Vaccinia virus in-vitro 
It has been noted that EEVs (which are the main means of cell-cell spread in-
vivo) appear to enter EGFR-rich cells better in the absence of EGFR 
blockade, implying that cell entry is partially dependent on EGFR signalling 
(possibly as macropinocytosis is upregulated by EGFR activation) (Mercer et 
al. 2010). Interestingly, Western Reserve VACV appears to favour entry into 
cells via macropinocytosis (Townsley et al. 2006). Data connecting VGF with 
the function of Extracellular Enveloped Virions (EEV) has been published 
previously: Yang and colleagues found that infection with VACV deficient in 
VGF led to smaller plaque size and comet formation on BSC40 cells (Yang et 
al. 2005). 
 
To determine if there was a detectable difference in EGFR phosphorylation, 
we exposed HaCaT cells to two strains of UV-inactivated virus: Western 
Reserve (VACVWR), and a strain with the VGF gene deleted (VACV DVGF). We 
exposed HaCaT cells to 1 x 104 PFU of each strain for 20 minutes; This is 
not enough time for virus replication or early gene expression (or barely for 
cell entry), but enough time for any VGF present in the virus sample to 
Control of regulatory T cell activity by endogenous and pathogen-derived EGFR ligands 
Chapter 2: VGF activates Treg via EGFR  
 94 
stimulate EGFR. We also exposed cells to HBEGF as a positive control, or 
vehicle only (FCS-deplete IMDM; negative control).  
 
Here we saw early phosphorylation induced by HBEGF, a well-known high-
affinity ligand for EGFR, but also with VACVWR (but not VACVDVGF; see Figure 
11-1). The degree of phosphorylation was roughly the same between HBEGF 
and VACVWR. This indicates that our purified UV-inactivated virus stock 
contains enough VGF that significant EGFR phosphorylation can occur. 
Whether this VGF is embedded in the viral envelope or present as a soluble 
protein in the purified virus stock is unclear.  
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Figure 11-1: HaCaT cell phosphorylation upon exposure to Vaccinia virus. Top row 
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11.2 Regulatory T cell Suppression Assay 
Regulatory T cell suppressive capacity can be determined by use of an in-
vitro assay (Collison and Vignali 2011), in which Treg are cocultured with 
naïve effector CD4 T cells (Teff), and the degree of proliferation of Teff 
quantified at a later timepoint.  
 
To compare the suppressive capacity of regulatory T cells exposed to UV-
inactivated virus (won’t replicate, but should express early genes such as the 
VGF gene C11R) (Tsung et al. 1996), we took CD4+ mouse splenocytes from 
WT or EGFRDCD4 mice and sorted them into Treg (CD25HI CD45RBLO) and 
Teff (CD45RBHI, CD25LO). CD4- cells were kept, irradiated (40 Grays) to 
prevent them replicating, and used as APC ‘feeder’ cells: these provide CD28 
co-stimulation to the T cells, which along with a stimulatory anti-CD3 antibody 
promotes T cell activation and proliferation. We incubated EGFRDCD4 feeder 
cells and Teff for 72h, in the presence of a stimulatory CD3 antibody, with 
either WT or EGFRDCD4 Tregs, with or without UV-inactivated VACV, 1,000–
10,000 PFU/well. These virions, as stated above, do not replicate, but have 
the ability to infect any live cell in the well to which they were added. As the 
total Multiplicity of Infection was low (0.016-0.16) and would not result in full 
infection of the cell, we did not think this would affect the outcome of our 
experiment. Additionally, it has previously been shown that non-inactivated 
VACV prefer to infect non-T cell leukocytes (Sánchez-Puig et al. 2004); given 
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this, we it is likely that the UV-inactivated VACV preferentially infected the 
CD4- APCs rather than the T cells directly.  
 
11.2.1 Determination of ideal VACV inoculation dosage.  
Early-phase experimentation using tritiated thymidine as our readout had 
demonstrated that doses of 1000 PFU/well or above provided optimal 
suppression of Teff proliferation (Figure 14-1). In fact, for wells containing WT 
Treg, incubation with 100 or 1000 PFU/well VACVWR was enough to generate 
enhanced (statistically significant) suppression when compared to wells 
incubated with VACVDVGF, which was not seen when Treg from EGFRDCD4 
mice were used.  
 
However, as tritiated thymidine incorporation is a flawed readout, as well as 
the logistical issues outlined above (in 10.2.3.1), we decided to move to 
CellTrace Violet (CTV) as our readout for future experiments, and to try and 
quantify the nature of the proliferation signal we were seeing in more detail.  
 
As no suppression signal was seen with VACVDVGF, it was not used further.  
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11.2.2 Naïve Effector T cells are not affected by EGFR 
ligand signalling 
One explanation for the suppressive effect seen so far is that VGF being 
released by virus-infected cells is acting directly on the Teff cells via EGFR. 
Our group has previously shown that naïve effector T cells are not directly 
affected by EGFR ligands such as Amphiregulin (Zaiss et al. 2013), and was 
also shown to be the case specifically with soluble VGF protein alone 
(Abdullah et al. 1989). Additionally, previous work has shown that VACV 
preferentially infects non-T cell leukocytes; an MoI of 10 resulted in a 2% 
infection rate (Sánchez-Puig et al. 2004). Wishing to corroborate this, we 
incubated Teff WITHOUT Treg, but with VACVWR (please note figure 14-1, 
where no suppression signal was seen with VACVDVGF). Here we saw no 
difference between Teff incubated with VACVWR or vehicle alone (Figure 11-
2). We concluded that any suppression signal seen was not operating directly 
through Teff. In any case, as EGFR signals tend to cause proliferation or 
differentiation (Zaiss et al. 2015), it is unlikely that a direct VGF-EGFR 
interaction on Teff would suppress Teff proliferation. To summarise, even if 
some Teff are infected with UV-inactivated VACV, proliferation of these cells 
is not significantly affected.  
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Figure 11-2 Proliferation of Teff exposed to 1000 PFUs UV-inactivated Vaccinia virus 
(VACVWR) in the absence of Treg; 72h incubation, proliferation measured by CTV 
dilution.   
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11.2.3 Regulatory T cells and Vaccinia Virus 
We then examined the effect of regulatory T cells in the presence or absence 
of VACVWR. We found that in the presence of WT Tregs, EGFR–deficient 
naïve T cells proliferated less in the presence of VACVWR. By contrast, when 
the Treg were deficient in EGFR (EGFRDCD4) this effect was not observed 
(Figure 11-3).  
 
From this we concluded that effector T cell proliferation was being 
suppressed in the presence of VACV; that this interaction was occurring 
indirectly via the co-cultured Treg; and that the EGFR was essential for this 
interaction to occur, as deletion of EGFR on Treg abolished this effect. We 
suggest that this is a VGF-EGFR signal, as in our preliminary work with 
tritiated thymidine and VACVDVGF, no such signal was seen.  
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Figure 11-3 Proliferation of Teff in presence of WT or EGFR-deficient Treg after 
incubation with 1000 PFUs UV-inactivated VACVWR or vehicle only. 1:8 Treg:Teff ratio. 
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11.3 Vaccinia Pneumonitis Model 
11.3.1 Vaccinia virus dose optimisation 
To test the physiological relevance of our in-vitro data, we decided to move to 
an in-vivo model of infection, namely pneumonitis brought about by intranasal 
inoculation of VACV. This has been used by multiple researchers, using 
inoculation doses ranging between 5 x 103 – 5 x 107 PFU per mouse (Yang 
et al. 2005; Tscharke et al. 2005; Stack et al. 2005; Becker 2003). Using 
wildtype (WT) C57BL/6 mice, we started with a VACV inoculation dose of 1 x 
104 PFU/mouse and compared weight loss to an uninfected control group. 
We observed no statistically significant weight loss (compared to baseline 
weight at inoculation) in any of the 3 groups (Figure 11-4). 
 
We therefore decided to carry out a dose-titration, to determine the optimal 
inoculation dosage for our particular mice (It has been shown that C57BL/6 
mice of different origins respond to VACV infection differently (Tscharke et al. 
2005)).  
 
Control of regulatory T cell activity by endogenous and pathogen-derived EGFR ligands 
Chapter 2: VGF activates Treg via EGFR  
 103 
 
Figure 11-4 Weight change from baseline in WT mice inoculated with 1 x 104 PFU 
VACVWR, VACVDVGF, or mock infection, over 7 days.  
 
 
Figure 11-5 Effects of increased VACVWR inoculation dosages on WT C57BL/6 mice; 
weight change and lung viral titre. Animals were culled at 7 days. Statistical analyses 
are t-tests with correction for multiple comparisons where appropriate.  
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Figure 11-5 shows the effects of 4 x 104 and 1 x 105 inoculations on weight 
loss and lung viral titre. Weight loss compared to mock-infected mice was 
similar between the 2 infected groups, but the higher inoculation dose 
produced an increase in lung viral titre that was trending to significance 
(p=0.15). It was therefore selected as the inoculation dose to be used in 
subsequent experiments, unless otherwise stated. 
 
11.3.2 Comparison of virulence  
After establishing an inoculation dose of VACVWR that would produce 
symptoms in wildtype C57BL/6 mice, we proceeded to compare the virulence 
of our 2 virus strains. We infected RAG1-/- C57BL/6, as they do not develop 
mature B and T cells, and would not be able to mount a substantial immune 
response to VACV infection (Mombaerts et al. 1992). We inoculated mice 
with 1 x 105 PFU of either VACVWR or VACVDVGF and monitored the animals 
over 7 days. Results are shown in figure 11-6.  
 
VACVWR was significantly more virulent, producing pronounced weight loss 
when compared to VACVDVGF-infected mice that was statistically significant at 
4 days. Additionally, lung viral titres between the two groups were 
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significantly different, with VACVDVGF infection producing a lung viral titre 
mean of ~1400 PFU (as opposed to ~240,000 PFU with VACVWR).  
 
Based on these data, we decided to repeat infection with VACVDVGF, using 
different inoculation doses, in order to find a dose which provided a similar 
level of pathology to 1 x 105 PFU of VACVWR.  
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Figure 11-6 Weight loss and lung viral titre of RAG1-/- mice infected with VACVWR or 
VACVDVGF. Animals were harvested for lung sample acquisition at 7 days. Analyses are 
t-tests with correction for multiple comparison where appropriate. Note lung viral titre 
is on logarithmic scale.  
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Figure 11-7 Effects of different VACVDVGF inoculation doses on weight loss and lung 
viral titre in RAG1-/- mice. A) Weight loss of all groups out to end of experiment. B) 
End of experiment weights and lung viral titre (4 and 5 x 105 inoculation doses only). 
Analyses are t-tests with correction for multiple comparison where appropriate. 
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Figure 11-7 shows that weight loss was more gradual with VACVDVGF as 
compared to VACVWR, with mice only approaching 20% weight loss 2 weeks 
after infection with 4 – 5 x 105 PFU. Lung viral titres were obtained from 
these 2 groups; Even an inoculation dose of 5 x 105 PFU only produced a 
mean lung viral titre of 17,500 PFU – significantly less than those seen with 
inoculations of 1 x 105 VACVWR. The difference in weight loss at D13 
between the 4 x 105 and 5 x 105 groups doesn’t correlate with the lung viral 
titre results but can be explained by a) natural variation in susceptibility to the 
virus, b) different starting weights in each group, and c) variation in actual 
administered dose during inoculation.   
 
From this we concluded that comparisons could not be made between 
animals of similar genotype infected with different strains of VACV, as these 
strains have markedly different virulence in-vivo, as had been previously 
described by other researchers (Buller et al. 1988; Lai and Pogo 1989).  
 
11.3.3 Vaccinia Growth Factor promotes in-vivo 
immunosuppression via EGFR-mediated activation of 
regulatory T cells 
Having established that our viral strains could not be directly compared, we 
conducted experiments using 2 strains of C57BL/6 mice: Egfrfl/fl (should be 
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phenotypically normal, hence hereafter termed WT), and Egfrfl/fl x FoxP3cre 
(hereafter termed EGFRDFOXP3), a strain in which EGFR is missing from 
FOXP3-expressing cells (i.e. Regulatory T cells).  
 
We started by infecting each strain with 1 x 105 PFU of VACVWR intranasally. 
By D3 there was a significant difference in weight loss between the groups, 
and this divergence continued until harvest at D7 (Figure 11-8 A). At the 
same time, we repeated this experiment with an inoculation dose of 1 x 105 
PFU VACVDVGF and saw no weight loss (Figure 11-8 B). We did not expect to 
see weight loss due to our previous findings with RAG-/- mice (see 11.3.2).  
 
We then went on to analyse lung viral titre and found that EGFRDFOXP3 mice 
were significantly more resistant to VACVWR infection, with VACV titres two 
orders of magnitude below that of WT mice. When this was repeated with 
VACVDVGF, the effect was not seen, and both mouse strains were equally 
resistant to the virus, producing lung viral titres similar to that of EGFRDFOXP3 
mice infected with VACVWR.  
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Figure 11-8 Weight loss and lung viral titre in mice infected with 100k PFUs of A) 
VACVWR and B) VACVDVGF virus; culled and lungs harvested at 6 days postinfection. 
Results representative of at least 2 experiments; statistical analyses t-test with 
correction for multiple comparison where appropriate. 
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From this we concluded that deletion of EGFR on Tregs confers resistance to 
VACV infection (Figure 11-8 A), and that this improved resistance is not seen 
in an infection using a VGF-deplete form of Vaccinia (Figure 11-8 B). This 
implies a VGF-EGFR interaction on regulatory T cells in this Vaccinia 
pneumonitis model.  
 
11.3.4 EGFRDFOXP3 mice infected with VACVWR have more 
cellular BALF, predominantly alveolar macrophages.  
We then proceeded to analyse the cellular components of bronchoalveolar 
lavage fluid (BALF) from mice infected with VACVWR virus. BALF of 
EGFRDFOXP3 mice contained more leukocytes than WT (p=0.04), and this 
seemed to be driven by an overall increase in cellularity, with no one cell 
population significantly increased in EGFRDFOXP3 mice compared to WT 
(Figure 11-9 A–D).  
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Figure 11-9 Cellular component of BAL fluid in mice infected with 100k PFUs VACVWR 
and culled at 7 days postinfection. A) Total cellularity, B) Alveolar macrophages, C) 
other granulocytes, D) lymphocytes. For details of cell gating strategy see 10.3.4. 
Statistical analyses are t-tests. 
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11.3.5 CD8 T cell responses 
CD8 T cells are a major means of clearing viral infections in general, and 
poxviruses in particular (Goulding et al. 2012; van Helden et al. 2012; Salek-
Ardakani et al. 2008; Goulding et al. 2014). We therefore took single cell 
preparations and stimulated them either with anti-CD3 or the synthetic VACV 
peptide B8R20-27 (Tscharke et al. 2005), in the presence of monensin, to 
stimulate production of intracellular cytokines. Staining was then carried out 
for CD4/CD8 and cytokine staining for CD8 IFNg.  
 
Figure 11-10 shows the effects of VACVWR infection on CD8 T cell responses 
in BALF, thoracic lymph node (tLN, as defined in methods) and spleen in WT 
and EGFRDFOXP3 mice. Across multiple experiments we saw either no change 
or a decrease in CD8 T cells present in BALF, and a trend to decreased 
responsiveness to restimulation with VACV peptide B8R20-27. Spleen-derived 
CD8 T cells from EGFRDFOXP3 mice consistently were less responsive to 
restimulation across multiple experiments. The reason for this is unclear but 
may relate to improved early viral clearance in EGFRDFOXP3 animals. These 
data do not support the hypothesis that an increase in activated CD8 T cell 
function is the cause of increased viral clearance in EGFRDFOXP3 mice.  
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Figure 11-11 shows similar data in mice infected with VACVDVGF. We again 
saw reductions in CD8 T cells in BALF, but not tLN or spleen, and a 
nonsignificant reduction in CD8 T cell responsiveness to restimulation. This 
signal was now completely absent in spleen samples.  
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Figure 11-10 CD8 T cell responses in BAL fluid, thoracic LN and spleen of WT and 
EGFRDFOXP3 mice infected with 100k PFUs VACVWR, and culled at 7 days. See 10.3.4 for 
gating parameters. Statistical analyses are t-tests, figure representative of ³2 
experiments. 
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Figure 11-11 CD8 T cell responses in BAL fluid, thoracic LN and spleen of WT and 
EGFRDFOXP3 mice infected with 100k PFUs VACVDVGF, and culled at 7 days. See 10.3.4 
for gating parameters. Statistical analyses are t-tests, figure representative of ³2 
experiments. 
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In summary, EGFRDFOXP3 mice infected with either strain of VACV 
demonstrate a reduction in BALF CD8 T cells, with a nonsignificant decrease 
in CD8 T cell activation. Spleen-derived CD8 T cells from EGFRDFOXP3 mice 
infected with VACVWR show reduced CD8 T cell expression of IFNg. These 
data do not support the hypothesis that CD8 T cells are the main method of 
VACV clearance in these experiments.  
 
11.3.6 TGFb is reduced in the BAL Fluid of EGFRDFOXP3 
mice infected with VACVWR 
As stated above, TGFb is an essential component of Treg function, and has 
been linked to the function of EGFR ligands such as Amphiregulin (Budhu et 
al. 2017; Minutti et al. 2019). Therefore, we decided to analyse the BALF 
supernatant for bioactive TGFb. Here we found that the BALF of EGFRDFOXP3 
mice had significantly less TGFb than WT mice (Figure 11-12).  
 
This suggests that Tregs of EGFRDFOXP3 mice are producing less TGFb than 
their WT counterparts, and therefore are less inhibitory. This would explain 
the general increase in cellularity seen in BALF of EGFRDFOXP3 mice.  
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Figure 11-12 Bioactive TGFb in mice infected with 100k PFUs VACVWR and culled at 7 
days. BAL fluid was then harvested, and the cell-free supernatant analysed for 
bioactive TGFb  by means of a luciferase assay. Statistical analysis: t-test 
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11.3.7 Effects of Treg depletion 
Treg depletion has previously been shown to be effective in reactivating 
antiviral T cells and reducing viral load (Reuter et al. 2012). Assuming that 
VACV is manipulating Treg via EGFR using VGF, we hypothesised that 
depletion of regulatory T cells may be enough to protect mice from VACV 
infection. We inoculated WT mice with 200k PFU of VACVWR and injected 
one group with the CD25-depleting anti-PC61 antibody (Setiady, Coccia, and 
Park 2010) on Day -3 and Day -1 preinfection. We observed similar levels of 
weight loss and lung viral titre in both groups out to D6 (Figure 11-13 A), 
despite a near-halving of spleen FOXP3+ CD4 T cells (Figure 11-13 C). 
PC61-treated mice had similar numbers of CD4 & CD8 T cells in, though the 
proportion of CD4 T cells was slightly greater (Figure 11-13 C). CD8 T cells 
in both BAL fluid and spleen (Figure 11-13 B & C) had had significantly 
reduced expression of IFNg upon restimulation with the VACV peptide B8R20-
27 (NB: in BAL there was a nonsignificant trend in this direction).  
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Figure 11-13 Effects of Treg depletion (by administration of PC61 anti-CD25 antibody 
on D-3 & D-1) on A) weight loss, lung viral titre and CD8 T cell responses in B) BAL 
fluid and C) spleens of mice infected with 100k PFUs VACVWR. Statistical analyses are 
t-tests. 
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11.3.8 Effects of EGFR blockade (Gefitinib) 
Finally, we attempted to test the effects of EGFR blockade in our VACV 
pneumonitis model. We inoculated WT mice with 100k PFU VACVWR, and 
gave Gefitinib 200mg/kg by daily gavage, or vehicle only. Unfortunately, due 
to poor tolerance of drug administration in both the placebo and Gefitinib 
group, faster than expected weight loss and unexpected deaths in both 
experimental groups, this experiment was abandoned, and not repeated.  
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12 Discussion 
Here we have shown that mice whose regulatory T cells are deficient for 
EGFR are more resistant to vaccinia infection, and clear the virus faster; that 
the BAL fluid of EGFRDFOXP3 mice is more cellular compared to wildtype; and 
that when VACVDVGF is used both WT and EGFRDFOXP3 mice are equally 
resistant. From this we hypothesise that Vaccinia virus has the ability to 
manipulate Treg using the EGFR, and that this signal likely occurs via VGF-
EGFR signalling. It does this in order to produce a locally 
immunosuppressive environment in which the virus can replicate 
unchallenged. In support of this, EGFRDFOXP3 mice had more cellular BAL 
fluid than WT, indicating a greater immune response to infection.  
 
VACVDVGF infection did not replicate any of these differences, indicating that 
both mouse strains are equally resistant to infection with this VACV mutant. 
EGFRDFOXP3 mice had less TGFb in their BAL fluid, which could be as a result 
of less Treg activation in these mice compared to WT (assuming Treg are the 
main source of TGFb, or are influencing the source cells). One interesting 
future avenue of inquiry would be to examine the effect of this reduced TGFb  
on the formation of tissue-resident memory CD8 T cells (TRMs); TRMs are a 
phenotypically distinct group of memory cells that remain within their ‘home’ 
organ, tend to be positive for CD103 and/or CD69, and generate a rapid 
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immune response to reinfection (Muruganandah et al. 2018; Wu et al. 2018; 
Schenkel and Masopust 2014). Interestingly, it seems that TGFb  is the main 
cytokine for maintaining the TRM phenotype in the long term (Nath et al. 
2019), and in some tissues is the signal that promotes the conversion of 
effector T cells to TRM (Ma et al. 2017). TRMs have been shown to be 
important in Vaccinia infection, where higher numbers correlated with rapid 
viral clearance upon reinfection  (Gilchuk et al. 2016); they also are induced 
within days of infection, and are detectable by D7 postinfection (Jiang et al. 
2012; Iborra et al. 2016; Kadoki et al. 2017; Puksuriwong et al. 2019). It is 
therefore possible that in subsequent exposure to Vaccinia infection, our 
EGFRDFOXP3 mice would be less protected against the virus due to defective 
formation of TRMs. 
 
In-vitro, we showed that cultured virus stock (purified through a sucrose 
gradient) contained sufficient amounts of VGF to elicit phosphorylation of 
EGFR in HaCaT cells. We did not attempt to qualify this further; one 
possibility is that, as the viral membranes are acquired from endoplasmic 
reticulum or the ER-Golgi intermediate compartment (Harrison et al. 2016; 
Moss 2015; Pechenick Jowers et al. 2015; Smith, Vanderplasschen, and Law 
2002), and VGF is assumed to be transported in precursor form to the cell 
surface before cleavage to a soluble form (Beerli et al. 2019; Chang et al. 
1988), that VGF is being passively integrated into the virus membrane. It has 
long been assumed that VGF is not present on the virus particle itself. 
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However, recent data from the group of Dr Buck (personal communication) 
has suggested that VGF may be present in extracellular vesicles harvested 
from the supernatants of infected cell cultures; if so, then it is possible that 
VGF precursors could become embedded in membranes other than the host 
cell plasma membrane, and so may find itself in membranes of viruses. The 
alternative explanation is the virus stock contained soluble VGF as impurities. 
One way to detect this would be to look for soluble VGF in our virus stock by 
SDS-PAGE; however, we did not pursue this any further due to time 
constraints and a desire to proceed to in-vivo experiments.  
 
As VGF is an early protein, it is still transcribed/translated by cells infected 
with UV-inactivated virions (Tsung et al. 1996). In our in-vitro assay of Treg 
function, effector T cell proliferation was suppressed by Treg when incubated 
with UV-inactivated VACVWR, but only when EGFR was present on the Treg 
cell surface. This was not due to a direct effect on the effector T cells, as 
incubation of these cells with VACVWR in the absence of Treg did not affect 
proliferation when compared to controls. As far as we can see, this is the first 
time the effect of VGF on regulatory T cells has been examined in-vitro. 
Given the increasing evidence of the importance of EGFR signalling on T cell 
function (Dai et al. 2015; Nosbaum et al. 2016; Tuettenberg et al. 2016; 
Wang et al. 2016; Zaiss et al. 2013), it is important to determine if this 
receptor can be manipulated by pathogens such as poxviruses, especially 
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given the potential for using EGFR-inhibiting drugs to treat such infections in 
outbreaks.  
 
For in-vivo experiments a VACV pneumonitis model was chosen due to its 
history of use in studying poxvirus infections, the well-described host 
response, and lung samples could be used for viral titres. EGFRDFOXP3 mice 
were more resistant to VACVWR infection than WT, with less weight loss, 
lower lung viral titres, greater cellular infiltrate in BAL fluid, and lower levels of 
bioactive TGFb in BAL fluid supernatant. These effects were not seen when 
VACVDVGF was used as the inoculation agent. These data imply that VGF 
derived from VACVWR is interacting with regulatory T cells via the EGFR, 
resulting in their activation and release of bioactive TGFb into the 
environment (cellular source undetermined); this then suppresses the local 
immune response to infection.  
 
It is interesting to note that depletion of WT mice Treg using anti-CD25 to 
near 50% baseline was not enough to replicate the effects seen when 
EGFRDFOXP3 mice were used. Clearly the protective effect we saw with 
EGFRDFOXP3 Tregs cannot be replicated by a ~50% depletion of WT Treg, as 
these mice lost similar amounts of weight compared to untreated. In contrast 
to this, previous work has noted an association between more severe Treg 
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depletion and enhanced antiviral CD8 T cell responses previously (Haeryfar 
et al. 2005). Other methods of Treg depletion exist, namely the use of 
DEREG mice (Lahl and Sparwasser 2011), which are considered to produce 
greater Treg depletion than that seen in my experiment, for a period of 6-8 
days (which would have been sufficient to cover a 7-day experiment) 
(Kastenmuller et al. 2011). Use of DEREG mice may have produced more 
consistent and more specific Treg depletion, which in turn may have affected 
the outcome of these experiments. 
 
The reduced CD8 T cell responses to restimulation with Vaccinia 
immunodominant epitope B8R20-27 in EGFRDFOXP3 mice is difficult to explain; 
this trend was consistently seen across multiple experiments. Given that CD8 
T cells are a major means of clearing viral infections (Goulding et al. 2012; 
van Helden et al. 2012; Salek-Ardakani et al. 2008), and previous authors 
have found that Treg depletion led to enhanced antiviral responses (see 
above) our findings were confusing. However, Freyschmidt and colleagues 
studied the effector CD8 T cell response in cutaneously-infected WT and 
FOXP3-/- mice (Freyschmidt et al. 2010), and found that FOXP3-/- mice failed 
to generate VACV-specific CD8 T cells, and those cells did not produce 
significant amounts of IFNg. They hypothesised that Treg deficiency led to a 
disordered T cell response to infection, and polarisation towards a Th2 
response. Our data on the face of it seems to reflect this, in that CD8 T cells 
of VACVWR-infected EGFRDFOXP3 mice had significantly lower levels of IFNg 
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expression; however, their FOXP3KO mice had worse outcomes compared to 
WT, whereas we found the reverse to be true in our EGFRDFOXP3 mice. One 
possible explanation is that, by interrupting VGF-EGFR signalling and Treg 
activation, the rest of the immune system is ‘unleashed’ from TGFb-mediated 
suppression, and so enhances viral clearance despite a relative lack of 
antiviral CD8 T cells, explaining the general increase in BAL cellularity in 
EGFRDFOXP3 mice. Another is that antiviral CD8 T cells are being sequestered 
in lung tissue, which we did not analyse for. Finally, the enhanced viral 
clearance seen in EGFRDFOXP3 mice may result in lower numbers of CD8 T 
cells at the time of analysis (almost always D7); Goulding and colleagues 
found that IFNg levels in VACV-infected lung peaked at D3-6 in WT animals 
(but was detectable out to D14) (Goulding et al. 2014); If the antiviral 
response in EGFRDFOXP3 mice was more pronounced, perhaps their 
population of Vaccinia-specific CD8 T cells had been depleted at the time of 
experimental harvest; this could have been determined by harvesting some 
experiments at earlier and later timepoints. Further studies could also look at 
alternative markers for CD8 T cell activation in Type 1 infections, such as IL-
2 or TNFa, as has been done elsewhere (Rodo et al. 2019; Kastenmuller et 
al. 2011); it is known that T cells produce various cytokines at multiple 
timepoints, and that polyfunctionality (production of multiple cytokines) is 
associated with improved response to infections and vaccination (Han et al. 
2012). However, in VACV infection models naïve CD8 T cells produce TNFa 
early, and subsequently acquire the ability to express IFNg as they 
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proliferate/differentiate (Brehm, Daniels, and Welsh 2005; Xiao et al. 2007). 
Other researchers have found that all CD8 T cells produce IFNg, whereas a 
subset of cells can make both IFNg and TNFa, and a third subset producing 
IFNg, TNFa and IL-2 (Harrington et al. 2002). For these reasons, we chose 
the IFNg as out readout for CD8 T cell activity at the D7 timepoint. 
 
To the best of our knowledge this is the first time that a specific interaction 
between regulatory T cells and Vaccinia virus via VGF has been proposed. 
As discussed above, many poxviruses carry EGFR ligands, but notably the 
smallpox virus gene D4R encodes Smallpox Growth Factor (SPGF), a near-
complete homologue of VGF (Kim et al. 2004). For the reasons discussed 
above, it would be advantageous to have an antiviral agent that could be 
used to treat patients in the event of a poxvirus outbreak. Perhaps EGFR-
blocking agents could be used to limit the severity of infection. This has been 
discussed previously (Beerli et al. 2019; Kim et al. 2004; Langhammer et al. 
2011; Yang et al. 2005), and Langhammer and colleagues have used the 
commercially licensed TKI Gefitinib in-vitro to block VGF-EGFR interaction, 
so stopping the paracrine ‘priming’ of uninfected epithelial cells (Langhammer 
et al. 2011). They also hypothesised that, based on previous work done by 
Mercer et al., that that Gefitinib could inhibit EGFR-dependent entry into 
cells, so reducing viral spread (Mercer et al. 2010). Our work would support 
an additional hypothesis: that EGFR blockade could inhibit host Treg 
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activation by poxvirus growth factors, and so expedite viral clearance by 
improving the host response to infection. As tyrosine kinase inhibitors of 
EGFR are reasonably well-tolerated in humans (Köhler and Schuler 2013), 
their use as an antiviral in the unlikely event of VARV exposure should be 
explored further. It was only limitations of time and difficulties with 
experimental animals’ intolerance to drug administration that prevented us 
from examining Gefitinib’s effects on VACV infection in-vivo.  
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13 Appendix: Tritiated Thymidine Protocol for 
assessment of T cell proliferation 
CD4+ mouse splenocytes were selected using a magnetic separation column 
and sorted into Treg and Teff as stated in 10.2.1, but the labelling of Teff 
cells with CTV was not performed. Instead, cells were incubated in ratios of 
1:4 – 1:8 under various experimental conditions in 200µl complete IMDM with 
anti-CD3 antibody at a final concentration of 2µg/ml and incubated for 72h. At 
66h, 0.1microCurie (3.7 kilobequerel [kBq]) of tritiated thymidine (3H-TdR) 
was added to each well.  
 
At 72-84h (varied with experimental conditions) plates were frozen to stop 
cell proliferation. At the time of analysis, frozen plates were transported to the 
Queen’s Medical Research Institute, University of Edinburgh, and thawed by 
use of a Thermolyne Plate Heater. Following this, wells were placed in a 
plate harvester and cell samples were washed onto 96-well scintillation paper 
(Printed Filtermat A, #1450-421, Wallac). Following this, a scintillation sheet 
(Metilex A, #1450-441, Perkin Elmer) was melted onto the scintillation paper 
before loading into a Scintillation counter (1450 Microbeta Trilux, Wallac). 
Samples were then acquired, and radioactivity of each well individually 
reported as counts per minute (NB: 30,000 cpm = 1kBq). Incorporation of 3H-
TdR into cell populations was rarely above 1%.   
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14 Supplemental Data:  
14.1 Initial titration of Vaccinia dosage for in-vitro 
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14.2 CTV Optimisation  
14.2.1 Optimisation of incubation conditions 
Optimal proliferation of effector T cells (Teff) was determined as follows, 
using division index (Mean number of divisions per cell) and % Divided 
(Number of cells that underwent at least one division).  
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Figure 14-2 Proliferation of Effector T cells incubated for 72, 96 or 120 hours in 




Figure 14-3 Proliferation at 72 hours of Effector T cells incubated with 1 or 2 x 105 CD4- 
APC feeder cells at various concentrations of CD3 antibody 
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Figure 14-2 shows that 72h of incubation results in higher division indices 
and %divided rates at almost all timepoints, likely due to increased cell death 
in the wells.  
 
Having determined 72h as the optimal analysis timepoint, we compared 1 or 
2 x 105 CD4- APC feeder cells per well (Figure 14-3). 2 x 105 feeder cells 
resulted in improved proliferation at all concentrations of CD3 antibody, and 
so was used for subsequent analysis.  
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Figure 14-4 Proliferation of Teff at various concentrations of anti-CD3 antibody. 
(Analyses are Bonferroni-corrected t-tests relative to 0.4µg/well). 
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Having established optimal incubation time and number of feeder cells, we 
then analysed optimal concentration of stimulatory CD3 antibody per well. A 
final concentration of 2µg/ml was already in use in our group: this correlates 
to 0.4µg in a well filled with 200µl medium, so this was used as a reference 
for comparison to all other wells.  
 
As demonstrated in 14-4, proliferation was only significantly reduced (relative 
to the 0.4µg wells) when the concentration of CD3 reached 0.1µg (equivalent 
to 0.5µg/ml final concentration). There was a trend in increasing proliferation 
between 0.1 and 0.4µg/well but increasing the dosage above 0.4µg/well did 
not lead to a significant increase in proliferation.  
We therefore determined that optimal conditions for Teff proliferation were:  
• 72h incubation 
• 200,000 Feeder cells per well 
• Anti-CD3 antibody: 2µg/ml final concentration 
 
14.2.2 CellTrace Violet Staining Optimisation 
Initial experiments with CTV were hampered by considerable cell death upon 
exposure to CTV (up to 90%). A CTV dose optimisation experiment was 
performed, looking at various parameters:  
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• Incubation volume (1, 2 or 4 ml) 
• CTV concentration (0.5 or 0.25 µM).  
• Incubation temperature (20 or 37 oC) 
• Incubation time (5 or 10 minutes) 
Results are shown in figure 14-5:  
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Figure 14-5 CellTrace Violet dose optimisation of Teff cells; A) Incubation volume, B) 
CTV concentration, C) Temperature, D) incubation time. Statistical analyses are either 
ANOVA with subsequent paired testing, or paired t-tests where appropriate.  
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These data were interpreted as follows:  
14-5 A): Higher total incubation volumes produced both poorer staining and 
reduced cell survival. Please note that 4ml sample data was excluded from 
subsequent analysis.  
14-5 B): A final concentration of 0.5mcM produced superior staining with a 
(nonsignificant) reduced cell survival.  
14-5 C): Incubation at 37oC did not improve cell staining, and slightly 
worsened cell survival (all nonsignificant).  
14-5 D) Incubation time of 10 minutes produced a slightly better staining, but 
slightly worse cell survival (all nonsignificant).  
From this the optimal CTV staining protocol was determined to be:  
• Incubation volume:   1ml  
• CTV final concentration  0.5 µM.  
• Incubation temperature  20 oC 
• Incubation time   5 minutes 
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Chapter 3: EGFR signalling does not significantly 
affect regulatory T cell function in the murine 
filariasis model Litomosoides sigmodontis 
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15 Abstract 
Helminth worms are multicellular parasites that generate a strong TH2 immune 
response, including the induction of regulatory T cells (Treg), which may benefit the 
host (by limiting immune-mediated damage to tissues), but also the parasite. The 
mouse filarial infection Litomosoides sigmodontis induces Tregs early in infection, 
and these Treg appear to induce a hyporesponsive TH2 response to infection. The 
aim of this chapter was to determine the extent to which endogenous Amphiregulin 
signalling on EGFR affected Treg proliferation and function.  
 
Initially we used transgenic C57BL/6 mice (Egfrfl/fl x FoxP3cre) to assess the effects of 
EGFR deletion on Treg activity in L.sigmodontis infection. We found an increase in 
TH2 cells in all tissues, but this did not correlate with an increase in TH2 cytokine 
expression in CD4 cells at early (D14) or later (D40) timepoints. Repeating this with 
Areg-/- mice produced similar results. Using BALB/c mice, which develop full 
L.sigmodontis infection, we examined the effects of EGFR blockade with the 
commercially available EGFR inhibitor Gefitinib, at a dose of 100mg/kg 3 times 
weekly. Compared to control mice, we observed no differences in numbers of plasma 
microfilaria at various timepoints, pleural exudate (PLEC) microfilaria or adult worms 
at harvest, or lymphocyte populations or cytokine expression in CD4 or TH2 cells. 
Based on these data, we conclude that AREG-EGFR signalling does not significantly 
affect the behaviour of Tregs in the context of L.sigmodontis infection.  
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Helminths are worm-like multicellular parasites that infect vertebrates worldwide, 
though the burden of human disease is in tropical regions (Lindquist and Cross 
2017). They can be either parasitic or free-living, and are typically transmitted by 
arthropod or mollusc vectors, but also from soil and contaminated food. 
Helminthoses can occur in any organ system, and are a significant cause of 
morbidity worldwide, especially in developing countries. In children in particular they 
are associated with limitations in physical and mental development. Overall, it is 
estimated that 25% of the world’s population are actively infected at any one time 
(Bethony et al. 2006). The majority of Helminthoses are listed as Neglected Tropical 
Diseases (WHO 2019). Treatment with anthelminthic drugs (and to a lesser extent 
doxycycline, which targets the symbiotic Wolbachia endobacteria in filarial worms) is 
commonplace, but must be repeated often as reinfection is common and host 
resistance limited (Hoerauf et al. 2011; Volkmann et al. 2003). 
 
Helminths are divided into 3 major classifications: Nematodes (roundworms), 
Trematodes (Flukes) and Cestodes (Tapeworms). Each have distinct anatomy, but 
all are characterised by an outer layer termed tegument (cuticle in nematodes), that 
serves to protect the worm from environmental conditions and the host response to 
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the parasite. Internal structures vary markedly between these 3 groups and will not 
be discussed further.  
 
16.2 Filarial Nematodes 
Filarial (threadlike) worms are nematodes that infect blood and lymph tissue, derived 
from the Filarioidea superfamily. There are eight species of worm that infect humans, 
but the four commonest pathogens are Wuchereria bancrofti and Brugia malayi/timori 
(causative agents of Lymphatic filariasis), Onchocerca volvulus (River Blindness) and 
Loa Loa (Loasis). All filarial worms are typified by residence in a human (definitive) 
host, and release of microfilaria into the bloodstream for uptake by an arthropod 
vector (Intermediate host), typically a mosquito (Taylor, Hoerauf, and Bockarie 2010). 
Figure 16-1 shows the typical life cycle of W.bancrofti.  
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Figure 16-1 Life cycle of W.bancrofti parasite. L3 larvae enter the bloodstream during a blood 
meal, and then migrate to the site where they will mature into adults (In this case lymphatic 
vessels). After developing into adults and mating, females will produce microfilaria that will 
enter the bloodstream at a time optimised for ingestion by their mosquito vector (typically 
10pm-4am). After entering the mosquito (Typically Culex and Aedes species) the microfilaria 
will mature into L1 larvae, then L2, then L3, after which they will migrate into the proboscis 
ready to infect the next human host. Image distributed under public domain from CDC Public 
Health Image Library, image credit: CDC/Alexander J. da Silva, PhD/Melanie Moser. (PHIL 
#3425), 2003.  
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Filarial infection in the tropics is commonplace, particularly sub-Saharan Africa (see 
Table 16-1), and though mortality is not high, morbidity with filariases is extensive: 
Onchocerciasis is a major cause of blindness in sub-Saharan Africa, and Loasis 
causes painful swellings and joint aches related to worm migration through tissues.  
Table 16-1 Overview of important filarial infections. Note most burden of disease is in sub-
Saharan Africa (CDC 2018; Vos et al. 2016). 
 
 Lymphatic filariasis is typically asymptomatic, allowing for occult transmission in 
endemic communities, but some individuals generate an abnormally aggressive 
immune response to the parasite, causing scarring and obstruction of the lymphatic 
vessel in which the adults reside; the resulting interruption of lymph flow causes 
irreversible stage 3 lymphoedema, termed Elephantiasis (Hoerauf et al. 2011). This 
causes significant disfigurement to the host.  
 
Eradication programmes set up by WHO have focused on mass drug administration 
programmes, tailored to the parasites that reside in that particular area. However, 
despite a variety of tailored control programmes spanning decades, including vector 
control, eradication of these diseases has proven difficult (Hoerauf et al. 2011). 
Disease Causative Agent Prevalence (million) Distribution 
Loasis Loa Loa 3-13 West and Central Africa 
Lymphatic filariasis W.bancrofti (90%), B.malayi/timori (10%) 38.4 
Sub-Saharan Africa, SE Asia, South 
America 
River Blindness Onchocerca volvulus 15.5 Sub-Saharan Africa, Brazil, Venezuela 
Control of regulatory T cell activity by endogenous and pathogen-derived EGFR ligands 
Chapter 3: EGFR signalling on Treg in Litomosoides sigmodontis infection 
146 
 
16.3 Litomosoides sigmodontis 
Litomosoides sigmodontis is a filarial nematode infection used as a model for human 
filariasis. It is a natural parasite of the cotton rat (Sigmodon hispidus), but was found 
to develop patent infection (defined as microfilaria detectable in blood) in the inbred 
laboratory mouse strain BALB/c in the 1990’s (Petit et al. 1992; Dittrich et al. 2008; 
Haben et al. 2013). Due to this ability to study patent infection, L.sigmodontis 
infection of BALB/c mice has become the standard model for investigating filarial 
infections in laboratory settings.  
 
16.3.1 Life cycle 
The life cycle of L.sigmodontis is maintained in Jirds (Meriones unguiculatus) or 
gerbils as detailed in Fulton et al. (Fulton, Babayan, and Taylor 2018). Briefly, 
Uninfected Ornithonyssus bacoti mites (the intermediate host) are kept in a cage and 
‘fed’ by exposure to an uninfected mouse. When time for infection, the mites are 
moved to a cage with an infected Jird (definitive host, ~90 days postinfection) and 
allowed to feed. Microfilariae (L1 larvae) are contracted from the Jird blood and take 
12-14 days to develop into L3 larvae in the mites. At this point, the mites are placed 
in a tissue culture plate with media containing horse serum and crushed, allowing the 
L3 larvae to escape into the media. They are then aspirated into a pipette and 
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transferred to a syringe for injection. Mice are infected subcutaneously, but 
Jirds/Gerbils are infected intraperitoneally.  
 
The above is the conventional way of obtaining L3 larvae, but other methods of 
infection including recovery of L3 larvae from a recently infected Jird pleural cavity 
(Hübner et al. 2009) for subsequent subcutaneous inoculation, and direct feeding of 
mites on BALB/c mice (though inoculation dosage in this method is undetermined). 
Once injected, L3 larvae migrate via lymphatics to the pleural cavity (D3 
postinfection), where they mature to L4 larvae (D8-12), then maturing into adults at 
D25-30 (Fulton, Babayan, and Taylor 2018; Haben et al. 2013). The difference 
between BALB/c and other mouse strains is that the adult worms reach sexual 
maturity, and start to release microfilaria at D50-55, which will be detectable in 
venous blood. If left unchecked, infection will usually be cleared in wildtype BALB/c 
mice by 100 days.  
 
16.3.1.1 The immune response to Litomosoides sigmodontis infection in 
C57BL/6 & BALB/c mice 
The immune response to L.sigmodontis infection mimics that of human filariases 
(Morris et al. 2013; Taylor et al. 2009), namely there is an upregulation of the Type 2 
cytokines IL-4, IL-5 and IL-13, leading to a TH2 dominant response. Individuals with 
a high parasite burden (but reduced pathology) show reduced T cell proliferative 
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responses, increased IL-10 and lower levels of IL-5 and IFNg, suggesting both that 
these are important for parasite expulsion, and that they are deliberately modified by 
the parasite to promote survival (see below) (Specht et al. 2012). BALB/c are 
susceptible hosts as stated above, and have a dominant TH2 response to infection, 
whereas the resistant C57BL/6 strain demonstrates a mixed TH1/2 response (Le 
Goff et al. 2002).  
 
Upon translocation to the pleural space, the chemokine CXCL12 is released by 
mesothelial cells, which attracts CXCR4+ cells (the receptor for CXCL12) such as 
neutrophils, eosinophils, monocytes and T cells, into the pleural space. From there 
they expand and work to quickly reduce filarial load (particularly in resistant C57BL/6 
strains); this is reduced in BALB/c mice, who produce less CXCL12 overall compared 
to C57BL/6 (Bouchery et al. 2012). 
 
Pleural macrophages expand quickly in response to infection, and assume a M2 
phenotype, facilitating parasite killing. In C57BL/6 mice tissue-resident macrophages 
expand and are gradually replenished from bone marrow, whereas in BALB/c mice 
monocytes are recruited to the pleura, and assume an immunosuppressive role, 
which aids parasite survival (Campbell et al. 2019). 
 
Some of the immune responses to infection do not result in parasite expulsion; they 
may benefit the host by limiting tissue damage, but also result in parasite survival in 
both larval and adult forms. This is common to human filariases too, where 
downregulation of IL-4, IL-5 and IFNg, together with upregulation of 
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immunosuppressive cytokines TGFb and IL-10, has been noted (Taylor et al. 2009). 
Clearance of L.sigmodontis infection in C57BL/6 mice is dependent on the type 2 
cytokines IL-4, IL-5 & IL-10 (Specht et al. 2012; Bouchery et al. 2012; Haben et al. 
2013). Interference with these cytokines alters the outcome of infection.  
 
In C57BL/6 mice, for example, deletion of the IL-4 gene renders the mice susceptible 
to patent infection, and in BALB/c mice causes a substantial increase (up to 160x) in 
microfilaraemia, though the number of adults in the pleural cavity is not increased 
(Haben et al. 2013; Volkmann et al. 2001, 2003; Bouchery et al. 2012). IL-4 has also 
been found to be important for control of microfilaria in the murine filariasis Brugia 
pahangi, implying a broadly similar immune response to filariases, namely that IL-4’s 
main effect is by limiting the fecundity of adult females. It seems, therefore, that IL-4 
in particular is important for control of microfilaria. 
 
IL-5, too, is important for clearance of the disease, and when knocked out on BALB/c 
mice results in many more adult worms (up to 200x), though levels of microfilaraemia 
are similar to IL-4-/- as above(Volkmann et al. 2003; Haben et al. 2013). It appears 
that IL-5 synergises with IFNg to increase resistance to the parasite and subsequent 
expulsion (Haben et al. 2013). However, C57BL/6 IL-5-/- mice infected with 
L.sigmodontis are as resistant to infection as wildtypes, implying that Eosinophils are 
not required to facilitate parasite expulsion (Le Goff et al. 2002). IL-5 production is 
opposed by IL-10, typically derived from M2 or alternatively activated Macrophages 
(Specht et al. 2012).  
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IL-10 plays an important part in L.sigmodontis infection. Infected IL-10-/- mice have 
smaller populations of T cells (along with B cells a major source of IL-10), and when 
mice were infected that had a T cell specific IL-10 deletion, they produced more IL-5, 
IL-13 and IFNg, and had a higher initial parasite burden (D17 postinfection), though 
not at later timepoints (D30 & D60). These changes were not seen when mice with a 
B cell specific IL-10 deletion were infected, implying that T-cell-derived IL-10 affects 
the TH1/TH2 response to L.sigmodontis infection, resulting in a transient 
improvement in parasite survival (Haben et al. 2013). Other researchers have found 
that overexpression of IL-10 in macrophages leads to alternative activation, reduced 
TH2 cytokines and higher parasite counts, confirming the importance of IL-10 
mediated suppression of the host response for parasite survival (Specht et al. 2012). 
Thus, it seems that IL-10 secretion from specific sources leads to tolerance of the 
parasite and suppression of the TH2 response.  
 
16.3.2 Litomosoides sigmodontis and regulatory T cells 
Filarial worms (as well as many other helminths) are known to suppress both TH1 
and TH2 responses (Taylor et al. 2005). It has become increasingly clear that 
regulatory T cells (CD4+ FOXP3+ T cells; Treg) and Tr1 cells (Type 1 Regulatory 
Cells; CD4+ FOXP3- T cells that produce IL-10 when activated in an antigen-specific 
manner (Zeng et al. 2015)) suppress the inflammatory response to infection in filarial 
disease (Taylor et al. 2009). In L.sigmodontis, Treg expansion occurs early, within 7 
days of infection with L3 larvae, and depletion of Treg (e.g. with anti-CD25 antibody 
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prior to infection) results in improved parasite rejection (Taylor et al. 2009; Taylor et 
al. 2007). At the site of infection Treg appear to promote a hyporesponsive TH2 
phenotype, which is mitigated by Treg depletion. Effector T cells themselves appear 
anergic, and postinfection depletion of Treg alone is not enough to reverse this 
phenotype: use of stimulatory anti-CTLA4 or anti-GITR monoclonal antibodies 
‘revitalises’ effector T cells, and re-establishes a resistant phenotype in C57BL/6 
mice (Taylor et al. 2009).  
 
Clearly, Tregs play a significant role in the suppression of the immune system and 
immunological tolerance of L.sigmodontis infection, being rapidly expanded early and 
remaining so for the duration of infection. Whether endogenous EGFR signalling is 
important for the function of Treg in L.sigmodontis infection is less clear. It has been 
previously established that in inflammatory conditions Treg express EGFR, and that 
Amphiregulin enhances Treg function via EGFR (Chen et al. 2012; Zaiss et al. 2013). 
We hypothesised, therefore, that endogenous AREG can activate Treg via the EGFR 
at the site of infection, as has been shown in other inflammatory models. We 
therefore decided to test this in-vivo as detailed below.  
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17 Hypothesis 
We hypothesised that Amphiregulin-EGFR stimulation would lead to the activation of 
regulatory T cells in a chronic murine filariasis infection, with a resultant decrease in 
TH2 responses. We also hypothesised that this could be ameliorated through the use 
of nonspecific EGFR inhibitors such as Gefitinib.  
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18 Methods 
18.1 Animal strains used 
BALB/c mice (all wildtype) and C57BL/6J mice (Egfrfl/fl, Egfrfl/fl x FoxP3cre, Areg-/- and 
Aregfl/fl, Hereafter referred to as WT, EGFRDFOXP3, AREG-/- and AREGfl/fl respectively) 
were bred and maintained at the University of Edinburgh in specific-pathogen free 
conditions. All mice were housed in individually ventilated cages at the Ashworth 3 
Level 5 animal unit, King’s Buildings, University of Edinburgh, until required for 
experiments, when they were transferred either to the Ann Walker Unit, King’s 
Buildings Campus, University of Edinburgh. Both sexes were used for experiments, 
but all mice in one experiment were of the same sex. Mice were 6-8-weeks old at the 
start of the experiment unless otherwise specified. Cages were randomly assigned to 
a treatment group; mice were not randomised within the cages themselves. 
Experiments were performed in accordance with the United Kingdom Animals 
(Scientific Procedures) Act of 1986, and all researchers were accredited by the UK 
Home Office. Dispensation to carry out animal research at The University of 
Edinburgh was approved by the University of Edinburgh Animal Welfare and Ethical 
Review Body and granted by the UK government Home Office; all research was 
carried under the project licence 70/8470. All in-vivo experiments were conducted 
with groups of 5-7 animals unless otherwise stated. All results are representative of 
at least 2 experiments. 
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18.2 Infection Protocol 
For infections, the L.sigmodontis life cycle was maintained by Ms A Fulton as 
detailed in section 16.3.1, in room B57, Ashworth Building 3, King’s Buildings 
Campus, University of Edinburgh. Prior to infection, mice were transferred to the Ann 
Walker Building and left to acclimatise for 24-48 hours.  
 
On the day of infection, infected mites were collected by Ms Fulton, crushed in a 
tissue culture plate containing media and horse serum, and left for 20 minutes to 
allow the L3 larvae to escape into the medium. Individual mites were then aspirated 
into a pipette, in doses of 30 L3s per pipette, and transferred into a rounded glass 
and left for 10 minutes. After this time, larvae would have localised to the bottom of 
the well and could be aspirated into a 1ml syringe via a blue needle (23G, 0.6 x 
25mm) in no more than 50µl media. Following this, prepared syringes were 
transferred to the Ann Walker Building, and mice were inoculated by subcutaneous 
injection into the dorsal skin. After injection, the needle was kept in the mouse for 3 
seconds to allow injected fluid to distribute into the subcutaneous space, then 
withdrawn slowly. This resulted in minimal ‘leak’ of serum back out along the needle 
tract. Mice were monitored for a short period of time afterwards for adverse effects. 
Anaesthetic was not required or used.  
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18.3 Administration of Gefitinib 
Experiments with BALB/c mice involved the administration of Gefitinib to one or more 
groups. Gefitinib was purchased from LC laboratories (#G-4408, LC labs) and kept 
frozen at -20oC until prior to experimentation. When making up aliquots, Gefitinib was 
dissolved in DMSO (up to 100mg/ml), then stored at -20oC until use.  
 
18.3.1 Dose calculation 
For our initial experiment, Gefitinib was added to the cage water to give a calculated 
dose of 5mg/kg to each mouse, assuming standard rates of water consumption.  
 
For subsequent experiments, a higher dose of 100mg/kg of Gefitinib was used, as 
this was closer to the equivalent Gefitinib dose used in humans: the standard daily 
dose of Gefitinib in humans is 250-500mg/d. Assuming a weight of 60kg, this would 
be per-kilogram dose of 4.17-8.34 mg/kg. Using a standard conversion of 12.3x for 
human to mouse dosages, 8.3 x 12.3 = 102.09 mg/kg (Center for Drug Evaluation 
and Research 2005). We considered this dose to be safe, as other researchers had 
only experienced adverse effects in A/J mice when doses of over 300mg/kg were 
used (Yan et al. 2006) Additionally, clinical effects have been seen when lower per 
kg doses have been used (Zheng et al. 2016; Song et al. 2016). We therefore 
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Due to the duration of experiments involving L.sigmodontis infection, it was 
considered unethical to administer Gefitinib by daily gavage. For initial experiments, it 
was decided to add the drug to the water supply. Using an estimated daily water 
consumption of 6ml for a 30g BALB/c mouse (Bachmanov et al. 2002), we 
determined that for a dose of 5mg/kg, 6ml drinking water would have to contain 
0.15mg Gefitinib, giving a desired concentration of 0.025mg/ml (note that as smaller 
mice should drink less, this dosage should remain constant regardless of mouse 
size). As water bottles contained 250ml, we added 6.25mg Gefitinib to reach this 
concentration.  
 
When trying to administer 100mg/kg doses (i.e. 125mg per bottle), we found that 
Gefitinib had the tendency to precipitate out and collect at the bottom of the water 
bottle. This method of administration was discontinued, and instead Gefitinib was 
added to food. For this, mouse energy requirements were calculated as follows: daily 
energy requirements = 160 kCal/kg0.75/d (Nutrition 1995). For a 20g mouse, this 
equates to 8.51kCal/d. Using Dietgel 76A dietary supplement 56g pots (#72-07-
5022X, ClearH2O), which have a calorific content of 0.94kCal/g, we calculated a 20g 
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mouse should consume 9.05g/d of food, in which there should be 2mg Gefitinib (a 
dose of 100mg/kg). Therefore, 12.4mg Gefitinib was added to each Dietgel 76A pot 
(0.221mg/g, or 2mg drug per 9g food). These pots were administered Monday, 
Wednesday and Friday. On days when pots were not administered mice were 
allowed standard dry food ad libitum. 
 
18.4 Monitoring 
L.sigmodontis infection is typically asymptomatic even in the susceptible BALB/c 
mouse strain. When using C57BL/6 mice, no monitoring during the experiment was 
performed, and no plasma samples collected for analysis.  
 
18.4.1 Weight monitoring 
For BALB/c experiments using Gefitinib, monitoring was performed. For the initial 
experiment, all groups were weighed daily for the first week, then twice a week for 
the second week, then weekly for the remainder of the experiment. For subsequent 
experiments monitoring of weight was less intensive. Mice were also assessed for 
signs of skin changes (namely rash and alopecia), which are signs of Gefitinib 
toxicity. None were observed in any experiment.  
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Water bottles were weighed twice weekly and the amount of water consumed per 
mouse in each group calculated and compared, to determine if mice were refusing to 
drink Gefitinib-contaminated water. This could not be done when Gefitinib was added 
to food, as food tended to be scattered around the cage.  
 
18.4.2 Sampling of venous blood 
After 50-55 days, venous blood was drawn from infected BALB/c mice to look for 
plasma microfilaria; this was repeated every 5 days until the end of the experiment. 
Venous blood was obtained either by tail snip or tail vein cannulation. For tail snip, 
the mouse was placed on top of the metal grille of a cage, and a small 
(submillimetre) section of skin on the distal tail removed by use of a pair of scissors. 
Following this, the tail veins were ‘milked’ (gentle pressure applied from the proximal 
to the distal tail, fingers running laterally over the tail veins) and blood collected onto 
a plastic surface until 25-30µl had been acquired (varied by experiment). This was 
then placed in 500µl FACS Lysing Solution (#349202, BD Biosciences). For future 
collections, the scar on the end of the tail was removed, which produced enough 
bleeding for further collections of blood. Animals displayed no distress during the 
procedure and did not need to be immobilised.  
 
Tail vein cannulation was performed as previously described (NC3Rs 2019): the 
mouse was immobilised in a restraint chamber and the tail vein located on the lateral 
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side. After puncture with a 25G needle, venous blood was collected onto a 
waterproof surface until 25-30µl had been acquired and then stored in FACS lysing 
solution as above.  
 
Following sample acquisition, they were visually inspected for microfilaria by Ms A 
Fulton using a microscope.  
 
18.5 Experimental harvest 
18.5.1 Sample Acquisition 
On the day of experimental harvest, animals were culled by exposure to CO2 in 
rising concentration and confirmed with cervical dislocation. Following this, mice were 
dissected, and venous blood taken from the inferior vena cava to look for plasma 
microfilaria on day of harvest (BALB/c experiments only). The spleen was then 
removed and placed in 2ml complete IMDM (see 10.3.7).  
In order to recover a) adult worms and b) Pleural Exudate Cells (PLEC) from the 
pleural cavity, a small incision was made in the diaphragm at the anterolateral edge. 
Using a Pasteur pipette and 10ml complete IMDM several irrigations of the pleural 
cavity were made through this incision. The irrigation fluid was collected in a 15ml 
tube and kept at 4oC prior to analysis. In BALB/c experiments, a 25µl samples of 
PLEC fluid was kept for analysing microfilarial numbers in the pleura. Following this, 
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thoracic lymph nodes (tLN; as described in chapter 2) were dissected out and placed 
in 1ml complete IMDM.  
 
18.5.2 Adult worm acquisition from PLEC wash 
To acquire adult worms from PLEC fluid, PLEC samples were sieved through a 70µm 
cell strainer (NB: 95% adult worms can be captured using this method (Morris et al. 
2013)). Adult worms remained in the 70µm cell strainers, which were placed in 6-well 
plates containing PBS and stored at 4oC. Worm numbers and length was determined 
by Ms A Fulton under microscopy.  
 
18.6 Flow Cytometric sample preparation and analysis 
Single cell suspensions of tissue samples were prepared as follows:  
• Spleen: Samples were forced through a 70 µm cell strainer, and the strainer 
washed with 10ml complete IMDM. Samples were then centrifuged (300g, 
5min, 4oC) and resuspended in Red Cell Lysis buffer (#R7757, Sigma-Aldrich) 
for 5 minutes. Samples were then quenched with 25ml complete IMDM, 
centrifuged as above and resuspended in 5ml complete IMDM.  
• Thoracic Lymph Node: Samples were homogenised by crushing between 2 
pieces of sterilised gauze swabs (in a petri dish containing 1ml complete 
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IMDM), which were then ‘washed’ with 1ml complete IMDM on each side to 
remove as many cells as possible from the swabs. The resulting 5ml complete 
IMDM containing tLN cells was then centrifuged (300g, 5min, 4oC) and 
resuspended in 1ml complete IMDM.  
• PLEC wash: The entire sample was centrifuged (300g, 5min, 4oC) and 
resuspended in 5ml Red Cell Lysis buffer (#R7757, Sigma-Aldrich) for 5 
minutes. Samples were then quenched with 25ml complete IMDM, centrifuged 
(300g, 5min, 4oC) and resuspended in 1ml complete IMDM.  
Using a Cellometer Auto T4 (Nexelcom), sample concentrations (of live cells, using 
trypan blue staining) were established, and standardised to a concentration of 2 x 
107/ml. Thus, a 100µl sample would contain 2 x 106 cells, which could be used for 
surface staining and intracellular cytokine staining (NB: if fewer than 4 x 106 cells 
were available for analysis, the whole sample was used: this was almost always the 
case with PLEC samples).  
 
100µl samples (containing 2 x 106 cells or fewer) were placed into two 96-well plates 
and used for analysis as stated below.  
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18.6.1 Surface Staining 
For surface staining, samples were kept in 96-well plates and all volumes given are 
per-well. Samples were washed in 150µl PBS, then centrifuged (300g, 2min, 4oC) 
and the supernatant removed (shaking the plate forcefully once upside down over a 
sink; the cells remained pelleted at the bottom of the well), viability stain added (as 
per section 18.8) and samples left for 10 minutes at room temperature. Following 
this, samples were incubated with Fc block (1mg/ml, diluted 1:200 in FACS buffer, 
10µl/well) to reduce nonspecific staining, and left for a further 10 minutes at room 
temperature. Then, cells were surface stained for CD4 and CD8 (diluted 1:200 in 
FACS buffer, 20µl/well) and left for 20min at 4oC. Samples were then washed with 
100µl FACS buffer, centrifuged (300g, 2min, 4oC) and resuspended in 100µl 
Fixation/Permeabilization solution (#00-5521-00, eBioscience). The whole plate was 
then left overnight at 4oC.  
 
The next day samples were centrifuged (300g, 2min, 4oC) and resuspended in 100µl 
permeabilization buffer (#00-8333-56, eBioscience, hereafter termed Perm buffer); 
this step was repeated once. Following this, samples were incubated in Fc block (as 
above, but with Perm buffer replacing FACS buffer) for 10 minutes at room 
temperature. Afterwards, samples were exposed to an intracellular staining panel of 
various factors (see results and 18.8 for details, 20µl/well), and left for 30 minutes at 
4oC. Following this samples were washed with 100µl Perm buffer, centrifuged (300g, 
2min, 4oC) and resuspended in 100µl Formalin 1% until analysis by flow cytometry.  
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18.6.2 Intracellular Cytokine Staining 
Samples were incubated (37oC, 5% CO2) for 6h in 200µl complete IMDM with a 
stimulatory anti-CD3 antibody (#553058, BD Pharmingen) at a concentration of 
2µg/ml, and monensin 10µM (Invitrogen). 
 
Following the viability and Fc Block steps described above, cells were surface 
stained with CD4 antibody, 20µl/well, and left for 20min at 4oC. Samples were then 
washed 1x with FACS buffer 100µl, centrifuged (300g, 2min, 4oC) and fixed with 
Paraformaldehyde 2% (in PBS; 100µl/well, 20 minutes, room temperature). 
Depending on experimental timings, samples were sometimes centrifuged (300g, 
2min, 4oC), resuspended in 150µl FACS buffer, and kept at 4oC overnight at this 
point.  
 
For intracellular cytokine staining, samples were resuspended in 0.5% Saponin (in 
FACS buffer) 100µl for 20 minutes at room temperature. 50µl cytokine staining panel 
was then added to each well, and samples were stored at 4oC for 30 minutes. 
Following this samples were centrifuged (300g, 2min, 4oC) and resuspended in 100µl 
FACS buffer; this was repeated once. Samples were then centrifuged (300g, 2min, 
4oC) and resuspended in 100µl Formalin 1%.  
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18.6.3 Flow Cytometry Analysis 
Samples were analysed by flow cytometry using a BD FACSCanto flow cytometer 
and FlowJo software v10.3 (FlowJo LLC).  
 
Cells were identified after gating for singlets and live cells, and typical lymphocytes 
appearance on forward and side scatter. CD4 and CD8 cells were then identified by 
fluorochrome positivity for same (NB: the tLN samples, cells which registered as 
double-positive were gated out and assumed to be thymic tissue contaminants). 
Intracellular cytokine and transcription factor staining was then quantified. Cells were 
classified as follows:  
 
Cell types were gated as follows:  
• TH2     CD4+  /  GATA3+  
• Treg    CD4+  /  FOXP3+ 
• TH1    CD4+  /  Tbet+ 
Intracellular cytokine staining samples were gated as follows: Singlets – Live – 
Lymphocyte gate on FSc x SSc – CD4 +/- TH2, followed by intracellular cytokine 
staining.  
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18.7 Statistical Analysis 
Student’s t-test was performed with GraphPad Prism 7 (GraphPad Software Inc.), 
with corrections for multiple comparisons where appropriate (See figure legends for 




FACS Buffer (PBS with 2% FCS):  
• PBS   500ml 
• Fetal Calf Serum 10ml 
 
Viability Stains:  
• Zombie Aqua Fixable Viability Kit, #423101, Biolegend 
• Dilute Stock Zombie dye 1:500 in PBS, use 20µl per well.  
 
Fixation/Permeabilisation Solution: 
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• Bioscience Foxp3 / Transcription Factor Fixation/Permeabilization concentrate 
and diluent (00-5521) 
o Concentrate: 1 part 
o Diluent: 3 parts 
• Use 100µl/well, i.e. for 20 wells use 500µl concentrate and 1500µl diluent, 
total volume 2ml.  
 
Permeabilisation buffer:  
• eBioscience™ Permeabilization Buffer (10X), 1 part 
• Distilled water, 9 parts 
• NB: After using eBioscience Fixation/Permeabilisation Solution, all further 
incubations and wash steps should be performed in Perm buffer.  
 
Surface Staining antibodies:  
Antigen Fluorophore Dilution Product 
code 
Manufacturer 
CD4 PB 1:200 100531 Biolegend 
CD8 PCP/Cy5.5 1:200 100734 Biolegend 
GATA3 FITC 1:8 130-100-651 Miltenyi Biotec 
FOXP3 APC 1:100 17-5773-82 eBioscience 




FITC 1:8 130-104-611 Miltenyi Biotec 
Hamster IgG (Helios 
Isotype Control) 
Pe 1:100 400908 Biolegend 
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Intracellular Cytokine Staining Antibodies (volumes per well):  
• 0.5% Saponin (in FACS buffer) 50µl  
• Antibody (1:100)   0.5µl  
NB: Surface staining with CD4 carried out in FACS buffer as described above, 
20µl/well).  
Antigen Fluorophore Product code Manufacturer 
CD4 AF700 100536 Biolegend 
IFNg FITC 505806 Biolegend 
IL-2 PeCy7 25-7021-82 eBioscience 
IL-4 Pe 504104 Biolegend 
IL-5 APC 504306 Biolegend 
IL-13 PcPeFl710 46-7133-82 eBioscience 
Rat IgG1 FITC 400405 Biolegend 
Rat IgG2b PeCy7 25-4031-82 eBioscience 
Rat IgG1 Pe 400407 Biolegend 
Rat IgG1 APC 400412 Biolegend 
Rat IgG1 PcPeFl710 46-4301-80 eBioscience 
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19 Results 
19.1 C57BL/6 Experiments 
As stated above, C57BL/6 mice are considered to be a resistant host for 
L.sigmodontis, as wildtypes animals do not develop patent infection. However, as our 
transgenic lines are on a C57BL/6 background, we were forced to use C57BL/6 mice 
for our initial experiments. 
 
19.1.1 Identifying an early timepoint for analysis of T cell 
responses.  
In order to identify the optimal time to look for early T cell responses to infection, we 
infected 6 wildtype C57BL/6 mice and culled 2 animals on D7, D14 and D21 
postinfection. Analysis was of flow cytometry alone. Results are given in 
supplemental data (21.1, figures 21-1 & 21-2). Over the time period D7 - D21 
postinfection we observed a reduction in CD4 T cells early on in all tissues, and an 
increasing proportion of TH2 cells in thoracic lymph node (tLN) and PLEC wash (but 
not spleen samples); this was more prominent from D14. We also observed early 
decreases in IL-2 expression in PLEC and spleen, and IL-5 in LN and PLEC. There 
was also an early reduction in IL-13 expression in PLEC wash CD4 T cells. Based on 
these data, it was decided to use D14 as an analysis timepoint for early T cell 
responses, as that seemed to provide a compromise timepoint where we could 
Control of regulatory T cell activity by endogenous and pathogen-derived EGFR ligands 
Chapter 3: EGFR signalling on Treg in Litomosoides sigmodontis infection 
169 
observe both increasing TH2 cell numbers and decreasing expression of TH2 
cytokines.  
 
19.1.2 Effects of EGFR deletion on regulatory T cells in 
L.sigmodontis infection: early T cell responses 
Using Egfrfl/fl x FoxP3cre (hereafter termed EGFRDFOXP3) and Egfrfl/fl (as CRE negative 
should be phenotypically wildtype, hence hereafter termed WT) were infected with 30 
L3 larvae and culled for analysis at 14 days.  At this stage we examined cell numbers 
and T cell responses only; as C57BL/6 mice are a resistant host, we did not think we 
would see a difference in L4 or worm numbers in the PLEC (see also 19.1.4). There 
were minor reductions in CD4 & CD8 T cells detected in EGFRDFOXP3 spleen samples 
and infected EGFRDFOXP3 mice when compared to infected WT (Figure 19-1 A&B). 
There were significantly more TH2 cells in infected samples compared to uninfected, 
but no difference between WT and EGFRDFOXP3 (Figure 19-1 C). Treg (Figure 19-1 D) 
were a lower proportion of singlet live cells in infected spleen samples compared to 
uninfected in both groups, but only in WT when looking at cell numbers. This was 
also true for Helios+ Treg (Figure 19 E). To summarise, L.sigmodontis infection 
promotes the development of TH2 cells, but the absence of EGFR on Tregs does not 
affect this significantly compared to WT.  
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Figure 19-1 Proportions and cell counts of different T cell populations in tissue samples of WT 
and EGFRDFOXP3 mice infected with L.sigmodontis or uninfected; Harvest at 14 days 
postinfection. A) CD4 T cells, B) CD8 T cells, C) TH2 cells (CD4+ GATA3+ FOXP3-), D) Treg 
(CD4+ GATA3- FOXP3+), E) Helios+ Treg. Statistical analyses are T-tests. Note: Spleen count is 
for 1/10 of the sample; for LN and PLEC the whole sample was analysed.  
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Differences in intracellular cytokine staining correlated with this TH2 response, with 
upregulation of IL-4, IL-5 and IL-13 in infected samples, notably PLEC and to a lesser 
extent spleen (Figure 19-2). However, no significant differences between infected WT 
and EGFRDFOXP3 mice were noted. Expression of IL-2 and IFNg was not significantly 
different between infected groups (except for IFNg in spleen, where the difference 
was minor).  
 
In conclusion, L.sigmodontis infection of EGFRDFOXP3 mice on the C57BL/6 
background does not result in an enhanced TH2 response or increased TH2 cytokine 
expression when compared to WT.  
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Figure 19-2 Intracellular cytokine staining of CD4+ T cells in tLN, PLEC and Spleen of WT and 
EGFRDFOXP3 mice infected with L.sigmodontis or uninfected. A) IFNg, B) IL-2, C) IL-4, D) IL-5, E) 
IL-13. Statistical analyses are T-tests. 
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19.1.3 Effects of EGFR deletion on regulatory T cells in 
L.sigmodontis infection: later T cell responses 
We then moved on to analysing the effects of infection at a later timepoint. As 
expulsion of L.sigmodontis adult worms tends to occur roughly at D40 in C57BL/6 
mice, we decided to use this as our second timepoint. We infected WT and 
EGFRDFOXP3 mice with 30x L3 larvae as before and culled for analysis at 40 days 
(NB: We did not include uninfected groups as we were aiming to detect differences 
between the infected groups as our main readout).  
 
Figure 19-3 shows results for surface staining. PLEC samples from EGFRDFOXP3 mice 
had minor reductions in CD4 and CD8 T cells compared to WT. All tissue samples 
demonstrated an increase in TH2 cells in EGFRDFOXP3 mice compared to WT, but no 
differences in proportions of Treg or Helios-positive Treg were noted.  
 
To summarise, we saw an increase in TH2 cells in EGFRDFOXP3 mice than WT, 
indicating the response to L.sigmodontis infection is pushed in this direction in our 
EGFRDFOXP3 mice; this effect was more pronounced at D40 than at D14.  
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Figure 19-3 Proportions of different T cell populations in tissue samples of WT and EGFRDFOXP3 
mice infected with L.sigmodontis; Harvest at 40 days postinfection. A) CD4 T cells, B) TH2 
cells, C) Treg, D) Treg positive for Helios, E) CD8 T cells. A and E are expressed as percentage 
of singlet live cells in the sample; B-D are expressed as a percentage of CD4 T cells. 
Representative of 2 replicates. Statistical analyses are T-tests. 
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Figure 19-4 shows results for intracellular cytokine staining, where similar to our D14 
data, we saw no significant differences between infected WT and EGFRDFOXP3 mice 
(though note the nonsignificant increases of IL-4 and IL-5 expression in EGFRDFOXP3 
compared to WT samples).  
 
Thus, we conclude that EGFRDFOXP3 mice infected with L.sigmodontis polarise 
towards a TH2 response, but that this does not lead to a significant upregulation of 
Type 2 cytokines in CD4 T cells as a whole.  
 
Control of regulatory T cell activity by endogenous and pathogen-derived EGFR ligands 
Chapter 3: EGFR signalling on Treg in Litomosoides sigmodontis infection 
176 
 
Figure 19-4 Intracellular cytokine staining of CD4+ T cells in tissue samples of WT and 
EGFRDFOXP3 mice infected with L.sigmodontis; Harvest at 40 days postinfection. A) IFNg, B) IL-2, 
C) IL-4, D) IL-5, E) IL-13. Representative of 2 replicates. Statistical analyses are T-tests. 
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19.1.4 Effects of Amphiregulin signalling on T cell immune 
response to L.sigmodontis. 
Based on the data we obtained with EGFRDFOXP3 mice, we hypothesised that the 
polarisation towards a TH2 response was being driven by AREG-EGFR interactions. 
AREG-mediated activation of EGFR has been proven to have a significant impact on 
regulatory T cell function, (Nosbaum et al. 2016; Minutti et al. 2017; Zaiss et al. 
2013). As a test of this hypothesis, we infected AREG-/- and AREGfl/fl mice (should be 
phenotypically wildtype, hence hereafter termed “WT”) as per previous experiments, 
and analysed cell proportions and responses both to each other and uninfected 
control groups of the same genotype. As this experiment was exploratory, and we 
were unsure if the AREG-/- phenotype was going to increase or decrease 
susceptibility to L.sigmodontis infection, we also collected adult worms from the 
PLEC wash for analysis. Harvest date was kept at 40 days.  
 
Figure 19-5 shows the numbers and length of adult worms recovered from PLEC 
wash of AREG-/- and WT groups (NB: Worm length is indicative of growth and overall 
health (Taylor et al. 2009)). We saw no significant differences between our 2 groups 
but note overall numbers of adult worms recovered from the pleural cavity were low.  
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Figure 19-5 A) Number and B) length of adult worms found in the pleural cavity of WT and 
AREG-/- mice infected with L.sigmodontis. Statistical analyses are T-tests. 
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We then moved on to FACS analysis. Surface staining revealed a reduction in CD4 
and CD8 T cells present in tLN and PLEC (Figure 19-6 A & D), but not spleen 
samples. There was a greater proportion of TH2 cells in infected samples, but no 
significant differences between infected WT and AREG-/- groups (Figure 19-6 B). 
Treg populations did not seem to be significantly different, even between uninfected 
and infected groups (Figure 19-6 C).  
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Figure 19-6 Proportions of different T cell populations in tissue samples of WT and AREG-/- 
mice infected with L.sigmodontis; Harvest at 40 days postinfection. A) CD4 T cells, B) TH2 
cells, C) Treg, D) CD8 T cells. A and D are expressed as percentage of singlet live cells in the 
sample; B & C are expressed as a percentage of CD4 T cells. Statistical analyses are T-tests 
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Figure 19-7 Intracellular cytokine staining of CD4+ T cells in tissue samples of WT and AREG-/- 
mice infected with L.sigmodontis; Harvest at 40 days postinfection. A) IL-4, B) IL-5, C) IL-13. 
Statistical analyses are T-tests. 
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Analysis for TH2 cytokines showed that infected samples of either WT or AREG-/- 
mice showed increased percentages of CD4+ T cells expressing IL-4, IL-5 and IL-13 
(Figures 19-7 A – C respectively); however, no differences were observed between 
the infected groups.  
 
These data would indicate that Amphiregulin signalling between T cells is not 
required for the generation of an immune response to infection with L.sigmodontis.  
 
19.2 BALB/c Experiments 
When analysing the effects of EGFR blockade with the commercially available EGFR 
inhibiting TKI Gefitinib, BALB/c mice were used so that they would develop full patent 
infection, allowing us to assess microfilarial levels and adult worm length/number as 
well as flow cytometry data.  
 
19.2.1 Establishing tolerance of BALB/c mice to Gefitinib 
administration 
For administering Gefitinib over a long period of time it was decided that gavage 
would be inappropriate. Instead Gefitinib was be added to the animals’ drinking 
water, which they could consume ad libitum. An initial experiment was performed to 
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assess if the mice would still consume Gefitinib-laced water at the same rate, with 
the dose set at 5mg/kg assuming standard consumption rates (see section 18.3.2). 
Infected and uninfected BALB/c mice given Gefitinib-laced water (Gefitinib group) 
gained weight at a similar rate to groups with plain water (control group) (Figure 19-8 
A), and per-mouse consumption rates averaged over the duration of the experiment 
did not differ between all four groups (Figure 19-8 B).  
 
Plasma samples were taken from D60-67 and showed no significant differences in 
microfilaria counts between the 2 infected groups (Figure 19-8 C). Animals were 
culled at D70; there was no significant difference between the 2 groups in terms of 
total adult worm count (Figure 19-8 D) or worm length (data not shown). Though the 
main aim of this initial experiment was to establish if the mice would tolerate Gefitinib 
administration, we nevertheless performed flow-cytometry on thoracic lymph node, 
PLEC and spleen cells, analysing proportions of CD4 & CD8 T cells, TH2 cells, Treg, 
and intracellular cytokine staining for IFNg, IL-2, IL-4 & IL-5 (in CD4 T cells); no 
significant differences were observed between the any of the groups (data not 
shown).  
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Figure 19-8 BALB/c mice infected with L.sigmodontis and then exposed to Gefitinib 5mg/kg in 
drinking water 3x weekly, compared to control mice and uninfected groups. A) Weight change 
over the duration of experiment, B) average water consumption by group, C) Plasma 
microfilaria in infected groups, D) Number of adult worms obtained from pleural cavity in 
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19.2.2 General EGFR inhibition has no significant impact on 
L.sigmodontis infection in BALB/c mice.  
As described in 18.3, having established that BALB/c mice would tolerate Gefitinib in 
their water supply, we attempted to increase the dose to 100mg/kg. However, at this 
concentration the drug precipitated out of water, and collected at the bottom of the 
bottle. Therefore, we changed our mode of administration and mixed Gefitinib in with 
the animals’ food, as detailed in 18.3. Again, there were no significant differences in 
weight between groups (Figure 19-9 A; only weight change in infected groups was 
documented). From day 55 until harvest at D74, Gefitinib-treated mice had 
significantly fewer plasma microfilaria compared to controls (analysis by 2-way 
ANOVA) (Figure 19-9 B). At end of experiment PLEC samples were analysed for 
both adult worms and microfilariae; there were no significant differences between 
infected groups (Figure 19-9 C+D).  
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Figure 19-9 BALB/c mice infected with L.sigmodontis and treated with Gefitinib 100mg/kg in 
food 3x weekly. A) Weight change, B) Plasma microfilaria, C) PLEC microfilaria and D) Adult 
worms recovered from PLEC at end experiment. Please note uninfected groups were not 
weighed. Representative of 2 experiments. Statistical analyses are T-test with corrections for 
multiple comparisons where appropriate, except for B), where 2-way ANOVA was used.  
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Thoracic lymph node and PLEC samples were analysed for both cell numbers and 
cytokine staining. There was a trend to increased TH2 cells (by total number) in 
infected groups in thoracic lymph node, and a significant increase in the infected 
Gefitinib group compared to both gefitinib only and infected only (Figure 19-10 D). 
Aside from this, we saw no significant differences in cell proportions of CD4 T cells, 
CD8 T cells, TH1s, and Tregs (Figure 19-10 A – C & E).  
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Figure 19-10 Cell proportions in thoracic lymph node and PLEC samples of BALB/c mice 
infected with L.sigmodontis and exposed to Gefitinib or control, with uninfected groups as 
comparators. A) CD4 T cells, B) CD8 T cell, C) TH1, D) TH2, & E) Treg cells. Representative of 2 
experiments. Statistical analyses are ANOVA with secondary T-testing where appropriate. 
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We then analysed cytokine production in CD4 T cells (Figure 19-11) and TH2 cells in 
particular (Figure 19-12). There were no significant differences in cytokine expression 
in CD4 T cells of infected animals given Gefitinib compared to controls (Figure 19-11 
A – E). Hypothesising that TH2 cells might be expressing Type 2 cytokines at an 
increased level, and that this signal might be masked by a lack of expression in other 
CD4 T cells, we analysed cytokine expression specifically on TH2 cells (defined as 
CD4+ GATA3+ lymphocytes). Again, we saw no significant differences in expression 
of IL-4, IL-5, IL-10 & IL-13 (Figure 19-12 A–D respectively).  
 
From these data we concluded that, at the dose administered to these mice, a 
general, Gefitinib-mediated blockade of EGFR signalling does not significantly affect 
the outcome of L.sigmodontis infection in BALB/c mice, a known permissive host, 
and does not affect the function of CD4 T cells in general and TH2 cells in particular.  
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Figure 19-11 Intracellular cytokine staining of CD4 T cells in mice infected with L.sigmodontis 
in the presence or absence of Gefitinib. A) IFNg, B) IL-4, C) IL-5, D) IL-10, E) IL-13, F) IL-21. 
Representative of 2 experiments. Statistical analyses are T-tests. 
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Figure 19-12 Intracellular cytokine staining of TH2 cells in mice infected with L.sigmodontis in 
the presence or absence of Gefitinib. A) IL-4, B) IL-5, C) IL-10, D) IL-13. Statistical analyses are 
T-tests.  
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20 Discussion 
Our experiments showed that deletion of EGFR signalling on regulatory T cells 
biases C57BL/6 mice towards a TH2 response to L.sigmodontis infection, which is 
visible at D40 postinfection but not D14. However, there was no significant increase 
in expression of Type 2 cytokines in CD4 T cells at D14 or D40 (though there was a 
nonsignificant trend seen at D40). Mice deficient in Amphiregulin were no more 
susceptible to L.sigmodontis infection than wildtypes, and proportions of T cell 
subtypes and CD4 T cell Type 2 cytokine staining was similar.  
 
These data would indicate that AREG-EGFR signalling on regulatory T cells is not a 
significant factor in the immune response to L.sigmodontis infection in C57BL/6 mice. 
Our hypothesis was that by blocking this signal (either by removal of EGFR on Treg 
or total deletion of Areg in the mouse) that Treg would be less activated, less 
suppressive, and therefore the mice would be more resistant to infection. Though it 
seems that there is a slight bias in EGFRDFOXP3 mice towards a TH2 response, and a 
trend at around the time of parasite expulsion for more Type 2 cytokine production, 
the difference between EGFRDFOXP3 and WT groups is not large. Also, when 
Amphiregulin is completely removed from the mouse, no differences are seen either 
in terms of T cell proportions or parasite length or number when compared to 
wildtype.  
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Previous work has demonstrated that Treg expansion predates TH2 response to 
chronic helminth infection, and that Treg depletion biases the immune response 
towards TH2 (Taylor, van der Werf, and Maizels 2012). If Treg were receiving an 
activation/expansion signal via EGFR, then this could explain the mild increase in 
TH2 cells we saw in EGFRDFOXP3 mice at D40. However, it would seem that 
Amphiregulin at least is not the signal of importance in this model. C57BL/6 is not a 
permissive host to L.sigmodontis infection, and as such we concluded that it was 
difficult to make them more resistant to infection than they already are. We decided 
to move to BALB/c experiments to study L.sigmodontis in a more permissive host.  
 
Wildtype BALB/c mice treated with Gefitinib up to 100mg/kg 3x/week were not less 
susceptible to L.sigmodontis infection than controls, lymphocyte populations were not 
significantly different, and no significant differences in cytokine staining were 
observed either in CD4 T cells or TH2 cells.  
 
To study the effects of a general blockade of EGFR signalling, we decided to use 
Gefitinib, a commercially available agent with a license for use in humans for a 
variety of cancers where EGFR overexpression is a feature (Carlson et al. 2012; 
Chen et al. 2013; Costanzo et al. 2011; Dutton et al. 2014; Köhler and Schuler 2013). 
Concerns surrounding long-term administration of Gefitinib meant that a thrice-
weekly dosing schedule was devised; it was hoped that this would ensure enough 
Gefitinib present in the animals to generate an effect, if one was present. However, 
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we saw no differences in worm numbers or PLEC microfilaria at harvest; no 
difference in T cell numbers; and no difference in cytokine expression, either in CD4 
T cells or specifically in TH2 cells. There were significantly fewer microfilaria in 
plasma at various timepoints up until experimental harvest, but this did not translate 
to fewer PLEC microfilaria or adult worms. Overall, these results would agree with 
our work in AREG-/- C57BL/6 mice, indicating that EGFR signalling is not an 
important influence on the behaviour either on Treg or T cells in general.  
 
It is possible that our BALB/c mice were underdosed with Gefitinib: When the drug 
was added to water mice drunk at the same rate as controls; however, it was not 
possible to weigh food pots when we moved to administration in food (the mice would 
throw food around the cage, and the pots were contaminated with sawdust), and so 
we used weight gain throughout the experiment as a proxy for food consumption. 
This has the flaw that if the mice ate less on the days they were given Gefitinib-laced 
food, and over-ate on subsequent days, they could still have gained weight whilst not 
consuming the drug. Additionally, our calculations were based on average energy 
requirements, food consumption rates and desired drug dose per unit bodyweight; 
we had no guarantee that an individual mouse would be consuming this amount of 
food, and it is likely that there was variability in terms of actual drug delivered to any 
one individual. The use of 100mg/kg was intended to partially combat this (as well as 
being close to the equivalent dose used in humans), as effects have previously been 
seen using doses of 50mg/kg (Zheng et al. 2016; Song et al. 2016), albeit when 
administered in the short term.  
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Taken as a whole, we conclude that endogenous AREG-EGFR signalling on Treg (or 
Amphiregulin signalling in general) is not a significant factor in the context of 
L.sigmodontis infection either in a permissive or resistant host.  
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21 Supplemental Data  
21.1 Time course of L.sigmodontis infection in C57BL/6 
mice.  
Animals were infected on the same date, and separate harvests at D7, D14 & D21 
were performed. Cell proportions and CD4 cytokine staining results are given below.  
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Figure 21-1 Cellular makeup of thoracic lymph node, PLEC wash and Spleen in C57BL/6 mice 
infected with L.sigmodontis. Analyses are t-tests with Bonferroni correction. 
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Figure 21-2 Cytokine Expression in thoracic lymph node, PLEC wash and Spleen of C57BL/6 
mice infected with L.sigmodontis. Analyses are t-tests with Bonferroni correction. 
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22 Abstract 
Previous work from the Maizels group with the murine helminth Heligmosomoides 
polygyrus has shown that H.polygyrus infection induces systemic Treg expansion, 
which can then suppress inflammation in an airway challenge model of lung 
inflammation. Exploratory work in my laboratory group noted that this effect was 
diminished in Areg-/- mice, implying that Amphiregulin-EGFR signalling was a cause 
of Treg activation in the lungs. Confirming this finding, and determining the cellular 
source of Amphiregulin, was the aim of this chapter.  
 
We performed an airway sensitisation and challenge with Ovalbumin and compared 
wildtype and various transgenic strains of C57BL/6 mice that were either infected or 
uninfected with H.polygyrus. We did not see a decrease in BAL cellularity in animals 
infected with H.polygyrus, in contrast to previous experimentation.  
 
Furthermore, deletion of EGFR on Tregs had no discernible effect on airway 
hyperresponsiveness. Additionally, deletion of Amphiregulin expression, either 
globally or in specific cell types, had no effect on cellularity or cell proportions. 
Infection with H.polygyrus promoted an increase in TH2 cytokine production but did 
not significantly alter cellularity in bronchoalveolar lavage fluid. We conclude that, as 
the initial finding of Treg-induced suppression of airway inflammation (obtained by 
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infecting mice with H.polygyrus) was not seen, that further interpretation of data is 
impossible.   
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23 Introduction 
23.1 Asthma is a chronic TH2 inflammatory condition 
Asthma is a chronic lung condition, thought to be multifactorial in origin, that affects 
an estimated 334m people worldwide (Global Asthma Network 2014; Stefan et al. 
2019). It is an important cause of disability and death globally, and considerable 
efforts have gone towards understanding the immunological mechanisms that are 
involved in the pathogenesis of asthma (Song et al. 2016). The Hygiene Hypothesis 
is the idea that early exposure to pathogens ‘trains’ the immune system to recognise 
antigens correctly, and therefore reduces the risk of harmless antigens (e.g. house 
dust mite or pollen) being misidentified as serious (Brooks, Pearce, and Douwes 
2013). Individuals not exposed to sufficient amounts of pathogen become atopic, and 
prone to develop the conditions eczema, allergic rhinitis and allergic asthma. These 
conditions are typified by a biased, TH2 response and in the case of asthma, 
infiltration of eosinophils, mast cells and lymphocytes into the lungs (Song et al. 
2016). A role for early childhood infections, notably RSV, has been highlighted 
(Krishnamoorthy et al. 2012; Jackson et al. 2008).  
 
Because of asthma’s global importance, mouse models have been developed to 
mimic the disease; mice are exposed to an allergen (typically Ovalbumin or house 
dust mite antigen), and then challenged a short time later with this antigen, typically 
by nebulisation (though other methods are available, and are more invasive) (Reddy, 
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Lakshmi, and Reddy 2012; Stumm et al. 2011). Typical results show an infiltration of 
eosinophils, neutrophils and lymphocytes, but similar numbers of alveolar 
macrophages (Reddy, Lakshmi, and Reddy 2012).  
 
23.2 Heligmosomoides polygyrus upregulates regulatory T 
cells in vivo 
As previously discussed in Chapter 3, helminths have a range of mechanisms to 
evade and manipulate the immune system to their own advantage. These 
mechanisms typically involve specific cells such as regulatory T cells, regulatory B 
cells and TH2 cells, and commonly alter the expression of TH2 cytokines and the 
anti-inflammatory molecules IL-10 and TGFb to promote an immunotolerant 
environment (McSorley, Hewitson, and Maizels 2013).  
 
Heligmosomoides polygyrus is a gastrointestinal helminth parasite of mice, and an 
analogue of hookworm in humans (Reynolds, Filbey, and Maizels 2012). Due to the 
ease of maintaining the life cycle in the lab, as well as the relatively mild pathology in 
infected mice, H.polygyrus has been developed as a model for induction of TH2 and 
Treg responses, as well as the analysis of the effects of secreted helminth products 
on the host (Reynolds, Filbey, and Maizels 2012; Camberis, Le Gros, and Urban 
2003; Johnston et al. 2015). 
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The life cycle of H.polygyrus has been described in Johnson et al. (Johnston et al. 
2015): eggs from an infected host are passed in faeces, where they hatch in the 
environment after 24h into L1 larvae. After 2-3 days they moult to L2 larvae and 
begin feeding on environmental bacteria. Within another 3 days they moult once 
more into L3 larvae, where they are ready for ingestion by a murine host. Once 
ingested, L3 larvae migrate to the duodenum where they form a cyst by day 5 
postinfection. Returning to the intestinal lumen by D8 as adults, they then mate and 
start producing eggs, which appear in the faeces by D14. Cambergris et al. have 
details of how to maintain the H.polygyrus life cycle in the laboratory (Camberis, Le 
Gros, and Urban 2003). It should be noted that C57BL/6 mice are more susceptible 
to H.polygyrus infection, as opposed to BALB/c mice, who are resistant, i.e. this is 
the opposite situation to that of L.sigmodontis infection. 
 
Mice infected with H.polygyrus adopt an immunosuppressive phenotype, with 
downregulated allergic and autoimmune responses. Regulatory T cells are more 
populous and activated, B cells are hyperstimulated and antigen-presenting cells are 
skewed in phenotype so as to produce an tolerant form of TH2 immunity (Maizels et 
al. 2012). Despite this, TH2 cytokines such as IL-4 and IL-13 are essential for 
parasite clearance, which occurs at any time between 4 and 20 weeks depending on 
mouse strain susceptibility (Reynolds, Filbey, and Maizels 2012; Camberis, Le Gros, 
and Urban 2003). In particular, mast cells appear to be important for clearance of 
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H.polygyrus, as mast-cell deficient mice show impaired TH2 priming, and reduced 
levels of IL-25 and IL-33 (Hepworth et al. 2012). Finally, recent work in our lab has 
shown that IL-13 mediated clearance of H.polygyrus is dependent on signalling both 
from Amphiregulin-EGFR and IL-33-T1/ST2 signalling complexes, as both signals 
had to be present for the production of IL-13 from TH2 cells (Minutti et al. 2017).  
 
23.2.1 HES 
The main way H.polygyrus affects the immune system appears to be via the 
excretion of a variety of factors that affect the host, termed H.polygyrus Excretory-
Secretory products, or HES (Maizels et al. 2012). In particular there is evidence that 
HES contains a mimic of TGFb that, though structurally distinct from mammalian 
TGFb, appears to be functionally identical, and induces the proliferation of Treg in the 
host (Johnston et al. 2017; Smyth et al. 2018; Grainger et al. 2010). HES has been 
used in a murine asthma model by McSorley et al., where addition of HES to OVA 
immunisation steps resulted in increased numbers of Treg in the bronchoalveolar 
lavage, fewer effector T cells and eosinophils, and fewer TH1, TH2 and TH17 
cytokines, particularly IL-5 (McSorley et al. 2012). This is in addition to TGFb  
produced by Tregs induced by H.polygyrus infection (Grainger et al. 2010), which 
has been seen in asthma modelling also (Wilson et al. 2005). Due to the fact that 
HES can be administered without the need to infect the target animal, and is more 
practical than the adoptive transfer of regulatory T cells (Wilson et al. 2005; Grainger 
Control of regulatory T cell activity by endogenous and pathogen-derived EGFR ligands 
Chapter 4: Cellular source of AREG in murine asthma model 
206 
et al. 2010), researchers have been exploring its use as an immunomodulator 
(Maizels et al. 2012). 
 
23.3 Treg-mediated immunosuppression of immune 
responses in a mouse asthma model is dependent on 
Amphiregulin-induced EGFR signalling 
Previous work done by Dittrich et al. has highlighted the effects of Treg induction in 
this asthma model: Working with L.sigmodontis, they showed that Treg induction led 
to decreased airway hyperresponsiveness, BAL eosinophilia, TH2 cytokine 
production and increases of both Treg cells and TGFb secretion overall (Dittrich et al. 
2008). These effects were reversed partially or fully by TGFb blockade or Treg 
depletion. Similarly, RSV infection has been correlated with impaired Treg function, 
which seems to lead to worsening asthma due to Treg cells class-switching to a TH2 
phenotype (Krishnamoorthy et al. 2012).  
 
Previous work performed by colleagues has shown that induction of Treg by 
coinfecting mice with H.polygyrus led to reduced lung infiltrates in a model of lung 
inflammation using both ovalbumin and house dust mite allergen, and that this was 
reversible with the use of an anti-CD25 antibody to deplete Treg (Wilson et al. 2005). 
Additionally, it was shown that IL-10 was dispensible for Treg-mediated 
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immunosuppression in this model, implying that TGFb was the likely effector 
molecule of Treg-mediated inhibition of cellular infiltration. This role for TGFb was 
also seen by Dittrich et al. HES-induced Tregs also suppress airway inflammation in 
asthma modelling (Grainger et al. 2010); as stated previously, HES also contains a 
TGFb  mimic, termed TGM, which induces Tregs in-vivo (Johnston et al. 2017).  
 
We have previously shown that Treg express the EGFR under inflammatory 
conditions, and respond to Amphiregulin in a source-specific manner (Zaiss et al. 
2013). Noting the above, we wondered if Amphiregulin-mediated EGFR signalling 
was important in the above asthma model. Preliminary work was performed in the 
Netherlands with wildtype and Areg-/- mice (by Dietmar Zaiss and Erinke Van 
Grisven), using ovalbumin as the sensitisation agent. They found that when WT mice 
were infected with H.polygyrus that there was a general reduction in BAL cellularity, 
in particular eosinophils; when Areg-/- mice were used, this effect was not seen, 
implying that Treg-mediated suppression of BAL infiltrate was dependent on 
Amphiregulin signalling. Determining the cellular source of Amphiregulin-mediated 
EGFR signalling in this model system was the aim of this chapter.  
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24 Hypothesis 
We wished to determine which cellular population is the source of Amphiregulin-
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25 Methods 
25.1 Animal strains used 
C57BL/6J mice of various genotypes (see table 25-1) were bred and maintained at 
the University of Edinburgh in specific-pathogen free conditions. All mice were 
housed in individually ventilated cages at the Ashworth 3 Level 5 animal unit, King’s 
Buildings, University of Edinburgh, until required for experiments, when they were 
transferred to the March Building, King’s Buildings Campus, University of Edinburgh. 
Both sexes were used for experiments, but all mice in one experiment were of the 
same sex. Mice were 6-8-weeks old at the start of the experiment. Cages were 
randomly assigned to a treatment group; mice were not randomised within the cages 
themselves, but mice of different genotypes could be co-housed within the same 
cage. Experiments were performed in accordance with the United Kingdom Animals 
(Scientific Procedures) Act of 1986, and all researchers were accredited by the UK 
Home Office. Dispensation to carry out animal research at The University of 
Edinburgh was approved by the University of Edinburgh Animal Welfare and Ethical 
Review Body and granted by the UK government Home Office; all research was 
carried under the project licence 70/8470. All in-vivo experiments were conducted 
with groups of 5-7 animals unless otherwise stated.  
 
Genotypes of mice used in this experiment were as follows:  
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WT, Egfrfl/fl or Aregfl/fl Wildtype controls 
Areg-/- Deletion of Amphiregulin signal from all cells 
Aregfl/fl x LysMcre Deletion of Amphiregulin signal originating from Alveolar 
Macrophages 
Aregfl/fl x RORacre Deletion of Amphiregulin signal originating from ILC2 cells 
Egfrfl/fl x FoxP3cre Deletion of EGFR receptor on Treg 
Table 25-1 List of transgenic strains of C57BL/6 mouse used to determine the cellular source of 
Amphiregulin in a murine lung inflammation model. 
 
25.2 Heligmosomoides polygyrus 
H. polygyrus and was maintained by serial passage through F1 mice (C57BL/6xCBA) 
as described previously (Johnston et al. 2015). L3 Larvae were stored in distilled 
water and refrigerated until ready for use. Life cycle was kindly maintained by Ms 
Elaine Robertson, of the Buck Laboratory, University of Edinburgh. On the day of 
infection, 200 L3 larvae (in 200µl distilled water) were administered to mice by oral 
gavage with a blunt-tipped needle.  
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25.3 Ovalbumin administration 
This procedure has been described previously (Reddy, Lakshmi, and Reddy 2012). 
For sensitisation to ovalbumin (OVA), Grade V Ovalbumin was purchased (#A5503-
5G, Sigma-Aldrich), and dissolved in PBS to a stock concentration of 1000µg/ml. A 
sensitisation dose of 10µg was used, dissolved 1 in 5 with PBS (i.e. 10µl OVA stock 
and 40µl PBS); this solution was mixed 1:2 with Alum (Imject Alum, #77161, Thermo 
Fisher) to give a final dose of 10µg OVA in 100µl. This was administered to mice via 
intraperitoneal injection on 2 occasions, at least 14 days apart, with the 2nd injection 
at least 7 days prior to nebulised exposure to OVA.  
 
21 days after the first OVA injection, nebulisation occurred daily as follows: OVA 
nebulisation solution was composed of OVA stock diluted 1:10 in PBS, giving a 
concentration of 100µg/ml. 10ml of this was used on any one occasion. Mice were 
placed (maximum 15 at a time) into a nebulisation chamber and exposed to 
aerosolised ovalbumin for 20 minutes. Nebulising air driver was an Omron CompAIR; 
Nebulising chamber was PARI LC Star Reusable Nebulizer Set. Mice were observed 
throughout the nebulisation period for signs of distress, and also for a short period of 
time after returning to their cage.  
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25.4 Experimental Procedure 
We gavaged mice of various genotypes with H.polygyrus in PBS or PBS alone, and 
then the following day started our sensitisation process to Ovalbumin as stated 
above. See figure 25-1 for details of timeline. 26 days after the first exposure to OVA 
i.p. the animals were harvested for analysis.  
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Figure 25-1 Timeline of Ovalbumin experiments. In some experiments H.polygyrus infection 
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25.5 Experimental Harvest 
25.5.1 Culling 
Animals were sacrificed by injection of 150µl of Pentobarbital (Euthatal 200mg/ml, 
Merial). After cessation of movement and heartbeat, animals were confirmed dead by 
dislocation of the neck.  
 
25.5.2 Adult worm acquisition from bowel 
The abdomen and thorax were opened by dissection with scissors, and the front ribs 
and sternum removed. An incision was made distal to the stomach, and the small 
and large intestine blunt-dissected up to the level of the caecum, where a second 
incision was made. Intestinal samples were collected into PBS. Adult worm burdens 
were later determined by exposing the intestinal lumen by dissection. Counting was 
performed by Ms A Fulton with a microscope.  
 
25.5.3 Bronchoalveolar Lavage Acquisition 
This method was based on a previously published protocol (Maus et al. 2001). After 
opening the thoracic cavity (to allow the lungs to expand fully during lavage), the 
neck was dissected open and the musculature surrounding the trachea removed. A 
White needle (19G, 1.1 x 40mm) was gently inserted into the tracheal lumen, and the 
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needle was clamped with artery forceps roughly 2mm proximal to the bevel. Using a 
1ml syringe, serial lung lavages were performed using 500µl BAL buffer (see Section 
3.8). Each 500µl wash was pushed in then aspirated 3 times before collection into a 
1.5ml Eppendorf tube. This was repeated 3 more times, aiming to obtain a total of 
1500µl fluid. Samples were placed on ice until analysis.  
 
25.6 Flow Cytometric sample preparation and analysis 
25.6.1 Sample preparation 
Single cell suspensions were prepared as follows: samples were centrifuged (300g, 
5min, 4oC) and resuspended in 210µl complete IMDM; 10µl was taken for cell 
counting, and 100µl into FACS tubes (for intracellular cytokine staining). the 
remainder aliquoted into a 96-well plate and used for surface staining.  
 
25.6.2 Surface Staining 
Samples contained in a 96-well place were centrifuged (300g, 5min, 4oC), the 
supernatant removed, and samples resuspended in 150µl PBS. Samples were then 
centrifuged again (300g, 5min, 4oC), supernatant removed, and the cell pellets 
loosened using a plate shaker.  
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Following this, samples were viability stained (IndoBlue, see section 25.8) for 10 
minutes at room temperature, then stained with Fc block and antibodies for surface 
markers (see section 3.8), 50µl/well, for 30 minutes at 4oC. Following this, wells were 
‘washed’ with 100µl FACS buffer, centrifuged (300g, 5min, 4oC) and the supernatant 
removed; this was repeated one more time. Samples were then placed in 
Paraformaldehyde 2% (100µl/well) and fixed for 20 minutes, before washing with 
100µl FACS buffer, centrifugation (300g, 5min, 4oC) and resuspension in 150µl 
FACS buffer. Samples were stored at 4oC until analysis.  
 
25.6.3 Intracellular Cytokine Staining 
Samples were incubated (37oC, 5% CO2) for 6h in 200µl complete IMDM with a 
stimulatory anti-CD3 antibody (#553058, BD Pharmingen) at a concentration of 
2µg/ml, and monensin 10µM (Invitrogen). This was performed in FACS tubes.  
 
Following this, samples were washed in 3ml FACS buffer, centrifuged (5m, 300g, 
4oC) and resuspended in 150µl PBS, then transferred to a 96-well plate. Samples 
were then viability stained (Zombie Aqua, see section 25.8) and left at room 
temperature for 10 minutes. Following this, samples were stained with antibodies for 
surface markers for CD4 and CD8 (see section 25.8) and incubated at 4oC for 30 
minutes. For intracellular staining, samples were fixed with 2% paraformaldehyde (in 
PBS) 100µl/well at room temperature for 20 minutes, centrifuged (5m, 300g, 4oC) 
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and resuspended in 100µl FACS buffer; this was repeated once more. Samples were 
then centrifuged again and resuspended in 100µl 0.5% Saponin at room temperature 
for 20 minutes to permeabilise the cells. Following this samples were centrifuged 
(5m, 300g, 4oC) and resuspended in 50µl 0.5% Saponin containing antibodies to 
intracellular cytokines and incubated for 30 minutes at 4oC. Following this samples 
were washed in FACS buffer as detailed above and fixed in 100µl 2% 
paraformaldehyde (in PBS) for 20 minutes at room temperature, before resuspension 
in 150µl FACS buffer.  
 
25.6.4 Flow Cytometry Analysis 
Samples were analysed by flow cytometry using a BD FACSCanto flow cytometer 
and FlowJo software v10.3 (FlowJo LLC).  
 
Cells were identified after gating for singlets and live cells, and CD45 positivity for 
surface staining. Cell types were then identified as follows:  
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Panel 1:  
• CD4 T cells:    Lymphocyte (FSc x SSc) / CD3+ / CD4+ 
• CD8 T cells:    Lymphocyte (FSc x SSc) / CD3+ / CD4- 
• B cells:    Lymphocyte (FSc x SSc) / CD19+ 
• Alveolar Macrophages:  CD11c + / SigF + / F4/80 + 
• Neutrophils:   Ly6G + 
• Eosinophils:    CD11c - / SigF + 
• Monocytes:    Ly6G - / Ly6C + 
 
Panel 2:  
• ILCs:    Lin- (BV421) / CD11c- / CD11b- / CD90.2+ 
• Dendritic cells:   Lin- (BV421) / CD11c- / MHCII+ 
• Mast cells:   Lin- (BV421) / FCeRI+ / c-kit+ 
• Basophils:    Lin- (BV421) / FCeRI+ / CD49b+ 
 
Intracellular cytokine staining samples were gated as follows: Singlets – Live – 
Lymphocyte gate on FSc x SSc – CD4 & CD8, followed by intracellular cytokine 
staining.  
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25.7 Statistical Analysis 
Student’s t-test was performed with GraphPad Prism 7 (GraphPad Software Inc.), 
with corrections for multiple comparisons where appropriate (See figure legends for 




BAL wash:  
• PBS   40 ml 
• BSA 1%  10 ml (BSA 5% stock) 
• EDTA 0.01mM 1 µl (EDTA 0.5M stock) 
 
FACS Buffer (PBS with 2% FCS):  
• PBS   500ml 
• Fetal Calf Serum 10ml 
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Viability Stains:  
• Intracellular cytokine stains:  
o Zombie Aqua Fixable Viability Kit, #423101, Biolegend 
o Dilute 1:500 in PBS, use 20µl per well. 
• Surface stain for cellular characterisation in BALF samples:  
o Live/Dead Fixable Blue Dead Cell Stain Kit, L34961, Invitrogen 
o Dilute 1:300 in PBS, use 10µl per well.  
 
Surface Staining Recipe (per sample):  
• FACS buffer:   50µl 
• Fc Block (1mg/ml) 0.25µl  
• Surface Antibody 1:200 0.25µl  
 
Intracellular Cytokine Staining Recipe (per sample):  
• 0.5% a (in FACS buffer):  50µl 
• Intracellular antibody 1:200 0.25µl 
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Antibodies used: 
Antigen Fluorophore Product code Manufacturer 
CD3 BV421 100228 Biolegend 
CD4 AF700 100536 Biolegend 
CD4 FITC 11-0041-82 eBioscience 
CD8 PCP/Cy5.5 100734 Biolegend 
CD8 PE 553032 BD Pharmingen 
CD11b BV711 101241 Biolegend 
CD11c BV605 117334 Biolegend 
CD19 APC 17-0193-82 eBioscience 
CD45.2 PCP 108926 Biolegend 
F4/80 Pe-Cy7 25-4801-82 eBioscience 
IFNg FITC 505806 Biolegend 
Ly6c AF700 128024 Biolegend 
Ly6g APC-Cy7 127624 Biolegend 
SiglecF PE 552126 BD Pharmingen 
IL-5 APC 504306 Biolegend 
IL-13 PcPeFl710 46-7133-82 eBioscience 
MHC-II FITC 11-5321-82 eBioscience 
CD49b PE 558759 BD Biosciences 
ckit PeCy7 105813 Biolegend 
FCeRI APC/AF647 134309 Biolegend 
CD90.2 APC-Cy7 105327 Biolegend 
Lineage 
negative gate 
(Panel 2):  
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26 Results 
26.1 Deletion of EGFR on regulatory T cells does not affect 
total BAL cellularity 
To determine the effects of deleting the EGFR signalling pathway on Tregs in a lung 
asthma model, we infected WT and EGFRDFOXP3 mice with H.polygyrus, and then 
sensitised them to ovalbumin (OVA) on D1 + D15 as described above. We then 
exposed the mice to nebulised OVA daily from D22-26 and culled for analysis on 
D27. Due to issues around colony health, we did not have enough female mice of 
genotype Egfrfl/fl x FoxP3cre (hereafter termed EGFRDFOXP3) to conduct an experiment 
alongside our other genotypes: it was therefore decided to use males, comparing to 
‘wildtype’ male controls (in fact these were littermate controls, Egfrfl/fl, hereafter 
termed ‘WT’). Please note that, due to constraints in mouse supply, it was not 
possible to include control mice that were exposed to nebulised PBS in place of 
OVA; consequently, this limits interpretation of this experiment.  
 
26.1.1 Worm counts 
Gut samples were taken at harvest (i.e. 27 days postinfection) to determine that there 
was no significant difference in infection rates between our 2 groups. This was true, 
with adult worm counts between 100 and 200 for each group (Figure 26-1; p=0.28).  
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Figure 26-1 H.polygyrus adults worms found in intestinal lumen of WT and EGFRDFOXP3 mice, 
27d postinfection. Note that D28 has been used previously as an analysis timepoint for 
H.polygyrus infection of C57BL/6 mice (Filbey et al. 2014). 
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26.1.2 BAL cellularity 
In contrast to previous investigations (as described in 23.3), we detected no 
discernible difference in amounts of BAL cellular infiltrate (defined as Trypan blue 
excluding cells, figure 26-2) in mice of either genotype, regardless of infection status.  
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Figure 26-2 Total cellularity of BAL samples does not vary by genotype or infection status. 
Animals were sensitised (D1, D15) then exposed to OVA by nebulisation (D22-26) before culling 
& sample acquisition on D27. Samples were stained with Trypan blue and counted using a 
Cellometer Auto T4 (Nexelcom). Statistical analysis was with 2-way ANOVA.  
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26.1.3 Number of leukocyte populations are not significantly 
different in WT or EGFRDFOXP3 mice.  
Following experimental harvest, we then analysed different leukocyte populations in 
BAL fluid, to see if these were present in different proportions. We saw no significant 
differences in proportions of granulocytes (Figure 26-3), mast cells, ILCs or dendritic 
cells (Figure 26-4 A – C). In the EGFRDFOXP3 group there was a small increase in 
basophils in infected animals (Figure 26-4D): the significance of this is unclear, and 
the result may be spurious.  
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Figure 26-3 Granulocyte populations present in BAL samples of WT and EGFRDFOXP3 mice, 
infected or uninfected with H.polygyrus, exposed to OVA in an airway allergy model. A) 
Eosinophils, B) Alveolar macrophages, C) Neutrophils, D) Monocytes. Statistical analyses are 
2-way ANOVA with subsequent t-testing where appropriate.  
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Figure 26-4 Other cell populations present in BAL samples of WT and EGFRDFOXP3 mice, 
infected or uninfected, exposed to OVA in an airway allergy model. A) Dendritic cells, B) Innate 
Lymphoid Cells, C) Mast cells, D) Basophils. Statistical analyses are 2-way ANOVA with 
subsequent t-testing where appropriate. The difference in basophil levels in infected vs 
uninfected EGFRDFOXP3 mice is significant, but may be spurious.  
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26.1.4 Lymphocyte populations and expression of intracellular 
cytokines is not significantly different in WT or EGFRDFOXP3 
mice.  
 
Figure 26-5 Lymphocyte populations present in BAL samples of WT and EGFRDFOXP3 mice, 
infected or uninfected with H.polygyrus, exposed to OVA in an airway allergy model. A) B cells, 
B) CD4 T cells, C) CD8 T cells. Statistical analyses are 2-way ANOVA with subsequent t-testing 
where appropriate.  
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Similarly, there were no significant differences in proportions of various lymphocyte 
populations between the groups (Figure 26-5). Analysis of intracellular cytokine 
expression in CD4 and CD8 T cells showed an increase in CD4 cell IFNg in infected 
EGFRDFOXP3 that was not seen in noninfected EGFRDFOXP3; this was not seen in WT 
mice (Figure 26-6 A). This change was not seen in CD8 T cells (Figure 26-6 D). IL-5 
and IL-13 expression was upregulated in the CD4 T cells of either group (Figure 26-6 
B – C), but there were no differences between genotypes. In CD8 T cells there were 
no significant differences in IL-5 expression (Figure 26-6 E), and IL-13 expression 
was increased in infected WT but not EGFRDFOXP3 mice, but at a much lower level 
than CD4 T cells (Figure 26-6 F).  
 
Based on these data, we concluded that EGFR deletion on regulatory T cells has no 
significant impact on the pathogenesis of airway hyperreactivity in an Ovalbumin 
sensitisation model, and that upregulation of TH2 immunity by H.polygyrus has no 
significant effect either. 
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Figure 26-6 Cytokine expression in CD4 (left) and CD8 (right) T cell populations in BAL samples 
of WT and EGFRDFOXP3 mice, infected or uninfected with H.polygyrus, exposed to OVA in an 
airway allergy model. Cytokines analysed are IFNg (A & D), IL-5 (B & E) and IL-13 (C & F). 
Statistical analyses are 2-way ANOVA with subsequent t-testing. 
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26.2 Identifying role of Amphiregulin in Treg activation in a 
murine asthma model.  
To determine the role of amphiregulin in airway inflammation, and identify the cellular 
source of amphiregulin in the lung, we performed an Ovalbumin (OVA) airway 
sensitisation experiment with mouse of various genotypes, and infected half the 
groups with H.polygyrus (NB: due to constraints in mouse supply, there was no 
uninfected Egfrfl/fl x LysMcre group). As described above, we infected the mice (or 
gavaged with PBS) on D1, Sensitised to OVA D2 & D15, then exposed them to 
nebulised OVA on D22-26 and harvested for sample acquisition on D27. Genotypes 
used were as detailed in table 25-1 and are hereafter referred to as (true genotype in 
brackets): WT (Aregfl/fl); AREGDLysM (Aregfl/fl x LysMcre); AREGDRORa (Aregfl/fl x 
RORacre); and AREG-/- (Areg-/-). LysM is a commonly used marker for alveolar 
macrophages, though it also induces deletions in neutrophils (Clausen et al. 1999; 
Abram et al. 2014). RORa was used as a lineage marker for ILC2 cells, as has been 
described previously (Spits et al. 2013). 
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26.2.1 Worm counts 
 
Figure 26-7 Gut worm counts from infected animals of various genotypes. Animals were 
infected with H.polygyrus and harvested 27 days later. Statistical analysis was 1-way ANOVA. 
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Though there was a trend towards greater numbers of worms in the AREG-/- and 
AREGDRORa groups, there were no overall significant differences seen, implying that 
all groups were equally susceptible to infection (Figure 26-7).  
 
26.2.2 BAL cellularity is not broadly similar across different 
genotypes, and the significance of this is unclear.  
We then went on to analyse the cellularity of BAL samples. Looking first at wildtype 
groups, we saw a significant increase in cellularity when the animals were exposed to 
OVA as opposed to PBS by nebulisation (Figure 26-8 A). However, infection with 
H.polygyrus did not reduce the cellularity of BAL fluid, as has been previously 
observed.  
 
Furthermore, there was heterogeneity of BAL cellularity both in uninfected and 
infected groups, with AREG-/- groups having significantly more cellularity than others 
(Figure 26-8 B – C).  
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Figure 26-8 Comparison of BAL cellularity of A) all WT, B) all uninfected, and C) all infected 
groups. Animals were sensitised (D1, D15) then exposed to OVA by nebulisation (D22-26) 
before culling & sample acquisition on D27. Samples were then stained with Trypan blue and 
counted using a Cellometer Auto T4 (Nexelcom). Statistical analyses are 1-way ANOVA with 
secondary t-testing. Note AREG-/- is significantly more cellular than other groups, a feature not 
seen in previous experiments.  
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When comparing cellularity between uninfected and infected groups of each 
genotype, no significant differences were seen (Figure 26-9). Please note that, in the 
absence of an uninfected AREGDLysM group, the infected AREGDLysM group was 
compared to uninfected WT.  
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Figure 26-9 Comparison of BAL cellularity of different groups, by genotype and infection status 
(infected groups are patterned). The infected AREGDLysM group was compared to uninfected 
WT, as no uninfected AREGDLysM group was available. Statistical analyses are 2-way ANOVA 
with secondary t-testing between uninfected and infected groups. 
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26.2.3 Leukocyte populations are not significantly different in 
mice infected with H.polygyrus.  
Noting the differences in BAL cellularity, we examined if there was any detectable 
difference in various leukocyte cell populations. Figure 26-10 shows the different 
numbers of granulocytes found in BAL; All groups exposed to OVA had significantly 
more eosinophils than PBS-treated WT controls, and also significantly fewer alveolar 
macrophages. There were no significant differences between infected and uninfected 
groups of each genotype for any of the cell populations studied, with the exception of 
monocytes in the AREGDRORa group (significance unclear). 
 
Figure 26-11 shows cell populations of dendritic cells, ILCs, mast cells and basophils. 
There was a slight decrease in dendritic cells seen in the AREG-/- infected group; 
again, given the lack of difference in other cell populations between the AREG-/- 
groups, the significance of this is doubtful.  
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Figure 26-10 Granulocyte populations present in BAL samples of mice sensitised, then 
exposed to nebulised OVA. Groups uninfected with H.polygyrus are blue, infected are red. A) 
Eosinophils, B) Alveolar macrophages, C) Neutrophils, D) Monocytes. Statistical analyses are 
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Figure 26-11 Other cell populations present in BAL samples of mice sensitised, then exposed 
to nebulised OVA. Groups uninfected with H.polygyrus are blue, infected are red. A) Dendritic 
cells, B) Innate Lymphoid Cells, C) Mast cells, D) Basophils. Statistical analyses are T-testing 
of infected and uninfected groups (infected AREGDLysM compared to uninfected WT). 
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26.2.4 Lymphocyte populations and expression of intracellular 
cytokines is not significantly different.  
Moving on to lymphocyte populations, we saw no between-group differences of 
infected and uninfected mice for B cells and CD4 T cells, and a small decrease in 
AREGDLysM infected mice compared to WT uninfected (Figure 26-12).  
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Figure 26-12 Lymphocyte populations present in BAL samples of mice sensitised, then 
exposed to nebulised OVA. Groups uninfected with H.polygyrus are blue, infected are red.. A) 
B cells, B) CD4 T cells, C) CD8 T cells. Statistical analyses are T-testing of infected and 
uninfected groups (infected AREGDLysM compared to uninfected WT). 
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Levels of cytokine expression in CD4 and CD8 T cells were quantified (Figure 26-13); 
there were significant increases in CD4 T cell IL-5 and IL-13 expression in infected 
groups compared to uninfected. Total levels of these cytokines in CD8 T cells were 
much lower but tended to be higher in infected groups of any genotype. CD8 T cell 
IFNg was higher in all infected groups than their uninfected controls, significantly so 
in AREGDRORa and AREG-/- groups. We also compared the infected groups alone 
(Figure 26-14) and found increased IL-5 production on AREG-/- CD4 T cells relative 
to WT and AREGDLysM groups, and IL-13 on AREGDRORa CD8 T cells compared to WT 
only.  
 
Based on these data, we concluded that whilst the presence of H.polygyrus promotes 
a significant increase in TH2 response, this had not been sufficient to alter cell 
populations significantly in the BAL when compared to uninfected controls in an 
Ovalbumin model of airway hyperreactivity. TH2 response seems to be more 
prominent in AREG-/- and AREGDRORa groups when compared to WT and AREGDLysM.  
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Figure 26-13 Cytokine expression in CD4 (left) and CD8 (right) T cells from BAL samples of 
mice sensitised, then exposed to nebulised OVA. Groups uninfected with H.polygyrus are blue, 
infected are red. Cytokines analysed are IFNg (A & D), IL-5 (B & E) and IL-13 (C & F). Statistical 
analyses are T-testing of infected and uninfected groups (infected AREGDLysM compared to 
uninfected WT) 
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Figure 26-14 Cytokine expression in BAL-derived CD4 (left) and CD8 (right) T cells; infected 
groups only. Cytokines analysed are IFNg (A & D), IL-5 (B & E) and IL-13 (C & F). Statistical 
analyses are 1-way ANOVA, with secondary T-testing.  
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27 Discussion 
The findings of these experiments do not corroborate previous work done in our 
laboratory, or by others using helminth infection to induce Treg in asthma models 
(Dittrich et al. 2008; Wilson et al. 2005). These experiments showed that an increase 
in Treg numbers and activation led to a decrease in the severity of TH2 response to 
airway allergen challenge, i.e. the presence of a Treg-inducing helminth led to 
decreased lung inflammation. This basic finding was not seen in our experiments, 
where mouse populations infected with H.polygyrus did not have significantly less 
cellular BAL when compared to uninfected controls. There were some differences in 
BAL cellularity across genotype (notably AREG-/- groups had more cellular BAL than 
other groups, whether infected with H.polygyrus or not), which may point to a 
difference in immune responses to OVA challenge; however, this finding in the 
AREG-/- group conflicts with earlier work done in our laboratory, where there was no 
appreciable difference in BAL cellularity between WT and AREG-/- groups.  
 
The reasons for these discrepancies are hard to explain: one possibility is that the 
mouse strains we used for these experiments are characteristically different to those 
used in our preliminary work: between experiments (several years apart) the 
microbiome of our mouse colonies was moved from a SOPF to an SPF background, 
due to an issue with anomalous results in the work of several groups using the 
Ashworth animal unit. In order to move our mice onto SPF background, newborn 
pups were fostered onto an C57BL/6 SPF mother, purchased from the Jackson 
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laboratory. This tends to produce mice with a ‘hybrid’ SPF/SOPF microbiome (Dr P 
Spence, Personal Communication), which, in combination with the phenotype of our 
transgenic strains, might have produced mice which are a) less susceptible to the 
effects of infection with H.polygyrus and b) broadly similar in their response to OVA 
airway challenge, regardless of genotype. It should be noted that there is a known 
interaction between H.polygyrus and the mouse microbiome during infection, and this 
has been shown to be important for H.polygyrus’ immunosuppressive effect in a 
house dustmite airway sensitisation/challenge model (Zaiss et al. 2015). Therefore, it 
is possible that the alteration of our mouse microbiome had an influence on its 
susceptibility to alteration by H.polygyrus infection.   
 
Another possibility is that changes in our experimental schedule led to our findings 
being discordant with our preliminary work. Our initial experiments involved a longer 
period between inoculation with H.polygyrus and the first injection of OVA; 28 days, 
as opposed to our shortened schedule, where mice were infected 1 day prior to first 
exposure to OVA. This shortened timeframe was chosen because the induction of 
regulatory T cells in H.polygyrus infection occurs early in infection, and ratios of Treg 
to conventional T cells have largely normalised by D28 (Finney et al. 2007; Rausch 
et al. 2008). By confining our experimental period to less than 28 days, we had 
hoped to capture our data during a period of optimal Treg expansion. However, 
please note that other experiments performed using AREGDLysM, AREG-/- and 
AREGfl/fl mice (data not shown above) used a gap of 14 days between infection with 
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H.polygyrus and first injection of OVA, and similar results on BAL cellularity and cell 
proportions was found.  
 
Finally, it is possible that there were issues either with the ovalbumin we used or the 
quality of H.polygyrus larvae. We tried to mitigate for this by a) using new grade V 
Ovalbumin stock, and b) checking for established infection by examination of gut 
samples for adult worms (Figure 26-1). Judging by the obvious infiltration of 
inflammatory cells in OVA-treated samples relative to our PBS-treated control, and 
the presence of adult worms in our bowel samples (and no significant differences 
between our infected groups), we do not think these are likely causes of our 
experimental failure.  
 
In conclusion, as we have failed to replicate the findings of previously published 
work, we do not believe any conclusions can be drawn concerning the cellular source 
of Amphiregulin for regulatory T cells in an airway inflammation model.  
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This thesis aimed to study the relationship between EGFR activation on regulatory T 
cells and the outcome of infection. To achieve this, we used Vaccinia virus, a 
poxvirus known to produce a soluble EGFR ligand, and 2 separate helminth worm 
infections, which are known to induce regulatory T cells as part of the host response 
to infection.  
 
Given the failure to replicate the findings of our initial experiments using 
Heligmosomoides polygyrus, it is difficult to infer anything from our data. Using 
Litomosoides sigmodontis, we found that EGFR signalling via AREG (or EGFR 
signalling on Treg in general) was dispensible for optimal Treg function in-vivo. 
L.sigmodontis infection produces a marked upregulation in Tregs, both systemically 
and in the pleural space (Taylor et al. 2005; 2007). This Treg induction is powerful 
enough to protect NOD mice from developing Type 1 Diabetes, even without biasing 
the immune response towards TH2, though TGFb is still required (Hübner et al. 
2012). As with most other helminth infections, L.sigmodontis produces a large 
number of excretory-secretory products, with over 300 molecules being identified in 
one study, most of these coming from adult gravid females (Armstrong et al. 2014). 
Many of these proteins have an immunomodulatory effect on the host, seemingly to 
benefit the survival of various stages of the parasite (Pfaff et al. 2002; Hartmann, 
Schramm, and Breloer 2015). Other researchers have found that, similar to 
H.polygyrus, L.sigmodontis produces an analogue to TGFb, which induces Treg that 
subsequently express IL-10; this induction of TGFb has been noted in other 
Helminthoses also (Grainger et al. 2010; Hartmann, Schramm, and Breloer 2015; 
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Maizels, Smits, and McSorley 2018). It is unlikely that this TGFb  analogue is the only 
excretory-secretory product that L.sigmodontis is releasing that affects Treg, given 
the diversity of molecules released from helminth worms (Maizels, Smits, and 
McSorley 2018); but even if so, it is likely that it is enough to overcome the effects of 
EGFR signalling inhibition in our Chapter 3 experiments. Hence, it seems that EGFR 
signalling is dispensible for activation of Treg in the context of L.sigmodontis 
infection.  
 
Using Vaccinia virus infection of C57BL/6 mice, we have shown that:  
1. Early protein products from UV-inactivated virus can induce Treg suppressive 
function in-vitro, and that with VACV that does not express VGF this effect is 
not seen;  
2. in-vivo infection of EGFRDFOXP3 mice results in less weight loss and lower viral 
titres in the lung compared to WT;  
3. BAL of VACV-infected EGFRDFOXP3 mice is more cellular; and  
4. BAL supernatant of infected EGFRDFOXP3 mice contains less TGFb than their 
WT counterparts. Based on these data, we conclude that VACV-derived VGF 
activates Treg at the site of infection, and these Treg subsequently suppress 
the immune response to VACV infection via TGFb mediated 
immunosuppression. This is clearly beneficial to the virus, as reflected in 
higher lung viral titres and more weight loss in WT animals as compared to 
EGFRDFOXP3. 
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Almost 40% of the poxvirus genome is composed of immunomodulatory proteins, 
which are summarised elsewhere (Bidgood and Mercer 2015). Other researchers 
have demonstrated an interaction between VACV and T cells: VACV M2 protein, 
which is released from infected cells, can suppress T cell activation by binding 
CD80/CD86, preventing these from being ligated by CD28 or CTLA4 (Kleinpeter et 
al. 2019). However, to our knowledge this is the first time a direct interaction between 
Vaccinia virus and regulatory T cells has been shown. Given the wide number of 
immunomodulatory proteins poxviruses produce, and the discovery that activated 
Treg express EGFR and respond to EGFR ligands, it is perhaps not surprising that 
as well as suppressing the innate and adaptive immune responses through a variety 
of means, VACV also manipulates Treg to achieve the same objective of a locally 
immunosuppressive environment that benefits the pathogen.  
 
As part of our work we decided to assess the influence of Gefitinib blockade on the 
outcome of VACV infection in WT mice; however, we were not able to complete 
these experiments as stated above in section 11.3.8, and time constraints meant that 
we had to discontinue this line of inquiry. If time had allowed, repeating this 
experiment using a monoclonal antibody inhibitor of EGFR might have been more 
tolerable for the experimental animals, and allowed us to establish the utility of EGFR 
inhibition in acute infection. Gefitinib was chosen as our inhibitor for practical 
reasons: it is commercially licensed for use in humans; the dosages used in humans 
and mice are comparable (after appropriate conversion); and treatment can be easily 
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ceased after resolution of infection (as opposed to monoclonal antibodies, which 
maintain their effect for several weeks after administration).  
 
Future directions arising from this thesis should focus on the applicability of EGFR 
inhibition in various infective processes. As discussed previously, poxviruses 
currently cause little disease in the human population, due to the eradication of 
Smallpox (Variola virus) in the late 1970’s. Concerns persist, however, about the use 
of Smallpox as a bioterrorism agent, and currently treatment in an attack using such 
an agent would be almost entirely supportive. Any medicine that improves the host 
response to infection without resulting in immune system-mediated damage to the 
host should be investigated further. EGFR-inhibiting medicines (TKIs and monoclonal 
antibodies) have mild side effect profiles when compared to older medicines, are 
already in mass-production and, in the case of TKIs, have a rapid onset and offset of 
effect. Given the importance of VGF and SPGF for providing optimal replication 
conditions for VACV and variola respectively, blocking the effects of these agents 
with EGFR inhibitors is a tempting avenue for future research.  
 
Would EGFR inhibition be effective against other pathogens? This is less clear: 
Other viruses use EGFR as means of entry into cells, and some (such as CMV) use 
EGFR to change the behaviour of monocytes so as to benefit the virus (Chan, 
Nogalski, and Yurochko 2009); but there also appears to be considerable 
redundancy, with viruses using multiple methods to enter cells. Poxviruses uniquely 
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produce a soluble mediator with EGF-like properties, making them an ideal candidate 
for this study. Other pathogens, such as those listed in section 4.2, appear to use 
EGFR signalling to enter or manipulate their target cells, but the effects of EGFR 
blockade in these situations would have to be examined case-by-case. There are 
certainly some pathogens (e.g. Helicobacter pylori), where due to already effective 
treatments existing the benefits of this line of inquiry are doubtful. However, in some 
cases (such as influenza) where antimicrobial resistance is a rising concern, 
research is more readily justified.  
 
In conclusion, Poxviruses use soluble growth factors with EGFR ligating properties to 
stimulate regulatory T cells, which in turn suppress the immune system using TGFb, 
so as to create a locally immunosuppressive environment in which the virus can 
replicate. The use of EGFR inhibitors to mitigate this process should be examined 
further.  
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